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Chronic neurodegenerative diseases, such as Alzheimer’s disease, prion diseases and 
many others are unified by the aberrant folding of a host encoded protein to a 
disease-associated isoform and the predictable cell-to-cell spread of disease-
associated misfolded proteins via a putative prion-like mechanism. Prion diseases, 
for example, are associated with the aberrant folding of host encoded prion protein 
(PrPC) to a disease-associated isoform, which acts as a seed for the further conversion 
of PrPC to misfolded protein species.  
 
The role of misfolded prion protein in neurodegeneration remains unclear. 
Accumulation and spread of misfolded prion protein is typically slow and 
progressive, correlating with neurodegeneration. A number of studies show that mice 
are susceptible to prion disease with characteristic hallmarks of prion pathology but 
in the presence of little detectable misfolded prion protein (e.g. the GSS/101LL 
model). In this thesis I test the hypothesis that detectable species of misfolded prion 
protein correlate with neurodegeneration and spreads in a predictable, progressive 
fashion from one anatomically distinct brain region to the next.  
 
Using the GSS/101LL model, misfolded prion protein was detected as mostly PK-
sensitive isoforms (PrPsen). The progression and pathological presentation is 
comparable to other prion diseases with larger quantities of PK resistant prion 
isoforms. A highly sensitive in vitro assay system (the QuIC assay) was subsequently 
used to establish the extent that misfolded protein was present within the brain. 
[iii] 
 
Amyloidogenic prion seeds were found to be widespread throughout the brain from 
an early stage and spread rapidly throughout the brain. Absence of 
neurodegeneration in certain brain regions is not due to differing quantities of prion 
seeds between regions or time exposed to prion seeds, as unaffected regions are 
exposed to comparative quantities of prion seeds for the same time-period as regions 
of the brain which eventually succumb to neurodegeneration. 
 
These results indicate a clear dissociation between prion seeds and neurotoxicity. 
They highlight the need to understand regional host responses to prion seeds that 
may evoke neurodegeneration in some but resilience in others. To test this, 
transcriptomic analysis was carried out on brain samples from regions undergoing 
neurodegeneration and unaffected regions. A gene profile signature of hybrid pro- 
and anti-inflammatory response was observed in regions undergoing 
neurodegeneration. However, large cohorts of genes were down-regulated across all 
regions tested, including pro-inflammatory genes and a large proportion of genes 
involved within transcriptional and translational regulation and function. These 
results highlight the possible molecular pathways in response to the presence of 
misfolded protein. 
 
In summary, misfolded prion protein accumulates rapidly across the CNS but only 
specific brain regions undergo neurodegeneration. In the presence of the misfolded 
protein, the host elicits a robust molecular response. The additional activation of glial 
cells within regions undergoing neurodegeneration highlights their importance in 
[iv] 
 
disease. It is therefore proposed that misfolded prion protein, alone, is not sufficient 
to trigger neurodegeneration. This gives rise to a “multi-hit” hypothesis whereby two 
or more factors, for example the accumulation of misfolded protein and glial cell 
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Chronic neurodegenerative diseases of the Central Nervous System (CNS) represent 
a range of heredity and sporadic conditions which are characterised by progressive 
degeneration of the nervous system. These include Alzheimer’s disease (AD), 
Huntington’s disease (HD), Parkinson’s disease (PD), Amyotrophic Lateral Sclerosis 
(ALS), Transmissible Spongiform Encephalopathies (TSEs or prion diseases), and 
others. 
 
The mechanisms of neurodegeneration within such diseases are unclear and few 
therapeutic targets have been identified to date. As a result, few therapies can treat 
these diseases, with those that are available offering only modest relief from 
symptoms with limited or no impact on disease progression. These diseases therefore 
represent a substantial socioeconomic burden. 
 
Particularly well-studied are fatal degenerative disorders of the CNS associated with 
aberrantly folded, host encoded proteins. These encompass intracellularly misfolded 
proteins, for example; α-synuclein in PD [1] or extracellularly misfolded proteins, for 
example; amyloid-β (Aβ) in AD [2] or the prion in TSEs [3]. That such a clinically 
and etiologically diverse range of diseases are associated with aberrant protein 
folding suggests that impaired protein homeostasis is a likely factor within the 




1.1. Prion Diseases 
Amongst the range of neurodegenerative diseases, Transmissible Spongiform 
Encephalopathies (TSE), or prion diseases, represent a distinctly unique group. This 
is namely due to the infectious nature of the disease [3-5], which is hypothesised to 
be a result of the aberrantly-folded protein acting as a template for the further 
conversion of cellular prion protein (PrPc) to a disease-associated conformation 
(PrPSc or PrPd) [6].  
 
Prion diseases typically present in four ways: (i) sporadic, (ii) familial, as a result of 
a mutation in the prion protein gene (PRNP), (iii) infection from a host to a recipient 
or (iv) iatrogenic infection from contaminated substances or instruments used in 
surgery. 
 
1.1.1. Prion Diseases: Background & History 
Human prion diseases include a sporadic form of Creutzfeldt-Jakob disease (sCJD) 
and its variant form (vCJD), familial forms Gerstmann-Sträussler-Scheinker 
syndrome (GSS) and Fatal Familial Insomnia (FFI) and Kuru. Animal prion diseases 
include scrapie in sheep, Bovine Spongiform Encephalopathy (BSE) in cattle, and 
Chronic Wasting Disease (CWD) in elk and deer, amongst others [7, 8]. Scrapie is 
the archetypal prion disease which has been endemic within the UK sheep flock for 
around 200 years. Scrapie was experimentally found to be transmissible to other 
sheep and rodents in the 1930s and 40s [9]. A remarkable instance of human to 
human transmission of a progressive disease with clinical symptoms of cerebellar 
[3] 
 
ataxia [10] was described shortly after in 1957 [11]. This disease, termed Kuru, was 
caused by ritual cannibalism practiced by people of the Fore Linguistic tribe, Papua 
New Guinea, and was quickly identified to share similarities with scrapie in 
epidemiology, clinical symptoms and pathological characteristics [12]. Kuru was 
subsequently demonstrated to be transmissible to non-human primates via a variety 
of routes [13, 14].  
 
In the 1980/90s, UK agriculture suffered an epidemic of BSE, followed by the 
identification of a novel form of CJD, vCJD, in the UK in 1996. It was quickly 
established that vCJD was likely contracted by the consumption of BSE-infected 
food produce [15]. Between October 1996 and November 2013, there have been 177 
reported cases of vCJD in the UK and a further 51 cases worldwide, spanning across 
11 different countries (www.cjd.ed.ac.uk). 
 
Efforts to comprehend the nature of the transmissible agent led to the understanding 
that these diseases are not caused by conventional infectious agents. The 
transmissible agents displayed unusual resistance to ionising radiation, heating and 
acetylethyleneimine exposure, suggesting the infectious entity may be devoid of 
nucleic acids [16]. Specific conserved properties of these diseases – for example, 
long incubation times, lack of immunogenicity and high heat inactivation curves, 
alongside continued scrapie transmissions, allowed researchers to categorise prion 




Later studies examining the infectivity of the transmissible agent used LD50 tests to 
evaluate the dilution at which 50% of recipients succumb to disease. The fact that the 
proteinaceous entity was partially protease resistant due to the protein 
conformational state [21] led to the isolation of the proposed transmissible agent, 
which was termed prion, for proteinaceous infectious particles [6, 22]. This was 
followed by the cloning of PrP cDNA, which identified the prion protein gene [23]. 
Subsequent structural analysis [24] and the identification that scrapie associated 
fibrils (later accepted to be PrPd) and PrPc are both encoded by the same gene, Prnp 
[25], led to the acknowledgement that the host cellular protein, PrPc, is misfolded 
into a disease specific conformation, PrPd. 
 
More recently, the establishment of transgenic mice strengthened the link between 
PrP and disease. Prusiner et al. 1990 [26] demonstrated that introducing the prion 
gene from the Syrian Hamster into mice and subsequent inoculation of hamster 
scrapie, which is not normally transmissible to wild-type (WT) mice, resulted in 
disease. This study, amongst others [27], indicates that sequence homology of Prnp 
is fundamental for susceptibility to infectivity, neuropathology and incubation time. 
Furthermore, introducing amino acid alterations within the mouse prion gene can 
render mice susceptible to prion diseases to which they would otherwise be resistant 
[28, 29]. This indicates that specific changes in protein conformation can influence 
the capacity of disease-associated conversion of PrPc to PrPd. Knockout of Prnp in 





1.1.2. Prion Diseases: Nomenclature  
The prion protein, PrP, is commonly referred to as either the cellular prion protein 
(PrPc) or an abnormal, infectious form of the protein, PrPSc. As described in further 
detail in 1.14. Prion Diseases: The Prion Protein, PrPc is a predominantly α-helical 
structure and in the context of this study refers to any conformation of PrP which is 
found in uninfected, healthy individuals. 
 
The term prion describes a protein species which can act as an infectious entity, 
commonly designated PrPSc. However, PrPSc contains a number of differing protein 
conformations. For example, the conformational rearrangement of PrPc to an 
abnormal isoform has been shown to produce PrP conformations which are partially 
protease resistant [21], termed PrPres. Subsequent studies identified protease sensitive 
isoforms of abnormally folded PrP, PrPsen, which retain their infectious properties 
[32, 33]. Alternate forms of PrP, such as cytoplasmic [34, 35] and transmembrane 
PrP [36] have also been linked with disease. Whether PrPSc or a subset of 
conformations is responsible for neurodegeneration is unknown. As discussed in 
1.4.1. The role of PrP in neurodegeneration, conflicting studies argue the toxic role 
of oligomeric, protofibril and fibrillar forms of misfolded PrP. It is unclear how such 
protein aggregates fit within the definition of PrPSc and therefore the term PrPSc may 
not be suitable when discussing potential toxic isoforms of PrP. To circumvent this, 
any detectable conformations of PrP within a known, prion-infected individual will 




Recent studies have developed in vitro techniques which measure conformational 
rearrangement of PrPc substrate to abnormal conformations using PrPd as a seed (see 
1.1.5. Prion Diseases: Misfolding of PrPc to PrPd). This effectively measures the 
capacity of a specific sample to misfold PrPc, or act as a “prion seed”. Whether the 
prion seeds detected using these assays represent the detection of all species of PrPd 
present in a sample is unknown. However, previous publications have shown these 
assays can detect prion seeds to a far greater sensitivity compared to other 
techniques, such as immunohistochemistry (IHC) or Western blot analysis. 
Therefore, in this thesis, PrPd is an operational term referring to detectable forms of 
misfolded prion protein using IHC or Western blot analysis. Conversely, a prion seed 
refers to the detection of misfolded prion protein which may or may not be detectable 
using IHC or Western blot analysis but is capable of generating fibrils from 
recombinant PrP (recPrP) which can be detected using Thioflavin-T (ThT). 
 
1.1.3. Prion Diseases: The Infectious Agent 
The prion hypothesis states that the infectious agent is composed solely or primarily 
of protein. This is supported by; (i) the fact that prion disease infectivity has been 
demonstrated to co-purify with abnormal PrP [37, 38], and (ii) the prion protein is 
essential for disease susceptibility. Despite strong evidence implicating an abnormal 
conformation of PrP as the infectious agent, there are some animal models of disease 
which question this hypothesis [28, 29, 39-41]. Furthermore, a component/isoform of 
PrP from misfolded prion protein fractions can be separated from infectivity using 
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differential detergent treatments [42-44]. One study demonstrated that nearly all 
detectable PrP was solubilised after detergent treatment of an infected brain 
homogenate; however the sediment still remained infectious [44]. The infectivity of 
some prion strains, demonstrated to inactivate (i.e. at the point LD50 cannot be 
measured) at relatively low temperatures, do not show any alterations in protease 
resistance of PrPd upon exposure to inactivating levels of heat [45]. These data 
combined suggest, at the structural level, the majority of detectable abnormally-
folded protein can be separated from infectivity, and thus is likely independent of 
infectivity. This has led to alternate theories regarding the infectious agent. Most 
prominently, it has been hypothesised that only a proportion of the total PrPd is 
infectious, termed PrP* [46]. This has been built upon by others, who suggest that 
intermediate species in the conversion process from PrPc to misfolded isoforms could 
represent the infectious entity [47]. Indeed, such a theory could go some way to 
explaining the results of previous experiments. For example, the denaturing 
conditions of high temperatures, demonstrated to diminish infectivity, could have a 
substantial impact upon the intermediate forms (or PrP*) of the prion conversion, but 
have little or no impact upon the β-sheet rich and highly stable fibril and amyloid 
aggregates of PrP. In accord with this, other studies have indicated that larger 
aggregates are likely not infectious [48-51], and, instead, oligomers could serve as 
more probable templates of prion conversion and infectivity [51, 52]. 
 
Despite the wide acceptance of the prion hypothesis, it is important to note this 
concept is not universally accepted. Primarily as a result of the huge diversity of 
identified strains occurring both naturally and experimentally, some investigators 
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suggest that the protein-only element of the prion hypothesis is inaccurate - instead, 
hypothesising that the infectious agent in prion diseases consists of two major 
constituents: the host encoded prion protein and an unidentified disease-specific 
genetic element [53, 54]. It is hypothesised that small viruses [55-58], or viroid’s [59, 
60] (non-coding, single-stranded RNA molecules lacking a protein shell) could 
constitute the proposed genetic element. A theoretical species, termed virino, has 
also been proposed, which consists of a genetic element wrapped in a coat of host-
encoded proteins, such as PrP [61, 62]. Despite reports of identified disease-specific 
nucleic acids [63-69], there is little independently-replicated published data to 
suggest a nucleic acid component. For this reason, this document reflects the balance 
of literature implicating the prion hypothesis as the most likely explanation for the 
infectious nature of prion diseases. 
 
1.1.4. Prion Diseases: The Prion Protein 
The mammalian prion protein is an N-glycosylated, glycosylphosphatidylinsitol 
(GPI)-anchored protein (figure 1.1) typically found on the cell surface within 
detergent insoluble membranes, termed lipid rafts [70-73]. The ‘normal’ 
conformation of PrPc has been characterised using recPrP expressed within 
prokaryotic cells and folded under specific acidic pH conditions. The atomic-level 
structures of a variety of prion proteins have been elucidated using Nuclear Magnetic 
Resonance (NMR) spectroscopy [74-80] and X-Ray Crystallography [81, 82]. The 
prion protein consists of an N-terminal flexible domain and a C-terminal globular 
domain. The N-terminal domain comprises 4-5 glycine-rich octapeptide repeats 
which have been shown to bind copper ions [83] and mediate the binding of 
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polyanionic compounds [84]. The N-terminal region is present in the majority of 
misfolded prion protein isolated from infected brains [85], however, is not essential 
for disease progression as mice lacking the N-terminal domain of PrPc are 
susceptible to disease [86]. The C-terminal of prion protein is a structured, globular 
domain consisting primarily of α-helices, with two short β-sheet strands (figure 1.1). 
This domain contains a disulphide bond and two sites of glycosylation – the latter of 
which has been shown to be differentially glycosylated in prion infected brains [87, 
88]. 
Figure 1.1 – Schematic diagram of prion protein indicating structural features of PrPc as a function of 
primary sequence. All residue numbers are approximate. 
 
Treatment of prion infected brain homogenates with proteinase K (PK) digestion 
results in the degradation of approximately 90 amino acid residues of the N-terminus. 
This is in contrast to PrPc, which is completely degraded upon PK digestion. This 
resistance of disease related PrP is indicative of a significant alteration in 
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conformation of the prion protein and is a phenotype specific to prion-infected 
individuals. The fact that the C-terminus remains intact upon PK digestion suggests 
this region is involved in the misfolding process. Due to the insolubility of PrPd, 
defining the tertiary structure has been challenging. Several low-resolution 
techniques suggest PrPd is a β-sheet rich protein, with some retention of the original 
α-helix folding [89-92]. On the other hand, recent hydrogen/deuterium exchange 
studies indicate a lack of α-helices within PrPd [93]. It is unclear whether such 
controversy within the literature is due to differences in PrPd conformations being 
detected or due to a simple lack of atomic-level resolution. Ultimately, without high 
resolution descriptions of PrPd it is challenging to define the prevalence of different 
PrPd conformations in (i) different regions of the brain, and (ii) between different 
prion strains. 
 
1.1.5. Prion Diseases: Misfolding of PrPc to disease-associated isoforms 
The underlying principle of the prion hypothesis is that misfolded prion protein can 
act as a template for the auto-catalytic conversion of PrPc to disease-associated 
conformations. An important study to demonstrate this was performed by Caughey et 
al. [94]. By adding enriched preparations of PrPd from prion-infected brain 
homogenates to recPrP in vitro, Caughey and colleagues were able to identify the 
formation of small quantities of PK-resistant aggregates as a result of cell free in 
vitro conversion. Thus, as a result of PrPd exposure, the conformation of PrPc 
misfolds to an abnormal entity. This technique is termed the Cell-Free Conversion 
Assay (CFCA), and has also been demonstrated to replicate specific phenotypes of 
disease. For example, hamster recPrP exhibits a relatively inefficient conversion rate 
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in the CFCA in comparison to murine recPrP in response to murine strains of scrapie, 
a phenotype generally observed in vivo. Conversely, murine recPrP was highly 
resistant to strains of hamster scrapie within the CFCA, again replicating in vivo 
findings [95] and in accord with earlier findings using a similar approach [96]. 
 
A development upon CFCA was the introduction of the Protein Misfolding Cyclic 
Amplification (PMCA) assay [97]. The PMCA assay differs from CFCA in two 
principle ways; (i) it uses uninfected brain homogenate as a source of PrPc substrate 
rather than recPrP, and (ii) it uses sonication to drive conversion. Sonication 
theoretically breaks down larger aggregates of misfolded protein into smaller 
particles, providing additional surface area for further misfolding events. The 
detection of a conformational rearrangement of PrPc to an abnormal species is thus 
determined by the gain of protease resistance of PrP. By sonicating and replenishing 
the PrPc substrate, this approach allows for the use of extremely small quantities of 
misfolded prion protein as a ‘seed’ for the conversion process. This gave scope for a 
sensitive diagnostic test to be developed. It is important to note, however, that 
PMCA is also capable of generating de novo PrPres in the absence of an initial 
misfolded prion protein seed [98, 99]. Similarly to ‘seeded’ PMCA reactions [100], 
the de novo generation of prions was also infectious. Such findings demonstrate that 
under specific conditions, the prion protein is capable of spontaneously misfolding to 
disease-associated conformations. Such a finding, however, questions the feasibility 
of using this approach as a potential diagnostic due to the inability to define 
differences between misfolded prion protein ‘seeded’ conversion and de novo 
[12] 
 
conversion. It is thought that the sporadic and spontaneous formation of de novo 
prions was the result of inconsistent physical conditions generated during sonication.  
 
To avoid the use of sonication other laboratories have developed vigorous shaking 
methods to drive conversion. This method is known as the Quaking Induced 
Conversion (QuIC) assay [101]. Similar to CFCA, the QuIC assay uses purified 
recPrP as the PrPc substrate. As a result, the reaction conditions of the QuIC assay 
are tightly controlled and consistent across larger numbers of samples, allowing the 
assay to be run on multi-well plates for higher throughput. The misfolding of recPrP 
was similarly detected by the appearance of PK resistant isoforms of PrP when the 
QuIC product was examined on a Western blot [101, 102]. As a result of the reaction 
conditions of the QuIC assay, the converted products are prone to form fibrils. This 
allows the QuIC assay to use a fluorescent compound, ThT, as a real-time detection 
method. ThT is a benzathiole dye which selectively binds to fibrils and exhibits a 
dramatic increase in fluorescence. As a result, this allowed the visualisation of 
fibrillar formation within the assay in real-time. This new protocol was thus termed 
Real-Time QuIC (RT-QuIC) [103, 104]. Figure 1.2 shows diagrammatic 
representation of the protein misfolding/aggregation in the QuIC assay, highlighting 
the tools used to detect the misfolded recPrP. Further developments have integrated 
an immunoprecipitation step using a PrPd-specific antibody (15B3) to isolate PrPd 
‘seeds’ prior to addition to the recPrP substrate. This step was introduced due to an 
unknown inhibitory factor within blood which acted to prevent seeded 






Figure 1.2 – RT-QuIC. Sample which may or may not contain misfolded prion protein is added to 
recPrP substrate. The reaction mixture undergoes cycles of intense shaking to break aggregates down 
followed by rest, whereby recPrP aggregates into fibrils which are detectable via ThT binding and 





The amino acid sequence and alterations within the Prnp gene have shed light on the 
regions of the protein critical for misfolding. Homology between PrPc and PrPd in the 
central region of the prion protein plays a critical role in determining whether a host 
is susceptible to disease [106, 107]. Similarly, there are a number of polymorphisms 
which confer resistance to prion disease, the archetypal example being the influence 
of Prnp polymorphisms on sheep scrapie [108-110]. In humans, a host of mutations 
in the PRNP gene are associated with onset of heredity prion diseases [111-117]. 
Post-translational processing of the prion protein may also play a significant role in 
protein folding. Three main areas of investigation are; (i) the disulphide bridge, (ii) 
glycosylation and (iii) the GPI-anchor. It was established that two cysteines in the C-
terminal globular domain of the prion protein were oxidised (i.e. were in a disulphide 
bond) [118]. This bond confers a strong influence upon ‘normal’ protein folding and 
stability. It was thus suggested that, during the conversion process, the disulphide 
bond is reduced, which leads to higher flexibility of the protein and potential 
unfolding of the α-helical structure(s). Upon re-oxidation of the cysteines (re-
forming the disulphide bond), the protein may take on a stable β-sheet-rich structure 
[119]. The mechanism enforcing reduction of the disulphide bond could be of critical 
importance when considering the mechanism of conversion. In contrast, other studies 
show that upon conversion from PrPc to PrPd, this bond is not broken down [120]. 
This highlights the need for further study to decipher the role of the disulphide bond 
in the conversion mechanism. 
 
Glycosylation and the GPI-anchor of the prion protein have been extensively studied. 
Glycosylation of the prion protein occurs at two sites [121] (figure 1.1). The state of 
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glycosylation has been shown to significantly affect the binding interactions of PrPc 
and PrPd [122]. A number of laboratories have generated gene-targeted mice lacking 
the specific glycosylation sites in vivo [123, 124]. These studies demonstrated that 
glycosylation is essential for the efficient and correct trafficking of the prion protein, 
as knock out (KO) of glycosylation sites results in uncharacteristic incubation 
periods and pathological targeting of well-defined and robust prion strains. Further 
study of PrP glycosylation-deficient mice demonstrated that upon infection with 
different prion strains the efficacy of infection is markedly influenced by the degree 
of glycosylation of the host PrPc [125]. It has been long established that the glycan 
structure binding the asparagine is highly variable in both PrPc and PrPd [126] and 
there is little understanding of the role that specific glycoforms could have within the 
mechanism of misfolding and progression of disease. 
 
The role of the GPI-anchor within the mechanism of conversion has been studied by 
gene-targeted deletion of the GPI-anchor site. GPI-/- transgenic mice express the 
prion protein but it cannot tether to the cell membrane and is thus secreted from cells. 
When the GPI-/- mice are experimentally infected with a prion disease, large 
accumulations of extracellular amyloid plaques are observed in the absence of overt 
neurodegeneration [127]. This highlights the requirement of PrPc expression on the 
cell surface for prion-associated neurodegeneration to occur. It is also important to 
note, however, these mice are also glycosylation deficient, therefore the results 




A number of other non-prion protein determinants have also been identified that 
contribute to the conversion mechanism. One such study added polyanionic 
compounds (e.g. RNA) to purified PrPc within the PMCA assay. Remarkably, in the 
absence of misfolded prion protein as a seed, de novo generation of PK-resistant PrP 
was observed. Moreover, when experimentally inoculated into mice, this de novo 
generated PrPres initiated a prion-like disease [128-130]. A further study has 
demonstrated high levels of infectivity as a result of amplifying recPrP in the 
presence of synthetic lipids and RNA purified from murine liver [131]. Notably, this 
suggests that the prion protein is capable of misfolding provided the conditions meet 
the minimal molecular requirements – critically, without the need for a misfolded 
prion protein template. It may be that in vivo, the molecular requirements for 
conversion are not readily reached and misfolded prion protein can act to lower this 
requirement for conversion. Despite determining, in vitro, what specific species of 
co-factors are minimally required for conversion, the identities of such entities in 
vivo represents a far more challenging prospect. Of course, understanding the 
localisation of the prion protein, and thus, what potential co-factors the prion protein 
will come into contact with is important. Some preliminary studies to identify co-
factors in vivo have identified that non-prion, proteinacious species co-purify with 
PrPd aggregates [132, 133]. More specifically, one study identified the Na+/K+-
ATPase protein as commonly co-purifying with scrapie associated fibrils extracted 
from infected murine scrapie brains and this appears to increase conversion 




1.1.6. Prion Diseases: Cell Biology of the Prion Protein 
After expression of the prion protein and post-translational modifications are added, 
the prion protein migrates to the cell surface, where it resides for the majority of its 
lifetime on the cell surface. Here it is found enriched in detergent-insoluble 
membranous fractions, termed lipid rafts [70]. The prion protein then moves out of 
these rafts and undergoes endocytosis, primarily by clathrin-mediated endocytosis 
[135], but other methods of re-entry have also been proposed [136]. A large fraction 
of the internalised prion protein is thus degraded by proteolytic processing. The 
remainder is thought to recycle back to the cell surface [137]. It is hypothesised that 
the most likely sites of conversion take place on the cell surface or within 
membranous intracellular compartments, such as endosomes. There are a number of 
studies which support this hypothesis [134, 138-141]. Recent studies detecting the 
trafficking of PrPd in neurons have shown similar cellular trafficking as identified 
with PrPc [142]. Figure 1.3 shows the normal intracellular trafficking of PrP and the 
hypothetical misfolding pathways within the cell. The majority of these studies have 
taken place within in vitro cell cultures or primary neuronal cultures. In spite of 
yielding a good understanding of the cellular processing of the prion protein within 
in vitro cell and primary cultures of neurons, the cellular processing of the prion 
protein in other cell types or in vivo is unknown. Certainly, in different 
microenvironments, unique co-factors may interact with the prion protein, 




Figure 1.3 - Cell biology of the prion protein. After transiting the ER and Golgi apparatus, the protein 
is secreted to the cell surface (A), where it resides in lipid rafts for the majority of time (B). The 
protein leaves the lipid rafts to undergo endocytosis (C). Both the cell surface and the endosomal 
pathway are the major candidates for prion protein misfolding. PrP is then either trafficked to the 
Golgi (D) where it is then shown to be trafficked to lysosomes for degradation (G), or migrates 
directly to lysosomes to be degraded (E) or recycled back to the cell surface (F). Grey cylinders 
represent PrPc whereas red cylinders represent PrPd. 
 
1.2. Other Chronic Neurodegenerative Diseases and the Prion Protein 
Similar to the key role that the prion protein appears to play in prion diseases, 
misfolded proteins are associated with a number of different chronic 
neurodegenerative diseases, which migrate between one neuroanatomical distinct 
region to another [143, 144]. Traditionally, prion diseases have been considered to be 
distinct from these other diseases, primarily due to the infectious nature of the prion. 
Recent advances show there is an increasing understanding of ‘prion-like’ spread of 
non-prion, disease-associated proteins in other chronic neurodegenerative diseases 
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[145-155]. Although no epidemiological evidence exists for the inter-individual 
transmission of other non-prion diseases, this data highlights that cell-to-cell 
transmission in a prion-like mechanism is a fundamental phenomenon shared 
amongst many, if not all, chronic neurodegenerative diseases associated with a  
misfolded protein [156]. 
 
Despite the diverse structural and etiological nature of disease-associated proteins, 
there are some consistencies and overlap between such diseases. For example, as 
discussed previously, the prion protein appears to readily misfold to a disease-
associated state both de novo and in the presence of a misfolded prion protein ‘seed’. 
The wealth of conformations that are hypothesised to occur are thought to give rise 
to strains, a concept mostly foreign in other chronic neurodegenerative diseases. A 
recent study however has shown the distinct groups of tau lesions aggregating within 
in vitro cultured neurons. These subsequently were inoculated into mice and 
produced distinct pathologies which were consistent across multiple inoculations in 
mice. The tau then reforms its original pathology when returned in vitro, showing the 
characteristics of the tau was not altered [157]. This study subsequently showed in 
vitro neurons exposed to human tissue exhibiting characteristically distinct tau-
lesions caused specific tau lesions in neurons, which were distinct between diseases 
[157]. Other studies have shown similar strain-like properties of non-prion misfolded 
proteins [158-162]. Some insights into the potential for strain establishment in other 
disease associated protein have also been hypothesised due to the structural diversity 




1.3. Prion Diseases as models for studying neurodegeneration 
Prion diseases manifest as fatal neurodegenerative diseases in a range of animals and 
are most commonly associated with the formation and aggregation of PrPd. The 
structure of PrPc and the post-translational modifications which contribute to 
conformational alterations of PrPc have been well characterised. However, due to the 
insolubility of PrPd, its precise structure remains unknown and this compromises the 
ability to assess the role that PrPd may play within the mechanism of 
neurodegeneration. Conversely, due to the infectious nature of prion diseases, 
experimental study of these diseases in vivo represents a significant advantage over 
other models of chronic neurodegeneration. For example, animals can be 
experimentally infected with a prion disease - this represents the ‘start-point’ of 
disease. Other neurodegenerative diseases typically rely on transgenic animal models 
which carry a human mutant form of the protein which is usually expressed at higher 
levels than the respective host gene. Furthermore the researcher cannot reliably 
elucidate the ‘start-point’ of disease since the transgene is expressed during 
development even in the prenatal period. In addition prion diseases are invariably 
fatal and exhibit predictable incubation periods of disease. Models of other 
neurodegenerative diseases usually only recapitulate limited components of human 
pathology, and often will not succumb to neuronal loss or death of the animal. As a 
result, the progression of pathology can be robustly and predictably dissected from 
start-point to death of the animal (see 1.4.3. Temporal pathological progression of 
prion disease). This highlights the benefit of using prion diseases as models for 




1.4. Mechanisms underlying neurodegeneration 
It is unclear what role misfolded PrP has within the mechanism of 
neurodegeneration. There are numerous avenues of study to elucidate this role. These 
include; (i) identifying what misfolded prion protein conformations are toxic to 
neurons, (ii) studying whether loss of PrPc function, as a result of its conversion to a 
misfolded isoform, plays a role and (iii) whether the mechanistic conversion of PrPc 
to misfolded prion protein compromises neuronal homeostasis.  
 
1.4.1. The role of PrP in neurodegeneration 
PrPc has a critical role within prion disease since PrPc deficient mice are resistant to 
prion disease [30, 31]. It is hypothesised that the conversion process of PrPc to 
misfolded isoforms and the presence and accumulation of aggregates are essential for 
neuronal loss. However, it remains unclear whether misfolded prion protein is 
directly toxic to neurons; whether the conversion of PrPc to misfolded isoforms 
compromises neuronal homeostasis or even if loss of PrPc function contributes to the 
toxic events associated with prion diseases. 
 
In order to answer whether PrPd would act as a direct toxic entity, Brandner et al. 
grafted PrPc-rich normal brain tissue into cerebral ventricles of mice which lacked 
the Prnp gene. Upon prion infection of these mice, the grafted tissue degenerated, 
however the host PrP-/- tissue remained unaffected. This was in spite of PrPd being 
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detectable within the PrP-/- host tissue [166]. This demonstrated that, in vivo, PrPd 
cannot act as a direct toxic entity to neurons in the absence of PrPc.  
 
Additionally, studies in GPI-anchorless mice show that when PrP cannot bind to the 
cell membrane the development of disease is substantially impacted. This indicates 
that PrP is required on the cell surface, or within intracellular membranous 
compartments, for prion-associated pathology to occur [127]. When GPI-anchorless 
PrP is overexpressed in mice, a spontaneous late-onset of neurodegeneration and 
eventual death of the animal is observed [167]. This suggests the PrPd generated in 
this model did exhibit some level of toxicity but this was perhaps impacted by the 
lack of PrPc on the cell surface and/or the inability of PrPd to bind to the cell surface 
and migrate into the cell. This highlights the importance to understand the 
intracellular and intercellular trafficking and processing of PrP in disease. 
 
Whether PrPd is directly toxic to neurons in the presence of host expressed PrPc is a 
critically unanswered question. This is a challenging concept to study but it would be 
assumed that PrPc on the cell membrane and in the presence of PrPd would result in 
the conformational rearrangement of PrP. This makes it impossible to discriminate 
between toxicity as a result of direct exposure of PrPd and toxicity as a result of the 
mechanistic conversion of PrPc to PrPd. Certainly, the location of conversion will 
play a critical role in any potential toxicity, as aforementioned, PrPd is not toxic to 
neurons in the extracellular space unless exposed at high levels [127, 167].  
Nevertheless, a study which can implicate or refute either of these concepts as the 
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toxic entities would be a substantial advancement in our understanding of the role 
that misfolded protein plays within the mechanism of neurodegeneration.  
 
In general, investigating toxicity of the misfolded protein has been challenging in 
vivo due to the diversity of PrP monomers and aggregates in prion infected animals. 
Many researchers use recPrP preparations which have been experimentally 
aggregated into oligomers, proto-fibrils and fibrils of differing sizes. A number of 
such studies have implicated small oligomeric protein species as highly neurotoxic 
within prion diseases and other neurodegenerative diseases [168-172]. As a result, 
there is a growing consensus that such oligomers disrupt cellular membranes, which 
result in a dysregulation of calcium levels within the cell [171-173]. How this occurs 
is unclear, however, some researchers suggest oligomers insert into the phospholipid 
bilayer of the cell membrane [174]. Alternatively, oligomers may form within the 
lipid bilayer [175]. As a consequence, the presence of oligomers in the membrane 
renders it relatively porous, thus affecting ionic homeostasis and consequently 
resulting in apoptosis of the cell. 
 
In contrast, when determining the toxicity of fibril aggregations in vitro some studies 
indicate that fibrils are not toxic to cells [171], whereas others have determined 
fibrils to be equally toxic as oligomers [170]. Another study also exposed cells to 
fragmented Aβ fibril structures which possess a high level of toxicity to cells and 
cause hyperphosphorylation of Tau in mice [176]. It is generally considered that 
fibrils represent the ‘end-point’ of the misfolding or aggregation pathway [51, 169] – 
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whereby monomeric PrPc is converted to PrPd. This consequently forms dimers and 
oligomers which develop into proto-fibrils. Finally, these aggregations form fibrils 
and in some cases, large amyloid plaques.  
 
Ultimately, there is an ongoing debate about the nature of the toxic proteinaceous 
species (reviewed by Haass and Selkoe [177]). As mentioned earlier, there are 
several studies demonstrating that levels of PrPd and neuronal loss are poorly 
correlated [28, 29, 39-41]. Nevertheless the underlying foundation that expression of 
PrPc is required for the pathological events associated with prion disease highlights 
the importance of PrP in neurodegeneration. 
 
1.4.2. Possible links between loss of PrPc function and neurodegeneration 
The understanding that PrPc is essential for pathogenesis and the current ambiguity 
regarding the role that misfolded prion protein has within neurodegeneration led to 
some theories that the loss of PrPc function may be toxic. It is clear that the loss of 
PrPc does not elicit the toxic effects observed within prion disease since mice lacking 
the prion protein gene develop normally [31, 178]. Subsequently, some subtle 
phenotypes were observed in these mice including abnormal morphology of 
mitochondria [179], defects in long term potentiation (LTP) [180, 181], an abnormal 
circadian rhythm [182] and age-related loss of myelin sheath surrounding peripheral 
neurons [183]. As a result, there are suggestions that the prion protein plays subtle 
roles in neuronal homeostasis and/or may exhibit some level of neuroprotection 
[184]. However, conditional knock-down of PrPc in neurons during prion disease 
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progression appears to protect neurons and demonstrate a recovery [185, 186]. 
Further studies have proven mice with conditional Prnp-/- in neurons will eventually 
die of a prion disease, but only after a significantly extended incubation period 
(Manson, personal communication). In this latter study, although neurons appear to 
be protected from the degenerative effects of the disease, it appears the astrocytes 
accumulate PrPd demonstrating a substantial shift in prion-pathology which 
eventually results in death of the mouse. 
 
Earlier studies generated mice devoid of murine-PrPc but which express hamster-PrPc 
only in astrocytes. Upon prion infection with 263K hamster scrapie, these mice 
exhibited a highly infectious, invariably fatal disease [187]. These studies show that 
PrPc expression is not required in neurons for disease to occur, and also show that 
astrocyte pathology may play a role in the disease process. This study also used mice 
which expressed hamster-PrPc on astrocytes alongside endogenously expressed 
murine-PrPc. Mice appeared to resist disease but accumulated PrPd, which when 
inoculated into WT hamsters and mice was capable of producing a prion disease in 
hamsters but not mice, and therefore retained its prion strain characteristics [187]. 
Thus, the mice accumulate hamster PrPd on murine astrocytes, but in the presence of 
murine-PrPc the animal was protected, suggesting PrPc acted as a protective entity. 
Indeed when considering how astrocytes interact with neurons within the tri-partite 
synapse and the fact that the synapse is amongst the earliest targets of pathogenesis 
(see 1.4.3. Temporal pathological progression of prion disease) – it is unsurprising 
that astrocyte pathogenesis could have such severe effects in the absence of direct 




1.4.3. Temporal pathological progression of prion disease 
An understanding of the pathophysiological progression of chronic 
neurodegenerative diseases is of critical importance for understanding how and why 
an abnormally folded protein may cause disease. In prion diseases, the pathological 
progression within the ME7 model of murine scrapie has been extensively 
characterised. Experimental infection of C57BL/6 mice with ME7 results in a 
consistent incubation period of approximately 24 weeks [188-193] (figure 1.4). The 
mice exhibit clinical symptoms of piloerection and urinary dysfunction – symptoms 
indicative of an autonomic nervous system failure. Mice also have a hunched posture 
with an abnormal gait – typically splayed hind legs. Autonomic neurons remain 
intact and appear ‘unaffected’ – despite numerous studies implicating this pathway as 
a probable route in the spread of infection from the periphery to the CNS [194-196]. 
Autonomic failure has been identified in a number of human prion diseases [197, 
198], but such phenotypes have been attributed to thalamic degeneration of the CNS 
rather than direct pathology of the neurons of the autonomic nervous system [199, 
200]. 
 
Neuronal loss in ME7/C57BL/6 animals is widespread across the CNS – including 
pyramidal neurons of the hippocampus. This is of significance as the hippocampus is 
central to cognitive function and loss of hippocampal neurons results in dementia, a 
key clinical feature in human prion diseases [201, 202]. The CA3 neurons of the 
hippocampus project axons along the Stratum Radiatum which synapse with 
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dendrites of CA1 neurons in this region - this is termed the Schaffer-Collateral 
pathway. Upon ME7 infection, synaptic deficits are observed early, typically 
identified by the loss of synaptic vesicle proteins, such as synaptophysin [189, 191, 
192]. Electron microscopy of the Stratum Radiatum at this time-point shows loss of 
synaptic vesicle integrity and a darkening of the presynaptic element [192]. Such 
pathological phenotypes suggest significant functional impairments of the synapse at 
early stages in disease. Indeed, further studies identified deficits in LTP of synapses 
in this region [203], findings which also temporally correlate with behavioural 
abnormalities in mice [188, 189]. Morphological changes including swelling and 
hypertrophy in pre-synaptic boutons has also been reported [204] (figure 1.4). These 
investigations demonstrate that synaptic degeneration is an early target of prion-
associated pathology. A schematic of behavioural and pathological (hippocampal) 




Figure 1.4 - Hippocampal pathology in the ME7/C57BL/6 murine model of prion disease. Total 
incubation period is around 24 weeks.  Initial detectable deposits of PrPd are identified around 8 
weeks of age which approximately coincides with the appearance of activated microglia and 
astrocytosis. Synaptic protein loss, electrophysiological deficits and hippocampal-dependent 
behavioural deficits are subsequently observed. Ultrastructure resolution images taken at EM then 
show morphological changes to the synapse. This coincides with a loss of perineuronal nets 
surrounding the GABAergic interneurons of the hippocampus and a hyperactivity behaviour observed 
in the open field test. Neuronal loss is observed substantially after synaptic degeneration in the CA1 
pyramidal neurons. All data in this figure is obtained from [188, 189, 191, 192]. 
 
Synapses are also highlighted as a critical target of pathology and for therapeutic 
intervention in a range of diseases (reviewed in [205-208]). It is unknown how 
misfolded protein can cause/contribute to synaptic degeneration. Synapses are rich in 
PrPc [209], however synaptic vesicles have been demonstrated to be almost 
completely devoid of PrPc [210]. Based on our understanding that PrPd is not directly 
toxic in the absence of PrPc [166], it may be argued that PrPd plays no direct toxic 
role on synaptic vesicles, which at early stages of disease are shown to undergo ultra-
structural abnormalities and synaptic vesicle protein loss [189, 191, 192]. Instead, 
synaptic vesicles may be affected as a result of upstream deficits, for example 
endoplasmic reticulum (ER) stress or loss of neuronal/synaptic activity. Studies by 
[29] 
 
Sudhof and colleagues in a transgenic model of neurodegeneration, by KO of CSPα, 
an important synaptic vesicle co-chaperone, demonstrate that CSPα KO leads to 
decreased SNAP25 levels. SNARE-complex assembly is consequently disrupted 
which is correlated with the neurodegenerative phenotype in this model [211]. This 
demonstrates that loss of synaptic function may therefore lead to neurodegeneration. 
It has also been suggested that neurons with higher metabolic/functional activity 
could play a role in defining the severity of synaptic degeneration. However, a recent 
study using Botulinum toxin to silence synapses has indicated that loss of activity in 
synapses does not result in the loss of the synapse. Therefore, alterations in synaptic 
activity as a result of disease may not contribute to the loss of synapses during 
disease [212]. 
 
Using other models of murine prion disease, Mallucci et al. have indicated that 
synaptic degeneration can be halted when PrPc is removed from the neuron during 
the progression of disease [186, 213]. This led to the amelioration of cognitive 
behavioural tasks, suggesting the mice somewhat adapt or even recover from the 
initial degenerative impacts of disease when PrPc is knocked out of neurons during 
disease progression. As mentioned above, other studies have demonstrated in a 
number of murine prion strains, mice which exhibit a conditional KO of PrP will 
eventually succumb to disease (Manson, personal communication). Therefore 
synaptic degeneration may play a critical role in driving early pathology possibly 





The post-synaptic density of the dendrites of neurons also represents an important 
early target of disease. Numerous studies implicate dendritic spine loss/abnormalities 
as amongst the earliest morphological changes of affected neurons [214, 215]. It is 
also found at the electron microscopic level that the post-synaptic density curves 
around degenerating pre-synaptic elements [192]. What part of the synapse is 
targeted initially is an interesting debate and could deliver a vital understanding in 
the role of misfolded prion protein in synaptic degeneration. Previous conflicting 
studies have been performed in different regions of the brain in different prion 
models. The route of infection, the area of study and the dose of infection are all 
variable factors in these studies. One investigation assessed neurons in the cortex of 
mice and found the dendrites, and more specifically the post-synaptic densities are 
the initial targets of neuronal degeneration [215]. Similarly, it was also shown that 
dendritic spine loss was an early pathological alteration [214], however this study did 
not address the pre-synapse. Furthermore, functional abnormalities associated with 
deficits of the post-synaptic density have been implicated as early markers of disease 
[216]. In contrast, a number of studies assessing synapses of the Schaffer-Collateral 
pathway show presynaptic degeneration preceding post-synaptic deficits [186, 189, 
191, 192, 217].  
 
Studies by Booth et al. have generated whole genome transcriptional profiles from 
cell bodies of the CA1 pyramidal neurons of the hippocampus [218]. These neurons 
are eventually lost as a result of disease and are the origin of the dendritic spine 
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projections which form post-synaptic densities with the axons of CA3 neurons. Such 
an approach identified a number of previously unidentified mRNAs and miRNAs 
being up- or down-regulated as the result of disease. At the earliest stages of disease 
there was a striking down-regulation of genes associated with synaptic structure and 
function, which correlates with previous findings of a loss of synapse-associated 
proteins [189, 191]. A number of ryanodine receptors and genes associated with 
calcium binding were also down-regulated. This is a notable finding when comparing 
to in vitro studies which suggest oligomeric aggregates of prions could affect 
calcium regulation of cells and therefore impact upon neuronal homeostasis [171-
175], such as activation of the endoplasmic reticulum (ER) stress pathways. 
Dysregulation of calcium signalling and/or the accumulation of misfolded proteins 
are capable of initiating the Unfolded Protein Response (UPR) which acts to restore 
ER homeostasis [219]. In the instance that ER homeostasis does not return, the cell 
up-regulates apoptotic pathways [220]. In prion diseases, it has been shown that ER 
stress-associated pathways may be induced [218, 221-227]. It is important to note 
that the specific ER stress pathways highlighted by Moreno et al.[225] do not show 
any observable alteration in gene expression profile in a number of microarray 
studies of prion diseases [218, 228-230]. Moreno et al. however demonstrate that 
inhibition of critical proteins in the pathways involved in translation [225, 226] or 
dephosphorylation [222] have been shown to ameliorate neurodegeneration. How the 
misfolded prion protein could cause such a phenotype is of significance for 
understanding the role that it plays in neurodegeneration. It is suggested that 
misfolded prion protein comes into contact with bip-proteins on the surface of the 
ER. This then initiates the protein kinase-like endoplasmic reticulum kinase (PERK)-
[32] 
 
signalling pathway which eventually results in the repression of translation [225]. 
When considering the cellular biology of WT mice (see 1.1.6. Prion Diseases: the 
cell biology of the prion protein), the prion protein is predominantly located either on 
the cell surface or within recycling endosomes. Therefore, it is unlikely that disease-
associated misfolded proteins readily come into direct contact with bip-proteins on 
the surface of the ER. The cellular dysregulation of calcium as a result of oligomer 
attachment/formation on the cell surface represents a far more likely, upstream, role 
that misfolded protein has upon induction of ER stress. Moreno et al. have indicated 
that PrPd interactions specifically with bip-proteins are activating only the PERK 
pathway; however there are certain caveats of this work that must be considered. 
Namely, the PERK pathway has been demonstrated to be activated as a result of 
Bip/Grp78 induction within mice overexpressing the prion protein by three-times the 
level of WT mice. It has been shown previously, mice overexpressing the prion 
protein exhibit an irregular distribution of the prion protein, including in the cytosol 
and mitochondria [210]. Therefore, prion infection in mice overexpressing PrPc is 
likely to result in significant accumulations of misfolded prion protein in the cytosol, 
which perhaps does not represent the distribution of misfolded isoforms in WT 
animal or human prion diseases. Indeed it has been shown that the PERK pathway is 
not up-regulated in human prion disease patients [231]. In this study, mice showed 
subtle up-regulation of this pathway, but this does not appear to correlate with the 
severity of disease [231]. Activation of the PERK pathway is thus likely a 
contributing factor rather than integral driver of disease [231, 232]. Other studies 
have indicated the activation of phosphatases, such as calcineurin as drivers of 
pathological phenotypes associated with prion diseases [222]. For example, 
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dysregulation of calcium in cells leads to disruption of the calcium/calmodulin 
complex which in turn can lead to the hyperactivation of calcineurin [233]. 
Hyperactive calcineurin has been previously shown to reduce the phosphorylation of 
the apoptosis inducer BAD [234] which leads to the dissociation of BAD from the 
14-3-3 protein scaffold and leads to the interaction of BAD with the Bcl-2 family of 
proteins in the mitochondria. Ultimately cytochrome C is released into the cytosol 
which leads to caspase pathway activation and apoptosis [234]. Hyperactivation of 
calcineurin also leads to the dephosphorylation of the transcription factor CREB, 
which is known to transcriptionally regulate a number of synaptic proteins, including 
synapsin-1 [235, 236], which are critically affected in prion diseases [189, 191, 218]. 
Inhibition of calcineurin within prion disease has been demonstrated to ameliorate 
disease phenotypes at the clinical stage of disease [222]. The effects of 
hyperactivation of calcineurin are insufficiently explored as this protein is known to 
regulate a number of critical cellular functions, such as; the ATF3 and NFAP 
transcription factors; calcium channels, such as Inositol 1,4,5-triphosphate and 
ryanodine receptors; and GABA and glutamate receptors. In addition, a relatively 
unexplored function of hyperactive calcineurin is the disinhibition of Protein 
Phosphatase 1 (PP1). PP1 is expressed throughout the CNS and plays a significant 
role in many CNS functions as a serine/threonine phosphatase. The hyperactivation 
of calcineurin therefore may play an important role in neurodegeneration. It is 
important to note, however, that further work is required as a number of CREB-
regulated proteins are found up-regulated in a transcriptional array analysis on the 
CA1 neurons of the hippocampus discussed earlier [218]. This suggests other 
[34] 
 
processes may also be activated which combat the effects of calcineurin 
hyperactivation. 
 
In addition to synaptic deficits/loss, a significant loss of perineuronal nets 
surrounding GABA-ergic interneurons of the hippocampus has also been identified 
at early stages of disease [237]. Furthermore, recent studies have temporally and 
spatially dissected different gross morphological, disease-associated changes in 
different neuronal populations in the brain [238]. These data suggest that distinct 
neuronal populations may undergo neurodegeneration in unique patterns – a result 
that may indicate different mechanisms of neurodegeneration in different regions of 
the brain. Thus, although synapses may represent a critical early target within prion 
disease, the pathological targeting is not restricted to the synapse.  
 
A recent study on human prion patients demonstrated severe thalamic pathology in 
the absence of detectable PrPd deposition in the thalamus. Instead, PrPd was detected 
in the somatosensory cortex of these patients [239], which is well established to be 
connected to the degenerating thalamic neurons in these patients [240, 241]. A likely 
explanation is the PrPd-targeting of neurons in the cortex resulted in pathology in 
both the cortex and in interconnected regions. The spatial and temporal distribution 




In the ME7 model of murine scrapie, the distribution of PrPd has been extensively 
mapped within the hippocampus. Initial detectable deposits of PrPd accumulate 
within the hilus of the dentate gyrus and subsequently spread to encompass the CA3 
pyramidal cell layer. This suggests the spread of PrPd along the Mossy-Fibre 
pathway. As discussed earlier, the pre-synaptic components of the CA3 projections 
along the Schaffer-Collateral pathway degenerate, and this pathology correlates with 
the apparent spread of PrPd to the CA1 region [188, 189, 191]. However, different 
prion disease models exhibit different spatial and temporal distributions of misfolded 
protein, and some models do not appear to correlate with misfolded prion protein. 
For example, in models which exhibit a highly infectious prion disease with 
vacuolation in the presence of little or no detectable PrPd [28, 39, 41]. Within these 
models, only vacuolation pathology has been assessed to determine degeneration. 
Further studies will therefore be required to study the correlation of misfolded prion 
protein with neurodegenerative phenotypes, such as neuronal loss or synaptic protein 
loss. Additionally, time-course studies have not been performed to dissect out the 
earliest pathological events. This would be essential to establish whether the 
appearance and accumulation of misfolded prion protein does or does not correlate 
with neurodegeneration. 
 
1.4.4. Astrocytes and prion disease 
Astrocytes are an abundant glial cell type in the CNS and are crucial regulators of 
CNS development, function and health. Astrocytes are morphologically categorised 
into two forms; protoplasmic and fibrous. Protoplasmic astrocytes are typically 
localised to grey matter regions of the CNS and exhibit a small cell body and 
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numerous fine processes which make contact with synapses to form the tri-partite 
synapse [242] and have specific ‘end-feet’ structures abutting the cerebral  
endothelial cells forming part of the blood-brain barrier (BBB). Fibrous astrocytes 
on the other hand are predominantly found in white matter regions of the CNS and 
have long, thin fibre-like processes. It is unclear whether different morphological 
categories of astrocytes produce different functions. 
 
As mentioned above, astrocytes have a role in a number of critical functions in the 
CNS, including CNS development, BBB formation and maintenance, 
synaptogenesis, neurotransmission and metabolic regulation  (reviewed in [243-
245]). Astrocytes are exquisitely sensitive to changes in homeostasis and injury to 
the CNS and undergo a complex response, morphologically characterised by 
hypertrophy of the cell body and shortening/thickening of processes [246, 247]. Glial 
Fibrillary Acidic Protein (GFAP), an intermediate filament protein, also exhibits 
significant up-regulation which mediates the substantial morphological changes 
observed in astrocytes [248]. Therefore GFAP is typically utilised as a marker of 
astrocyte responses to changes in CNS homeostasis/injury.  
 
The specific stimuli driving astrocyte responses can range from degenerating axons 
and their dying terminals [249], BBB breakdown [250, 251], cytokines [252], 
changes in neuronal homeostasis [253-255], overexposure to purines, such as ATP 
[256], reactive oxygen species, such as Nitric Oxide [257], hypoxia and glucose 
deprivation [258] and misfolded proteins [259]. In prion diseases, astrogliosis is a 
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well-documented pathological response in humans [260, 261] and other animals 
[189, 262]; however what stimulates the astrocytic response, or how the astrocytic 
response impacts disease progression is unknown. During disease, it has been 
reported that PrPd accumulates in the astrocyte [263] and therefore it could be argued 
that astrocyte dysfunction during disease could potentially contribute to or drive 
neurodegeneration as a result of loss of astrocytic function. Genetic KO of GFAP 
does not impact upon prion disease progression [264]. Whether GFAP plays an 
important role in reactive astrocytes is unknown, but further studies are required to 
address whether functional deficits of the astrocyte contribute to disease. 
 
During prion disease, astrogliosis is observed prior to functional synaptic deficits and 
concurrently with the appearance of detectable PrPd [189]. These observations 
indicate that astrocytes are more likely responding to the presence of misfolded 
protein than the functional deficits of synapses. More work is required, however, to 
establish the true relationship between astrocytes, PrPd and neurodegeneration. 
Nevertheless, by mapping the response of the astrocyte, using GFAP as a marker, 
early events of pathology can be elucidated prior to the appearance of 
neurodegenerative features. 
 
1.4.5. Microglia and prion disease 
Microglial cells are the predominant resident macrophage of the CNS parenchyma. 
These cells are constantly monitoring their local microenvironment and can rapidly 
respond to neuronal signals and damage [265]. For example, one study created 
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highly focal cortical lesions using a laser and visualised microglia directing their 
processes towards the site of damage [266]. At a structural level, microglia have a 
highly plastic morphology. Within a ‘healthy’ CNS, microglia exhibit a ramified 
morphology, typically consisting of a small cell body with long thin processes. Upon 
exposure to CNS injury, foreign material and/or changes in CNS homeostasis the 
microglia undergo substantial structural and morphological alterations, typically 
exhibiting a hypertrophied cell body and short, thick processes.  
 
Microglia have recently been implicated to have a role in synaptic phagocytosis [267, 
268] and function [269-271]. Such studies have led to the proposition of a ‘quad-
partite synapse’ with microglia constantly surveying the synaptic and astrocytic 
connections of the tri-partite synapse [272]. During neurodegenerative disease, 
however, the true role microglia play remains unknown. A review by Block et al. 
hypothesise that microglia could have a neurotoxic role in neurodegeneration [273]. 
This is thought to be due to a potential release of pro-inflammatory cytokines, 
reactive oxygen species, proteases and complement proteins. However, others 
suggest microglia could play a neuroprotective role [274]. Ultimately, whether a pro- 
(or anti-) inflammatory, response would act as a protective or toxic entity within 
chronic neurodegenerative diseases is unclear. Recent advances in our understanding 
of microglial function, notably with synapses, would indicate that changes in 




During prion disease, a remarkable activated morphological response by microglia is 
observed. This morphological response does not appear to be solely associated with a 
pro-inflammatory response [275]. Instead, a concurrent anti-inflammatory response, 
driven by TGFβ-1 appears in the CNS as a result of ongoing pathology [275, 276]. 
Further studies exposed prion-infected mice peripherally with the bacterial 
endotoxin, lipopolysaccharide (LPS), at focal time-points to induce a systemic 
inflammatory event during the prion disease incubation. Following exposure to LPS, 
a rapid systemic pro-inflammatory response is observed, initially by increases in IL-
1β [190, 277]. Further, systemic inflammation induced with bacterial (LPS) or viral 
(poly I:C) mimetics were demonstrated to impact upon the progression of disease 
[278, 279]. This data indicates that a switch in the innate immune response, which is 
likely driven primarily by microglial activation, may play a substantial role in 
disease. Recent studies have shown that the local proliferation of microglia in prion 
disease has a detrimental effect on disease severity as by reducing the numbers of 
microglia present in the CNS by inhibiting cellular proliferation the prion disease 
incubation period increases [280]. 
  
Whether microglia respond to PrPd or neurodegeneration is unclear. Morphological 
microglial activation is observed prior to the earliest behavioural and 
neuropathological events, and concurrently with appearance of PrPd. As a result, 
many studies use proteins that are solely expressed within microglia in the CNS, 
such as Allograft Inflammatory Factor 1 (AIF1 or Iba1), as markers of activated 




1.4.6. Spread of PrPd via neuroanatomical connections 
Spread of pathological lesions in neurodegenerative diseases is a precise and 
predictable process which appears in a pattern resembling neuronal connectivity 
[281]. In AD and PD, the spread and distribution of specific pathological lesions has 
been mapped extensively [143, 144]. It is well established that the infectious and 
toxic agent(s) of prion disease are capable of spreading via neurons. This was 
originally demonstrated using the extensive anatomical understanding of the visual 
pathway in mice. Around 90% of axons from retinal ganglion cells to the superior 
colliculus send projections to the contralateral hemisphere of the brain [282]. Prion-
infected brain homogenate was injected into one eye of mice and both the 
propagation of infectivity and the pathological lesions were initially observed in the 
contralateral superior colliculus [283]. Microglial activation and an increased T-
lymphocyte infiltration has further been described as the earliest pathology in the 
contralateral superior colliculus using the same approach [284]. This demonstrated 
that the infectious and toxic agent(s) of prion disease had spread specifically via the 
neuron. It has also been shown that PrP is capable of migrating throughout the CNS 
and PNS via fast axonal transport [285]. 
 
A number of studies have presented convincing evidence of a “prion-like” 
propagation mechanism associated with a number of different non-prion disease-
associated proteins, such as Aβ [146, 286, 287], Tau [161, 288, 289], α-synuclein 
[290-292] and others [154, 293]. Minute quantities of misfolded Tau fibrils in one 
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study has been shown to be sufficient to induce the propagation of further misfolded 
Tau species, suggesting a self-perpetuating template-conversion mechanism [153]. In 
vivo, the injection of inoculums known to contain protein aggregates have 
demonstrated the spread of protein aggregates from the site of injection to neuro-
anatomically connected regions of the brain [161, 286, 288, 290-292]. 
  
Defining the correlation of misfolded proteins with neurodegeneration and the 
mechanism of spread is therefore of critical importance for understanding the role 
that the misfolded protein may have within neurodegeneration.  
 
1.5. Thesis aims and outline 
The correlation between detectable misfolded prion protein and neurodegeneration 
remains unclear. For example, it is known that PrPd species can accumulate without 
any observable neurodegeneration [40]. This highlights the need to understand the 
relationship between spread and distribution of misfolded prion protein, the 
mechanism by which this spread occurs and neurodegeneration. This study will use a 
highly infectious animal model of prion disease, GSS/101LL, which has been 
previously demonstrated to accumulate extremely small quantities of detectable PrPd 
[28, 41]. Whether the detectable PrPd in this model is solely the required entity for 
neurodegeneration to occur is therefore important to answer. The aim of this thesis is 
to test the correlation between the small quantities of PrPd detected in GSS/101LL 
animals and neurodegeneration. If the correlation is upheld, further studies will aim 
to understand the mechanism that PrPd utilises to migrate between specific regions of 
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the CNS and how such mechanism relate to neurodegeneration. Demonstration that 
PrPd and neurodegeneration do not correlate however, draws a question mark over 
current detection methods for the toxic agent within prion diseases. 
 
The content of this thesis will be split into four results chapters (chapters 3, 4, 5 and 
6). Chapter 3 tests a number of pathological phenotypes in GSS/101LL mice at 
clinical onset of disease to evaluate whether such observations correlate with the 
detection of PrPd. The major finding in this chapter was the detection of larger 
quantities of PrPd comparative to previous publications using this model. The 
predominant species of PrPd detected were mostly sensitive to proteinase K digestion 
(PrPsen), as determined by Western blot analysis and correlate with 
neurodegeneration. Other PrPd isoforms were also detected, such as PrPres, but these 
did not correlate with neurodegeneration. 
 
Chapter 4 thus uses a time-course study to further test the correlation of IHC 
detectable PrPd and neurodegeneration and the temporal and spatial spread of PrPd 
between one neuroanatomical distinct region to another. PrPd is initially detected 
associated with specific neurons of the midbrain, such as the interpeduncular nuclei 
and substantia nigra, pars compacta. This is followed by microglial activation and 
astrocytosis. Spread of PrPd is observed correlating with pathological spread in a 




Chapter 5 uses the QuIC assay to detect the presence of prion seeds within 
GSS/101LL brain regions. A widespread distribution of prion seeds was observed in 
both regions undergoing neurodegeneration and regions which appear pathologically 
“unaffected”. This data represents a critical dissociation between IHC detectable 
PrPd, prion seeds and neurodegeneration. Therefore it is predicted that understanding 
the host response to prion seeds will elucidate how some regions of the brain remain 
resilient to neurodegeneration whilst others are susceptible. 
 
Chapter 6 uses microarray as a tool to characterise the host transcription profile of 
regions undergoing neurodegeneration and regions which appear unaffected. A 
mixed pro- and anti-inflammatory response is found to predominate in regions 
undergoing neurodegeneration. Stress responses were observed across all regions of 
the brain tested, suggesting prion seeds are potentially detrimental, however this 
response was not sufficient to trigger neurodegeneration. An additional group of 
genes, predicated to be microglial-specific, were observed down-regulated across all 
regions of the brain. 
 
Chapter 7 discusses the correlation of misfolded prion protein and neurodegeneration 
and the paradoxical lack of correlation between prion seeds, PrPd and 
neurodegeneration. Finally, based on the host response to prion seeds across all brain 
regions tested and the specific innate immune response restricted to regions of 
neurodegeneration, a “multi-hit” hypothesis will be proposed, whereby prion seeds, 
alone, are not sufficient to trigger neurodegeneration, instead two or more factors 
[44] 
 



















2. Materials & Methods 
 
2.1. Ethics statement 
All experiments were approved by the Roslin Institute Ethical Review committee and 
in accordance with the United Kingdom Home Office Regulations [Animals 
(Scientific Procedures) Act of 1986]. Ethical consent for the use of human materials 
for research was obtained and approved by the Lothian National Health Service 
Board Research Ethics Committee (reference: 2000/4/157). 
 
2.2. Animal husbandry 
The “101LL” transgenic mouse line contains an amino acid alteration from Proline to 
Leucine at codon 101 of the 129/Ola (129/OlaHsd, Harlan, UK) murine prion gene 
by gene-targeting [28]. 129/Ola mice homozygous for the targeted allele were 
crossed and bred over multiple generations to generate progeny homozygous for the 
PrnpL101L (101LL) allele which can be used for experimental purposes. All mice 
were bred at the Roslin Institute in derogated containment level 3 (CL3) conditions, 
according to Advisory Committee to Dangerous Pathogens (ACDP) guidelines and 
under a temperature controlled, 12 hour light/12 hour dark cycle. Mice were housed 
with wood-chip bedding and a wood chew stick for environmental enrichment. Food 




All experiments henceforth are performed under derogated CL3 conditions according 
to ACDP guidelines, with exception of work not using animal material or using 
ME7/C57BL/6, 87V/VM or 263K in Syrian hamsters, which are performed at 
containment level 2 (CL2) according to ACDP guidelines. 
 
2.3. 101LL genotyping 
  
2.3.1. DNA extraction 
To confirm the presence of the targeted allele alteration, mice were genotyped before 
and after studies. Prior to inoculation of animals, DNA extraction was performed 
using DNeasy Blood and Tissue kit (Qiagen) on ear clips. After the study, DNA 
extraction was performed by lysing tail tissue (10mM Tris-HCl pH 7.6, 10mM 
EDTA, 0.5% sarcosyl, 10mM NaCl and 100µg/mL PK) overnight at 37°C. Phenol 
was then added, followed by chloroform (1:1) and DNA was precipitated with 
isopropanol and pellet resuspended in nuclease-free water at 4°C until use. 
 
2.3.2. PCR analysis 
Presence of the 101LL mutation was determined by PCR analysis using primers 
specific for positions 107-130 and 871-848 of the prion protein gene; the 5’ primer 
used was (5’-ATGGCGAACCTTGGCTACTGGCTG–3’; DDBJ/EMBL/GenBank 
accession number M18070) and the 3’ primer used was (5’–
TCATCCCACGATCAGGAAGATGAG–3’; DDBJ/EMBL/GenBank accession 
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number M18070). PCR was set up using a Type-it mutation detection kit (Qiagen) 
with 2μL extracted DNA added to the provided master-mix. PCR cycle conditions 
were: 94°C for 3 minutes, followed by 30 cycles of 94ºC for 30 seconds, 62ºC for 30 
seconds, 72ºC for 1 minute. A final extension phase of 72ºC for 10 minutes was 
performed and samples were subsequently stored at 4ºC. The induced alteration of 
proline to leucine in 101LL mice forms a DdeI restriction enzyme cut site, which 
allows for identification of 101LL homozygous mice. The PCR product was 
incubated for 3 hours at 37°C with DdeI restriction enzyme (Promega) before being 
run on a 1.5% agarose gel (Invitrogen) for 1 hour 30 minutes at 125V prior to 
imaging. 
 
2.4. Prion disease inoculum and challenge 
Human frontal cortex brain material (Tissue ID: RU13/2006), which was 
pathologically identified as positive GSS carrying the PRNPL102L mutation, was 
obtained from the CJD Brain and Tissue Bank (Edinburgh Brain and Tissue Banks). 
The GSS brain tissue was obtained from a snap frozen half brain, therefore it is not 
possible to define the precise region of the frontal cortex that was dissected. 
However, in clinical cases of GSS, the cortex suffers from a heavy burden of 
misfolded prion protein, in the form of diffuse and amyloid plaque staining [294]. 
The tissue was homogenised in 0.9% sterile saline (Martindale Pharmaceuticals) to a 
10% (w/v) homogenate, aliquots made and stored at -80°C until used. The 
homogenate was checked for sterility prior to inoculation by spreading an aliquot of 
the homogenate on blood agar cultures and incubating both at aerobic and anaerobic 
conditions at 37°C for 7 days. No visible growth was observed confirming the 
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sterility of the tissue for inoculation. The 10% GSS brain homogenate was then 
further diluted 1:10 in 0.9% sterile saline and 101LL mice were injected 
intracerebrally (i.c.) into the right hemisphere with 20μL of 1% homogenate under 
anaesthesia. Animals were monitored and any that did not recover were culled 
(Home Office Schedule 1) and excluded from experimental analysis.  Due to the 
difficulty in obtaining uninfected human tissue as a negative control, an i.c. injection 
of 20μL uninfected hamster normal brain homogenate (NBH) (1% w/v in saline) was 
performed instead. These form the GSS/101LL and NBH/101LL groups respectively, 
which hereafter will be referred to throughout the text. All animals were aged-
matched and were injected between 10-14 weeks of age.  
 
2.4.1. TSE clinical scoring 
All animals were assessed daily from approximately 100 days post inoculation (dpi) 
by an independent researcher to this study using parameters that have been 
previously described [295]. At latter stages of the disease incubation period, mice 
were found to exhibit clinical symptoms of ataxia and symptoms typical of an 
autonomic failure, such as piloerection and weak bladder control. Other causes of 
death were defined as intercurrent and therefore animals were excluded from the 
study. A time-course analysis was set up in this study, ranging from 150dpi (n=24), 
200dpi (n=24), 220dpi (n=12), 240dpi (n=12) and upon clinical symptoms of disease 
(n=24) (figure 4.1). The groups of animals at each time-point were halved, and 12 (or 
6 for groups of 12) 101LL animals were inoculated with 1% GSS inoculum and 12 
(or 6 for groups of 12) 101LL animals were inoculated with 1% NBH inoculum. All 
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mice were killed by CO2 asphyxiation according to Schedule 1 of the [Animals 
(Scientific Procedures) Act of 1968]. 
 
2.5. Preparation of brain tissue for pathological analysis 
The brains of 101LL mice were removed and halved along the midline between the 
right and left brain hemispheres. The left hemisphere was flash frozen in liquid 
nitrogen and stored at -80°C for later use. The right hemisphere, which contains the 
injection site, was immersion fixed in 10% formaline saline for 48 hours, before 
being exposed to 98% formic acid for 90 minutes to minimise the infectious titre of 
the sample. The tissue was subsequently re-washed in 10% formaline saline for at 
least 24 hours to remove residual formic acid. The tissue was cut into five coronal 
sections for vacuolation scoring (figure 2.1) [296] which encompasses nine gray 
matter (GM) regions (medulla, cerebellum, superior colliculus, hypothalamus, 
thalamus, hippocampus, septum, retrospinal cortex, cingulate and motor cortex) and 
three white matter (WM) regions (cerebellar peduncle (CP), decussation of superior 
CP, basal cerebral peduncle). Tissue was then paraffin-embedded. Haematoxylin and 
eosin (H&E) staining of 6μm sections were taken for vacuolation (spongiform) 
severity scoring, scoring was performed on a scale of 1 to 5 for GM and 1-3 for WM 
[296]. Vacuolation scoring was performed blind by a researcher independent to this 
study. For further pathological analysis, serial 10μm sections were cut through the 
brain to encapsulate regions outlined in figure 2.1.  
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Figure 2.1 - Schematic of mouse brain viewed at sagittal plane of section. Black dashed lines 
represent each cut made when processing the brain, according to the parameters outlined in [296]. 
Grey scale areas surrounding dashed lines highlight the approximate areas of serial section performed 
for pathological analysis. *note* diagram and Bregma coordinates are an approximation. 
 
2.6. Immunohistochemistry 
Paraffin-embedded tissue was dewaxed by immersing in xylene and re-hydrated 
through a series of decreasing alcohol concentrations at room temperature. For PrP 
immunostaining, the slides was either immersed in distilled water (dH2O), according 
to previously published protocols [41], or citric buffer (0.1M citric acid, 0.1M 
Sodium Citrate, pH 6.4) and autoclaved at 121°C for 15 minutes. Slides were then 
cooled in running water for 5 minutes before immersing in 98% formic acid for 10 
minutes. Subsequently slides were thoroughly washed in running water for 20 
minutes. To block for endogenous peroxidase, slides were immersed in 1% 
H2O2/methanol before washing in running water for 5 minutes followed by PBS/1% 
BSA wash buffer for 5 minutes. Sections were subsequently incubated with Normal 
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Goat Serum (Stratech) for 20 minutes before application of either BH1 ([297] used at 
0.02µg/mL) or 6H4 (Prionics used at 3µg/mL) anti-prion protein antibodies. The 
primary antibodies were incubated overnight before washing with PBS/1% BSA 
wash buffer. Goat anti-mouse secondary antibody (Jackson ImmunoResearch) was 
applied for 1 hour at room temperature, washed with PBS/1% BSA and Vector ABC 
Elite kit (Vector Laboratories) was applied for 30 minutes then washed. Peroxidase 
activity was visualised using diaminobenzidine (DAB):H2O2 and slides were 
counterstained in Harris’ haematoxylin. 
 
For the immunohistochemical detection of other proteins, sections were either given 
no antigen-retrieval step (e.g. GFAP) or immersed in citric buffer (pH 6.0) and 
autoclaved for 15 minutes at 121°C. The protocol replicated that of prion protein 
detection, with exception of 10 minute incubation in 98% formic acid. All antibodies 
used in this study are shown in table 2.1. 
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Table 2.1 – All primary antibodies used in this study and the methods and concentrations each was 
used at 
 
2.7. Cell counts 
To interpret neuronal cell loss in GSS/101LL animals throughout the disease 
incubation, ten serial sections from three GSS/101LL and three NBH/101LL mice at 
each time-point (150dpi, 200dpi, 220dpi, 240dpi and clinical stage pathology (see 
figure 4.1 for details) were used. These encompass neuronal populations from two 
anatomically distinct brain regions; the gigantocellular reticular (Gi) nucleus of the 
brain stem and the retrosplenial granular cortex (RSGc). These regions represent the 
cell counts of figure 3.3 and were performed at approximately Bregma -6mm (brain 




Images of Gi nuclei were taken at x20 magnification using a Nikon E800 bright-field 
microscope. To ensure minimal variability in cell counts between sections, the 
midline below the medial longitudinal fasciculus (mlf) and the 4th ventricle was used 
as a landmark with the image adjacent to the midline. An example of MAP2 IHC 
staining of an uninfected murine brain stem [Bregma -6.1mm] is given in figure 
2.2A. This demonstrates the approximate area of cell counting performed. In some 
animals, sections were omitted from the study due to tissue damage and adjacent 
sections were used. In these instances, the raphe obscurus nucleus (ROb) was present 
along the midline [Bregma -6.25mm] but does not compromise the standard 
parameters set out here.  
Figure 2.2 – immunohistochemical staining of (A) brain stem [Bregma -6.1mm) and (B) cortex 
[Bregma -1.8] using anti-MAP2 antibody. White boxes represent area where cell counts were 




Similarly images of the RSGc were taken at x20 magnification. Due to the proximity 
of this cell population to the midline and the corpus callosum, these were used as 
landmarks to minimise variability in cell counts between sections. Each section was 
stained with anti-MAP2 antibody and counterstained with haematoxylin to allow 
visualisation of neurons. Cell counts were performed on layer III of the RSGc. Figure 
2.2B shows an example of uninfected murine cortex [Bregma -1.8] stained with anti-
MAP2 antibody, highlighting the area of cell counting performed. 
 
Counts of Iba1 positive cells which identify microglial cells were performed in 
clinical stage mice in the substantia nigra, pars compacta (SNc) and substantia nigra, 
pars reticularis (SNr). To do this, five serial sections from three GSS/101LL animals 
and three NBH/101LL animals taken from 200dpi group at approximately Bregma -
3.5mm. Slides were stained with Iba1 and images taken at x20 magnification using 
the medial lemniscus as a landmark to minimise variability in cell counts between 
sections. Cells positive for Iba1 were counted regardless of cellular morphology.  
 
All quantification was performed by the researcher, but sections were blinded using 
only mouse reference numbers to discriminate between sections. Furthermore, during 
disease, tissue atrophy may occur due to cell loss – therefore the overall tissue size 





2.7. Biochemical analysis of brain material; Western blot 
The flash frozen tissue was dissected in artificial cerebrospinal fluid (CSF; 125mM 
NaCl, 26mM NaHCO3, 25mM Glucose, 2.5mM KCl, 1.25mM NaH2PO4, 1mM 
CaCl2, 4mM MgCl2) into broadly four anatomically distinct brain regions (brain 
stem, cerebellum, thalamus and cortex) (figure 2.3). As highlighted, the term ‘brain 
stem’ refers only to tissue obtained between the coordinates Bregma -6mm to 
Bregma -8mm. Due to the distinctive tissue morphology of the cerebellum, the brain 
stem and cerebellar can be defined easily. Similarly, the cortex sample refers only to 
mouse brain coordinates Bregma -1mm to Bregma -3mm. For simplicity, each region 
herein will be referred to as brain stem, cerebellum, thalamus and cortex.  
Figure 2.3 - Schematic of mouse brain viewed at sagittal plane of section. Highlighted areas represent 





2.7.1. Total protein measurement 
The total protein was assessed for each sample used for Western blot using a 
bicinchoninic acid assay (BCA; Pierce). This uses bicinchoninic acid to detect the 
reduction of copper ions which typically occurs in the presence of proteins. A 
standard protein curve was created using known protein concentrations of bovine 
serum albumin (BSA) diluted in the same buffer as the samples ranging between 20-
2000μg/mL. The experimental homogenate samples were diluted to give a 1:10 (1% 
of the tissue mass w/v) dH2O and a 1:100 (0.1% of the tissue mass w/v) before 
addition of the copper/BCA solution. The resultant change in spectrometric read-out 
at 564nm was then detected using a PolarStar Omega (BMG Labtech) plate reader 
Final absorbance was calculated by subtracting the blank reading and the 1:10 and 
1:100 concentrations were plotted against the spectrometric read-out from the 
standard curve to work out total protein concentration in each sample. 
 
2.7.2. Sample preparation and Proteinase K treatment 
Samples were exposed to 25U/μL Benzonase (Merck) and 25mM MgCl2 for 30 
minutes at 37°C. A 4% (w/v) Sarcosyl/PBS solution was added 1:1 to the sample and 
incubated for 10 minutes at 37°C. For detection of PrPres, samples were further 
exposed to 20μg/mL PK (Sigma) for 1 hour 15 minutes at 37°C. The PK digestion 





2.7.3. Protein denaturing and separation 
Samples were diluted to a total protein concentration of 15μg and mixed with sample 
loading buffer and sample reducing agent (Invitrogen) before denaturing at 80°C for 
15 minutes. Samples were run in MES running buffer (Life Technologies) on 10% 
Bis/Tris polyacrylamide gels (Invitrogen) with see blue pre-stained protein standard 
(Life Technologies). 
 
After separation, proteins were transferred onto a polyvinylidene difluroride (PVDF) 
membrane by wet transfer electroblotting (Invitrogen) at 25V for 60 minutes. The 
PVDF membrane was subsequently blocked using 1% Western Block Solution 
(Roche) for 60 minutes at room temperature. Antibodies specific to the protein of 
choice were thus added to the blocking solution and incubated overnight at room 
temperature under constant shaking. Unbound primary antibody was subsequently 
washed off with TBS-Tween before incubating in secondary HRP antibodies for one 
hour at room temperature, before washing with TBS-Tween. The protein of interest 
was detected using West Dura ECL substrate (Pierce). All primary antibodies used in 
this study are summarised in table 2.1. As see blue pre-stained protein standard (Life 
Technologies) was used as markers, which do not show up after immunoblotting 
onto film, the markers in this text are superimposed onto the Western blots to show 
molecular weight. 
 




2.8.1. Inclusion body preparation 
Prnp DNA sequences encoding Syrian hamster residues 23 to 137 followed by sheep 
residues 141 to 234 of the R154 Q171 polymorph [accession number AY907689] 
(Ham/Shp chimeric PrP) were previously amplified and ligated into the pET41 
vector (EMD Biosciences). After transforming the plasmids into E. coli Rosetta cells 
(EMD Biosciences) the bacteria were frozen in a glycerol stock and stored at -80°C. 
This was performed at the NIH Rocky Mountain Laboratories, USA, by researchers 
independent of this study, as described previously [298, 299]. The glycerol stocks 
were transported to our laboratories. Kanamycin culture plates were subsequently 
streaked with the glycerol bacterial stock and incubated overnight at 37°C. Colonies 
were picked from this plate and further grown at 37°C with shaking in 3mL media 
(LB-M Broth, 50mg/mL Kanamycin and Chloramphenicol 34mg/mL in 100% 
ethanol) for 5-6 hours. The recPrP was expressed using the Overnight Express 
Autoinduction system (EMD Biosciences). Cell pellets from 0.25L cultures were 
frozen at -20°C. The cell pellet was then lysed using 1x BugBuster master mix 
(EMD Biosciences). The lysed cells were centrifuged at 16,000 x g for 20 minutes at 
4°C followed by resuspension of the pellet in 1x BugBuster and repeating the 16,000 
x g centrifugal step. A 0.1x BugBuster solution was then added before centrifugation 
at 7,900 x g for 15 minutes at 4°C to pellet the inclusion bodies. The inclusion bodies 
were then frozen at -20°C prior to recPrP purification. 
 
2.8.2. recPrP purification 
The inclusion body pellet was denatured in 8M GuHCl (pH8) and centrifuged at 
16,000 x g for 5 minutes at 4°C. The denatured protein present in the supernatant 
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was then bound to Ni-NTA superflow resin (Qiagen) that had been equilibrated in 
denaturing buffer (100mM NaPO4, 10mM Tris, 6M GuHCl [pH 8]) and mixed at 10 
rpm for 1 hour at room temperature. The resin was loaded into a column and, using 
an AKTA Explorer system (GE Healthcare), further denaturing buffer was run 
through the column for 25 minutes before the denatured protein was refolded on the 
column using a linear gradient of denaturing buffer to refolding buffer (100mM 
NaPO4, 10mM Tris [pH 8]) over 200 minutes at a flow rate of 1mL/minute. After 
this gradient was complete, 100% refolding buffer was run through the column for a 
further 30 minutes. To elute the protein from the column, a linear gradient from 
refolding buffer to elution buffer (500mM Imidazol-HCl, 100mM NaPO4, 10mM 
Tris [pH 5.8]) was performed at a flow rate of 1mL/minute for 60 minutes. Protein 
concentration being released from the column was determined by measuring UV 
absorbance at 280nm. Upon an increase in 280nm absorbance, protein fractions were 
collected and diluted 1:1 in dialysis buffer (10mM NaPO4 [pH 5.8]). Each protein 
fraction was then run on 10% Bis/Tris gels and total protein detected using Instant 
Blue coomassie staining (Expedeon) to ensure purity. Figure 2.4 shows an example 
protein purification with protein detected most intensely with the first and second 
elutes. These were then dialysed in snakeskin dialysis tubing (Pierce) overnight in 
dialysis buffer (10mM NaPO4 [pH5.8]) at 4°C. RecPrP preparations were then 
portioned into aliquots and stored at -80°C.  
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Figure 2.4 - Bis/Tris gel stained with Instant Blue coomassie. Samples were taken at several points 




A RT-QuIC master mix is composed as follows: 10mM phosphate buffer [pH 7.4], 
130mM NaCl, 10μM Thioflavin T [ThT], 10μM EDTA and a final concentration of 
0.1mg/mL recPrP. 98μL of this master mix were loaded onto black 96-well clear 
bottom plates (Nunc). The 10% brain homogenates described in section 2.7 were 
serially diluted in 0.1% SDS in PBS containing 130mM NaCl with N2 media 
supplement (Gibco). Reactions were then seeded by addition of 2μL diluted brain 
homogenate sample or with dH2O as a negative control. All reactions contained a 
final concentration of 0.002% SDS. Plates were then sealed with a plate sealer film 
(Nalgene Nunc International). A PolarSTAR Omega (BMG Labtech) plate reader 
was used to incubate the samples at 42°C for 60 hours with cycles of 1 minute rest 
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and 1 minute 700 rpm double orbital shake. ThT fluorescence was then measured 
(450nm excitation/480 emission) every 15 minutes during the 60 hour incubation. 
 
2.10. RNA extraction 
Brain stem, thalamus, cerebellum and cortex were dissected from six GSS/101LL 
animals at terminal illness and from six NBH/101LL aged matched mice as 
described in figure 2.3. The tissue was weighed then homogenised in 1mL Trizol 
(Life Technologies) per 100mg of tissue. Trizol is a monophasic solution of phenol 
and guanidinium isothiocyanate that solubilises biological material and denatures 
protein. The homogenate was thus centrifuged at 11,500 x g for 10 minutes at 4°C. 
The pellet was discarded. Choloform (0.2mL/mL Trizol) was then added to cause 
phase separation, whereby protein constitutes the organic phase, DNA the interphase 
and RNA the aqueous phase after a 11,500 x g centrifugal step for 15 minutes at 4°C. 
The aqueous phase was transferred to fresh RNase free tubes (Life Technologies). 
Isopropanol (0.5mL/mL Trizol) was added and incubated for 10 minutes at room 
temperature. The RNA sample was then centrifuged for 10 minutes at 11,500 x g at 
4°C. The RNA pellet was washed in 75% ethanol (1mL/mL Trizol) then centrifuged 
for 5 minutes at 8,000 x g at 4°C. The RNA pellet was then resuspended in Nuclease 
Free dH2O (Life Technologies), aliquoted and stored at -80°C. 
 
2.11. Microarray 
RNA was extracted from individual animal brain regions. To remove non-disease 
specific inter-animal variation, each sample consisted of a pool of two animals for an 
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individual brain region. This resulted in 24 arrays, as highlighted in table 6.1. A 
minimal RNA concentration of 180ng/μL was required for microarray analysis, 
which as exemplified in table 6.1, all RNA samples exceeded. The microarray was 
performed by Edinburgh Genomics (www.genomics.ed.ac.uk) using an Affymetrix 
Mouse Gene 2.0 array (Affymetrix) and transcript intensity analysed using 
Affymetrix GeneTitan instrument (Affymetrix). Samples were then returned to our 
laboratories with raw array data. The data was normalised using Affymetrix 
Expression Console software. Data was saved as an ‘.expression’ file containing a 
unique identifier for each transcript (gene annotation concatenated to probe ID). In 
subsequent columns, the gene and gene ontology (GO) annotations were included for 
assigning class-sets for the analysis of information contained in the network graph. 
Finally, the normalised raw data were included in following columns, which each 
column representing a single sample. The ‘.expression’ output file is subsequently 
loaded into the network analysis tool, Biolayout Express 3D [300]. Each transcript 
had pairwise Pearson correlations calculated as a measure of similarity between 
transcripts where r≥0.7. A modified Fruchterman-Rheingold algorithm [301] was 
used to create a graph, whereby each node represents a single transcript which are 
connected by weighted, undirected edges which represent the correlation. Groups of 
highly correlated transcripts were then ‘clustered’ using the Markov cluster 
algorithm [302]. To confirm the changed expression of transcripts between GSS and 
NBH/101LL brain regions, two-tailed t-test analysis was used to compare within a 
region. A p-value cut-off of 0.05 was selected as the significance threshold by which 




3. Characterisation of GSS/101LL clinical stage pathology 
 
Chapter aim: To define the pathology in the GSS/101LL model to establish if the 




Models of murine prion disease exhibit a range of measurable pathological 
phenotypes within the CNS. These include vacuolation [296, 303], gliosis [262, 263, 
304], neuronal loss [305, 306], synaptic degeneration [189, 191-193, 204, 214, 217] 
and cell/tissue atrophy [191]. It is well established that the neuropathology observed 
in animal models of prion disease recapitulates that seen in human prion diseases 
(reviewed in [307]). Expression of PrPc is essential for susceptibility to prion disease 
[30, 31]. The accumulation of misfolded prion protein appears to correlate with 
pathology. In animal models of prion disease, the accumulation of PrPd has 
consistently been observed a number of weeks prior to initial detectable neuronal 
deficits [189, 191, 214]. Other pathological observations appear to occur 
concurrently with the accumulation of PrPd, such as gliosis [191]. 
 
Antibodies specific for detection of PrP are the most commonly used detection 
method for PrP; however these cannot differentiate between PrPc and disease-
associated forms, PrPd. To solve this, different sample pre-treatments are performed 
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which enables the detection of PrPd isoforms which are distinct from PrPc. This 
distinctiveness of these PrPd species could be the result of protein misfolding, 
aggregation (e.g. dimer, oligomer, fibril), other unidentified co-factors, or a 
combination of these. Figure 3.1 shows a diagrammatic representation of different 
hypothetical PrPd species and their methods of detection. 
Figure 3.1 - Diagrammatic representation of different conformations of PrPd which are distinct from 
PrPc. These can aggregate, either PrPd autonomously or potentially with co-factors. Different 
aggregates may be morphologically similar, but require specific techniques for their detection. For 
example, the hypothetic blue and grey shading may represent forms which can be identified in 
Western blot (blue) or IHC (grey). Although both detection systems can detect many similar species 
of PrPd, some techniques may identify specific isoforms which others cannot. Moreover, other species 
of PrPd may yet remain undetected. 
 
Immunohistochemistry (IHC) typically relies on using specific conditions, for 
example formic acid, trypsin or PK exposure, prior to the application of the prion-
specific antibody. These conditions are thought to destroy PrPc epitopes within CNS 
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tissue. As a result, when applying PrP specific antibodies to uninfected tissue, no PrP 
is detected. Application of these same antibodies to known prion-infected samples, 
however, results in IHC detection of PrP. This PrP is likely the result of a 
conformational alteration, rendering the increased resistance of PrP to such 
conditions, and therefore represents PrPd. The advantage of using IHC is the ability 
to localise PrPd detection to specific regions of the CNS. The limitation is the 
inability to define the isoform of PrPd that is being identified. For example, it is 
known PrPd can consist of both PK-resistant and sensitive isoforms [21, 308]. 
 
PrPc is PK-sensitive, and therefore detection of PK-resistant isoforms of PrP, PrPres, 
in prion disease is indicative of a disease-associated isoform, PrPd. Western blots are 
commonly used to detect PrPres as a diagnosis of the presence of PrPd [21]. In 
humans and animals with prion disease, for example, PrPres isoforms are commonly 
observed [3]. However, PK-sensitive isoforms have also been recognised in some 
prion strains exhibiting high PrPres levels [308]. In contrast to IHC, Western blot 
analysis allows the interpretation of the species of PrPd present in a sample, but 
cannot effectively define localisation of PrPd. As a result, using Western blot analysis 
to detect the species of PrPd present and IHC to identify the targeting of PrPd 
represents an appropriate approach to further correlate PrPd with neurodegeneration. 
 
It is unclear what role either PrPres or PrPsen have within neurodegeneration. It has 
been shown previously that smaller aggregates of PrPd represent the most infectious 
species of PrPd [51]. Due to the size of these aggregates, it is assumed these fractions 
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of PrPd consist predominantly of oligomers. As discussed in 1.4.1 The role of PrP in 
neurodegeneration there is much conflict regarding whether such oligomers or fibrils 
represent the toxic entity within prion disease. There is, however, little data to define 
whether oligomers, for example, are predominantly PrPsen or PrPres, or both. What 
role all/any isoform of PrPd has within neurodegeneration has also been brought into 
question due to models which exhibit little or no detectable PrPd [28, 39, 41]. In one 
such study, only extremely small quantities of PrPd could be identified by both IHC 
and Western blot analysis which correlated with high infectivity levels, vacuolation 
and a robust and predictable incubation period [41]. This study incorporated a proline 
to leucine mutation at codon 101 of murine Prnp. This mutation is the equivalent to 
the disease-associated P102L mutation in human GSS but unlike humans, does not 
cause spontaneous disease in mice [28]. Upon experimental infection with human 
GSS, these mice exhibit the disease phenotype described above (briefly low PrPd, 
high infectivity) [41]. This model is henceforth abbreviated as GSS/101LL. 
 
In order to assess the apparent low quantities of PrPd in the GSS/101LL model, a 
range of mono- and polyclonal antibodies across the length of the protein were 
previously used. These detected only extremely small levels of PrPd via IHC and no 
detectable PrPd using Western blot. Denaturing techniques to expose epitopes that 
may not be presented due to the PrP protein conformation in this model were also 
used [32]. For example, increasing concentrations of guanidine hydrochloride were 
used to denature the protein, and subsequently the samples were analysed using 
conformation dependent immunoassay (CDI). This involves measuring the ratio of 
native vs. denatured protein present in a sample (d/n ratio) via a sandwich ELISA. 
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An increase in d/n ratio would indicate the presence of PrPd, due to the increase in 
antibody binding to denatured product (i.e. a higher level of exposed epitope). In the 
GSS/101LL model, the d/n ratio was equivalent to uninfected 101LL mice [41].  
 
The GSS/101LL model therefore indicates a critical dissociation between the large 
accumulation of PrPd detected in many prion disease models and pathology. The 
limited PrPd accumulation observed in this model may therefore represent the sole 
toxic species of PrPd or suggest a minimal role of PrPd in neurodegeneration. Prior 
studies, however, only examine the relationship between deposited PrPd and 
vacuolation and show no clear correlation. Conversely, PrPd may be associated with 
other aspects of pathology, such as neuronal loss, microglial activation or 
astrocytosis.   
 
To determine the pathology of GSS/101LL mice compared to NBH/101LL animals, 
most interpretation in this chapter will be performed as a descriptive pathological 
analysis. Where possible, quantitative or semi-quantitative analysis will be 
performed, such as neuronal counts or vacuolation scoring. In all instances, it is 
important for quantitation to be performed blind and if possible, by a researcher 
independent to the study. Vacuolation scoring in this thesis is performed by a 
researcher independent to this study and who is scoring the samples blinded and 
according to parameters which have been outlined previously [296]. To quantify the 
number of neurons present, in order to interpret whether neuronal loss is occurring in 
one brain region and not another, one must not only consider counting the number of 
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cells within a well-defined brain region of the brain using multiple sections for 
counting. This is because the tissue being studied is a 3D structure, but the sections 
that are being counting are a 2D representation of the structure. Therefore it is 
important to include measurements which take into account the measurements of the 
tissue within which the neuronal counts are being performed. This is especially 
important in this study, as disease-specific brain regions are being compared to 
region matched uninfected controls. It is therefore possible that brain regions 
undergoing neurodegeneration may also be undergoing gross brain region atrophy. 
As a result the neuronal cell counts will need to take this into account to prevent any 
possible bias as a consequence of differences in total tissue size [309]. 
 
This chapter thus examines a number of pathological phenotypes in GSS/101LL 
mice at terminal illness and aims to test whether such observations may be associated 
with the detection of PrPd.  
 
3.2. Results 
To assess the different parameters of the neuropathology at clinical stages of disease, 
paraffin-embedded tissue from previous studies was available and used. Due to 
limited availability of tissue for biochemistry analysis (such as Western blot), a 
further cohort of GSS/101LL and NBH/101LL animals was set up to examine other 
aspects of the disease at late stages of disease progression, namely clinical onset. 
The paraffin-embedded tissue from nine GSS/101LL and three NBH/101LL animals 
used in previous studies [28] was serially sectioned throughout the brain. This tissue 
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was then used to assess the pathology at clinical stages of disease. The brains from 
12 GSS/101LL and 12 NBH/101LL animals set up for biochemical analyses were 
halved and four regions were dissected (brain stem, cerebellum, thalamus, cortex; see 
chapter 2 for details). The regional dissection is based upon the vacuolation profile 
from previous studies (figure 3.2) to incorporate regions of targeted pathology and 
unaffected regions. This tissue was used to assess what isoforms of PrPd exist in 
GSS/101LL animals.  
 
3.2.1. Incubation period and vacuolation severity scoring in “archive” and 
“recent” GSS/101LL animals 
Prion diseases produce remarkably consistent incubation periods. Alongside this, the 
disease appears to target predictable, specific regions of the brain and traditionally, 
this regional vulnerability has been scored by the presence of disease-specific 
vacuolation [296, 303]. In this study, two cohorts of GSS/101LL animals were used; 
nine “archive” GSS/101LL animals and twelve “recent” GSS/101LL animals. The 
average incubation period of the archive group was 286.66 ± 2.95 days compared to 
291.11 ± 5.29 days in recent GSS/101LL animals. 
 
The vacuolation severity scoring was performed blind by a researcher independent to 
this study. Vacuolation severity was scored according to the parameters outlined in 
chapter 2, which are based upon previously published standards [296, 303]. The 
vacuolation severity in GSS/101LL mice is relatively minor compared to other prion 
diseases [296, 303, 310] (figure 3.2). The vacuolation scores are highest at four areas 
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of grey matter in archive tissue. These are medulla, superior colliculus, 
hypothalamus and thalamus. In the recent group, however, a relatively high level of 
vacuolation is observed in the medulla but is lower in all other regions but still 
represents a similar pattern (i.e. higher levels of vacuolation in medulla, superior 
colliculus, hypothalamus and thalamus, but also in the septum) (figure 3.2). Within 
white matter, there is a difference between high vacuolation severity scores in 
archive tissues and low vacuolation scores in recent GSS/101LL tissues. Increased 
vacuolation cannot be attributed to differential aging as all animals in the recent 
GSS/101LL group were injected at a similar age to those in the archive GSS/101LL 
group. Ultimately, the similar incubation period and consistency of vacuolation 
scoring in neuronal-rich grey matter tissue demonstrate the conserved properties of 
this model. Due to the low levels of vacuolation, however, little can be made of the 
importance of this as a pathological feature. 
Figure 3.2 – Vacuolation profile of “archive” and “recent” groups of GSS/101LL clinical stage 
animals. Grey matter scores (medulla [brain stem], cerebellum, superior colliculus [midbrain], 
hypothalamus, thalamus, hippocampus, septum, retrospinal cortex and cingulate and motor cortex) are 
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scored blind on a scale of 0-5, whereby 5 represents severe vaculation and 0 represents no 
vacuolation. Blue line indicates archive tissue, red line indicates recent tissue. 
 
3.2.2. Neuronal loss is restricted to specific regions of the brain 
Neuronal degeneration and loss is thought to be the fundamental causal factor behind 
the establishment of overt clinical symptoms and subsequent death of the animal. 
Within chronic neurodegenerative diseases, selective vulnerability of specific 
neuronal populations is well established (reviewed in [311]). When considering the 
extremely small quantities of PrPd present in GSS/101LL animals, it will be 
important to precisely define the extent of neuronal loss to determine whether 
neurodegeneration progresses to similar cell loss fate as demonstrated in previous 
studies examining different murine prion strains [189, 225]. 
 
To identify whether neuronal loss occurs in GSS/101LL mice, neuronal cell counts 
were performed in two areas; brain stem and cortex. This allowed for the 
comparative analysis of cell loss in regions exhibiting a higher vacuolation score 
(brain stem; medulla) against regions showing minimal vacuolation (cortex). The 
specific neuronal populations counted were the gigantocellular reticular nuclei of the 
brain stem (Gi) and layer III of the retrospinal granular cortex (RSGc). To do this, a 
series of ten sections were taken throughout a coronal-section tissue slice. Each 
section was stained with anti-MAP2 antibody, to detect microtubule-associated 
protein 2 (MAP2) which is commonly observed in dendrites and cell bodies of 
neurons in the CNS. The number of neurons within a specific pre-defined neuronal 
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population were then counted and averaged according to the mean number of 
neurons per section.  
 
Figure 3.3 shows the average number of neurons per section in the Gi and RSGc 
from ten serial sections of three GSS/101LL and three NBH/101LL animals. The Gi 
exhibits significant neuronal loss compared to NBH/101LL controls (t-test; 
p=<0.001). The RSGc does not appear to suffer any discernible neuronal loss in 
GSS/101LL animals comparated to NBH/101LL controls. To ensure that these cells 
counts were performed accurately and are compared to NBH/101LL region and aged 
matched controls appropriately, the total brain region was measured to test for any 
changes, such as tissue atrophy. Results are presented as the percentage size of 
GSS/101LL brain regions compared to the respective region and aged matched 
NBH/101LL controls. No significant changes in either brain region tested were 
observed compared to NBH/101LL controls, although there appeared to be a general 
decrease in total tissue size in GSS/101LL brains compared to NBH/101LL controls 
– but this was not statistically significant. 
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Figure 3.3 - Neuronal cell counts. (A) Each bar represents average number of neurons per section 
(n=10) per animal tested (n=3). Gigantocellular reticular nuclei (Gi) of the medulla are lost at clinical 
onset of disease, compared to NBH/101LL animals (t-test, p = <0.001). Retrosplenial granular cortex 
(RSGc) nuclei showed no statistically significant change in neuronal number compared to 
NBH/101LL controls (t-test, p = >0.05). (B) No change in tissue area could be observed in 
GSS/101LL brain regions compared to the respective region and aged matched NBH/101LL controls. 
 
3.2.3. Synaptic degeneration is observed only in regions of neuronal loss and 
vacuolation 
Synapses are known to degenerate early in prion disease, long before loss of the 
neuronal cell body occurs [189, 191-193, 204, 214, 217]. Within regions of neuronal 
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loss it will therefore not be surprising to observe synaptic degeneration. Detection of 
synaptic degeneration in other regions may, however, indicate earlier stages of 
pathology. The integrity of the post-synaptic structure was assessed using the actin-
binding protein drebrin. This protein exists predominantly within the dendritic 
processes of neurons and thus is a useful probe to detect the post-synaptic structure, 
which has been shown to degenerate early in prion diseases [193, 214]. Drebrin only 
appeared significantly expressed in NBH/101LL animals within specific neuronal 
populations within the brain stem, such as the facial nuclei, and the hippocampus. 
Repeated attempts to optimise the antibody to detect post-synaptic structure in 
additional regions were unsuccessful. Nevertheless, this antibody was used to define 
the post-synaptic structure of neurons in a region exhibiting neuronal loss and pre-
synaptic degeneration (brain stem facial nuclei), compared to neurons which do not 
(hippocampus). Figure 3.4A shows the loss of drebrin staining in brain stem neuronal 
populations in GSS/101LL animals. Within the facial nuclei, it is clear the neuronal 
cell bodies have not been lost (see green and red arrows in NBH and GSS – figure 
3.4A) but the neurons in GSS/101LL have atrophied. To quantify this, Image J was 
used to measure the cell area in GSS/101LL and NBH/101LL facial nuclei. Figure 
3.4B shows the significant cell shrinkage of GSS/101LL facial nuclei (t-test; 
p<0.001). In the hippocampus, drebrin staining intensity or morphology does not 
appear to differ between GSS/101LL or NBH/101LL animals, see figure 3.4C. 
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Figure 3.4 – Drebrin staining of facial nuclei and hippocampal nuclei. (A) Facial nuclei stained with 
anti-drebrin antibody shows highly structured morphology of post-synaptic densities which is lost in 
GSS/101LL facial nuclei. Green arrows show neuronal cell bodies in NBH/101LL facial nuclei but 
red arrows show significant cell shrinkage (atrophy) of these nuclei in GSS/101LL facial nuclei. Scale 
bars = 50μm. (B) Quantification of cell body area using Image J software. The cell bodies of facial 
nuclei are significantly reduced in GSS/101LL animals comparative to NBH/101LL facial nuclei (t-
test; p=<0.001). (C) Drebrin staining in hippocampus shows significant level of staining in CA1 
hippocampus which is unchanged in NBH or GSS/101LL animals. These results were observed in all 
animals used in this study. Scale bars = 200μm. 
 
Taken together, this data shows that both pre- and post-synaptic deficits occur in 
GSS/101LL animals in regions which also show neuronal loss. No synaptic deficits 
could be observed in regions not exhibiting neuronal loss, such as the cerebellum or 
cortex. 
 
3.2.4. Neuronal specific structural proteins are compromised only in regions 
of neuronal loss 
Neuronal atrophy is a common neuropathological feature of chronic 
neurodegenerative disease [312, 313], and figure 3.5 demonstrates atrophy in 
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GSS/101LL animals. This suggests a deficit or loss of proteins involved in 
maintenance of neuronal structure. Microtubule-associated protein 2 filaments 
(MAP2a and MAP2b) are expressed specifically within the dendrites and cell body 
of neurons. Detection of MAP2a, MAP2b (hereby referred to as MAP2) is thus an 
ideal approach to study the structure of the neuronal cell body and dendritic 
processes. Antibodies specific to MAP2 strongly stained numerous neuronal 
populations throughout the CNS. Figure 3.5 demonstrates the substantial loss of 
MAP2 within the thalamus of GSS/101LL animals. High magnification shows that 
some neurons remain with MAP2 staining in the cell body. This indicates the 
neurons remaining in the thalamus do not lose MAP2 proteins, and therefore are 
perhaps structurally intact. Within the cortex and cerebellum however, the staining 




Figure 3.5 – MAP2 staining of thalamus (A) and cortex and cerebellum (B). (A) Significant loss of 
MAP2 staining is observed in the ventral-lateral thalamus. This represents a loss of neurons, although 
neurons which remain in these regions are still positively stained for MAP2. Low magnification scale 
bars = 100μm. High magnification scale bar = 50μm. (B) Left panels represent NBH/101LL cortex 
and cerebellum, right panels represent GSS/101LL cortex and cerebellum. An increase in staining 
intensity in both cortex and cerebellum is observed in GSS/101LL regions. This does not correlate 
with vacuolation, neuronal loss or synaptic protein loss. These results were observed in all animals 
used in this study. Cortex scale bar = 200μm. Cerebellum scale bar = 100μm. 
  
To further test this, antibodies to parvalbumin were used. Parvalbumin is highly 
expressed in the Pukinje cells of the cerebellum which project dendrites into the 
cerebellar molecular layer. This therefore is an ideal method to detect the structural 
morphology of a major cell type in the cerebellum. No change in the staining quality 
was observed in parvalbumin positive cells in GSS/101LL animals compared to 
NBH/101LL (figure 3.6). Overall, this data confirms the neurodegeneration is 
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observed in specific regions, such as the brain stem and thalamus. Conversely, 
increased protein expression of MAP2 was observed in both the cerebellum and 
cortex of GSS/101LL animals. 
Figure 3.6 – Parvalbumin staining of GSS and NBH/101LL cerebellum. Left panel represents 
cerebellum from GSS/101LL animal, right panel represents cerebellum from NBH/101LL animal. No 
change in staining intensity, quality or morphology could be observed. These results were performed 
in three GSS/101LL and three NBH/101LL mice from the ‘recent’ group. Scale bars = 50μm. 
 
3.2.5. Glial responses are restricted to regions undergoing 
neurodegeneration 
Two glial cells of the CNS are known to be consistently morphologically and 
functionally altered within a range of chronic neurodegenerative diseases, these are 
microglia and astrocytes. The functions of both cell types have been discussed 
previously (see 1.4.4. Astrocytes and prion disease and 1.4.5. Microglia and prion 
disease). Both cell types are known to exhibit substantial morphological responses in 
prion disease, typically by hypertrophy of the cell body and shortening/thickening of 
cell processes. This morphological response has been shown to be associated with 




Ionized calcium-binding adapter molecule 1 (Iba1), also known as allograft 
inflammatory factor 1 (AIF1), is a protein expressed specifically within 
macrophages, including microglia [314]. Antibodies to detect this protein can thus be 
used as a tool to study microglial phenotype within different regions of the brain. 
Figure 3.7 shows the GSS/101LL cortex and cerebellum do not exhibit any changed 
microglial morphology in comparison to region matched NBH/101LL mice. In the 
GSS/101LL brain stem and thalamus, the microglial morphology is characteristic of 
disease-associated activated microglial morphology, i.e. hypertrophied cell body and 
short, thick processes. This is in stark contrast to NBH/101LL brain stem and 
thalamus which exhibit quiescent microglial morphology. 
 
Astrocytes are known to express low levels of GFAP within a healthy brain. Upon 
alterations to neuronal homeostasis astrocytes undergo a morphological alteration, as 
described above. GFAP, an intermediate filament protein, is up-regulated within 
morphologically “reactive” astrocytes [248, 315]. This allows antibodies specific to 
GFAP to be used as tools to assess the morphological change of astrocytes in 
response to prion-disease [262]. Figure 3.8 shows GFAP staining in a characteristic 
astrocytic morphology (small cell body, long thin processes) in GSS/101LL cortex.  
This is comparable to NBH/101LL astrocyte morphology. Very little GFAP staining 
is observed in the molecular layer of the cerebellum in GSS/101LL mice. Some 
positive staining can be observed in the granular cell layer, but this is also seen in 
NBH/101LL animals. GFAP staining in GSS/101LL brain stem and thalamus was 
indicative of reactive astrocytes, both in up-regulation of GFAP and their cellular 
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morphology. This was a disease specific phenotype, as these phenotypes are not 
observed in NBH/101LL brain stem or thalamus. 
Figure 3.7 – Microglial morphology in brain stem, thalamus, cortex and cerebellum. Iba1 staining 
shows the microglial morphology is altered in GSS/101LL brain stem and thalamus comparative to 
NBH/101LL. No change in microglial morphology could be detected in cortex or cerebellum. These 
results were observed in all animals used in this study. Scale bars = 50μm. 
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Figure 3.8 – Astrocyte morphology in brain stem, thalamus, cortex and cerebellum. GFAP staining 
shows an increased number of GFAP positive astrocytes in GSS/101LL brain stem and thalamus 
comparative to NBH/101LL. No observable changes in the number of GFAP positive astrocytes could 
be observed in cortex or cerebellum. These results were observed in all animals used in this study. 
Scale bars = 50μm. 
 
3.2.6. Comparatively larger quantities of PrPd observed in GSS/101LL 
animals than previously identified 
There has traditionally been an association between the accumulation of PrPd and 
neurodegeneration in prion diseases, with a few exceptions, including the 
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GSS/101LL model [28, 39-41]. To confirm that only the extremely small quantities 
of PrPd are detected in regions shown here to undergo neurodegeneration; IHC and 
Western blots were performed. Using a PrP-specific antibody, BH1 [297] in an IHC 
protocol described in previous studies [41], very small quantities of PrPd were 
detected in some GSS/101LL animals (figure 3.9). At high magnification, small 
aggregates of granular PrPd staining could be observed in the thalamus and midbrain, 
but not in every animal tested. No PrP staining could be detected in NBH/101LL 
animals or using an isotype (IgG1) control antibody on GSS/101LL tissue. This 
indicates the PrP staining observed in a subset of GSS/101LL animals is disease-
associated, or PrPd. Mice infected with ME7 or 87V were used as positive controls to 
confirm the staining protocol was effective. Large quantities of PrPd were identified 
in these prion strains under these experimental conditions (figure 3.9). 
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Figure 3.9 – PrP staining using previously defined protocol [41]. Some GSS/101LL mice present no 
detectable PrPd, whereas others present some small quantities of PrPd. When using this protocol on 
ME7 or 87V clinical stage material as positive controls, these clearly show large quantities of PrPd 
staining. Low magnification scale bars = 200μm. High magnification scale bar = 50μm. 
 
To investigate the influence of the staining protocol and in particular the pre-
treatment steps on the detection of PrPd, other immunohistochemistry protocols were 
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tested using BH1. It was found upon changing the water autoclave step in the 
previously published protocol [41] to an autoclave step using citric acid buffer in 
place of water, comparatively larger quantities of PrPd could be detected in 
GSS/101LL animals. Figure 3.10 shows the “citric acid protocol” in the same IHC 
experiment as the “water protocol”. The now detectable PrPd did not appear 
morphologically different from the smaller quantities identified previously, with the 
same appearance of granular aggregates of PrPd. No detectable PrP could be 
observed in NBH/101LL animals and no non-specific staining could be identified 
when using an isotype (IgG1) control. The detectable PrPd using the altered IHC 
conditions showed PrPd widespread in the brain stem, midbrain and thalamus (figure 
3.11A), but none could be detected in the cortex or cerebellum (figure 3.11B). 
Figure 3.10 – PrP staining using modified IHC conditions (citric) comparative to previously 
published IHC conditions (water). Left panel shows GSS/101LL VM thalamus, middle panels show 
hypoglossal nuclei of brain stem and right panels show locus coeruleus nuclei of the pons. 
Substantially larger quantities of PrPd could be detected using modified IHC conditions. Scale bars = 




To identify whether the additional conformations of PrPd detected using 
immunohistochemistry with a citric acid buffer–autoclave step exhibit a protein 
conformation that is PK-resistant, homogenates of different brain regions (brain 
stem, thalamus, cortex and cerebellum) were exposed to PK (see chapter 2 for 
detailed methods). Western blots were then used to detect whether any PrPres 
isoforms of PrPd exist. Figure 3.12 shows Western blots using BH1 antibody 
demonstrates that PrPres isoforms could not be identified in brain stem, cerebellum or 
thalamus from GSS/101LL animals. A very faint band was observed in GSS cortex, 
thereby suggesting small quantities of PrPres present in this region. This however was 
only observed in two of nine GSS/101LL animals tested. In all other cases, no PrPres 
was detectable in any brain regions. In comparison, PrPres could be identified in 
every animal tested under these same conditions in 79A murine prion disease (n=3). 
This data indicates the presence of IHC detectable PrPd in GSS/101LL animals, 
which correlates with regions of neurodegeneration, but is not PrPres. Conversely, an 
extremely small quantity of PrPres was observed in the cortex of some GSS/101LL 
mice, which is not associated with neurodegeneration identified in this chapter. 
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Figure 3.11 – PrP staining in regions of neurodegeneration (A) but none observed in regions of no 
overt neurodegeneration (B). (A) Left panel shows substantia nigra, pars compacta, middle panel 
shows medial raphe nuclei and right panel shows ventral-lateral thalamus. Scale bars = 50μm. (B) Left 
panel shows representative images of cerebellum and right panel shows representations of cortex of 








Figure 3.12 – Western blot for PrP. 79A shows large quantities of PrP, even after PK exposure, 
indicating PrPres present in every brain region tested. GSS/101LL shows PrP staining but no PrPres 
present in all brain regions with exception of a faint band in GSS/101LL cortex. This result occurred 
in two out of four animals GSS/101LL tested, the remain two samples did not show PrPres detection in 
any brain region tested. NBH/101LL shows small quantities of PrP present and no PrPres.  
 
3.3. Results summary 
- No significant changes in incubation period or in grey matter vacuolation in 
past and present models of GSS/101LL. 
- Neurodegeneration, including neuronal loss, atrophy and synapse loss is 
observed in specific regions of the brain, such as: brain stem and thalamus 




- Larger quantities of PrPd identified in GSS/101LL animals compared to 
previous studies [41] using a modified IHC protocol 
- No PrPres isoform of PrPd could be identified in regions of neurodegeneration 
- Extremely small detection of PrPres in cortex which does not correlate with 
neurodegeneration 




In prion diseases PrPd, as defined by IHC detection of PrP isoforms resistant to 
specific denaturing conditions and Western blot detection of PrPres, is generally 
associated with regions of the brain undergoing neurodegeneration and glial cell 
responses. The establishment of animal prion disease models which provide 
exceptions to this are therefore useful platforms to further study and identify the 
species of PrPd that are necessary and sufficient to cause neurodegeneration [28, 39-
41]. The GSS/101LL model has previously been characterised to exhibit a highly 
infectious, invariably fatal neurodegenerative prion disease, but in the presence of 
extremely small quantities of PrPd after infection with human GSS inoculum [41]. 
This model, however, does not show spontaneous disease associated with the human-
like mutation at codon 101 either in this study or in previous studies [28, 41]. 
Further, in human GSS, a vast majority of the cortex suffers from heavy misfolded 
prion protein burdens and associated neurodegeneration. In this study, we show that 
the cortex does not suffer from such neuropathology. Therefore, this model is used as 
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a tool to study the association between PrPd and neurodegeneration, but not 
necessarily as a model of human GSS. 
 
The brains of GSS/101LL mice at clinical stages of disease were assessed for signs 
of previously described prion-associated pathology [189, 191-193, 204, 214, 217, 
262, 263, 296, 303-307]. Loss of proteins the post-synapse (Drebrin) and in the 
dendrites of neurons (MAP2) in brain stem and thalamus, alongside neuronal loss 
concurs with previously defined pathology in murine models of prion disease [189, 
191-193, 204, 214, 217, 262, 263, 296, 303-307]. No overt neurodegeneration could 
be detected in other regions, such as the cortex and cerebellum. 
 
In prion diseases, changes in both astrocyte and microglial morphology occur 
concurrently with appearance of PrPd, and prior to overt neurodegenerative 
phenotypes [189, 191]. In clinical stages of GSS/101LL animals, microglia and 
astrocytes change morphology to a phenotype typical of an activated cell. The 
absence of activated microglia or astrocytosis in other regions, such as cortex and 
cerebellum, is indicative that these regions remain pathologically “unaffected”, as 
defined by neurodegeneration and glial cell responses. 
 
There appears to be a difference in severity of vacuolation scoring in white matter 
tracts of archive and recent groups of GSS/101LL mice. The reason for these 
differences in the two cohorts used in this study is unclear. Vacuolation can occur as 
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a phenotype of ageing [316], however GSS/101LL animals from both cohorts 
(archive and recent) of mice used in this study were of comparable age. The human 
GSS inoculum used was from the same region of the same GSS brain used 
previously. The human GSS is sourced from the Edinburgh Brain Bank (see chapter 
2) and tissue is obtained as a dissection of frozen tissue. It is feasible different 
quantities of PrPd may be present between GSS tissue used in archive and recent 
experiments. If this were the case, it might be assumed the incubation periods 
between archive and recent experiments would differ significantly. However, 
previous studies have shown vacuolation lesion profiles are unaffected by dose of the 
agent [317] and furthermore the incubation periods of the two cohorts of animals 
were very similar. Therefore, the reasons for this difference in WM tracts are not 
known but importantly, the vacuolation severity appeared similar in grey matter 
regions of the brain between both groups. 
 
To test whether the presence of extremely small quantities of PrPd identified 
previously [41] is associated with pathology outlined in this chapter, IHC and 
Western blots were used to identify PrPd. Following a previously published IHC 
protocol, very small quantities of PrPd were identified – in accord with previous 
results [41]. Altering the protocol to autoclave in citric acid buffer instead of water 
revealed the presence larger quantities of PrPd in GSS/101LL animals. The detection 
of PrP could not be identified in NBH/101LL animals and thus is a disease-specific 
conformation of prion protein, PrPd. Moreover, the presence of IHC detectable PrPd 
is associated with brain regions undergoing neurodegeneration. Western blot analysis 
however shows a small quantity of PrPres in two of nine GSS/101LL tested cortex 
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samples. The cortex wasn’t found to exhibit any overt neurodegeneration in this 
study, therefore suggesting the PrPres species that are observed in the cortex in the 
two out of nine GSS/101LL animals is not associated with neurodegeneration. This 
demonstrates the requirement to study the GSS/101LL model in further detail to 
question the relationship between IHC detectable species of PrPd and 
neurodegeneration.  
 
In the brain stem and thalamus, which show IHC detectable PrPd, but no PrPres, the 
predominant species of PrPd present is likely PrPsen. It is becoming increasingly 
evident in many prion stains; both PrPres and PrPsen isoforms comprise total 
detectable PrPd [308]. These results show that PrPsen isoforms, rather than PrPres, are 
directly, or perhaps indirectly, involved in driving neurodegeneration in prion 
diseases. 
 
In summary this chapter shows PrPsen isoforms of PrPd are related to prion-associated 
pathological phenotypes. This data indicates that PrPsen isoforms of PrPd may 
represent the toxic species, however further elucidation of the temporal progression 
of disease is required to strengthen this association. In order to study the role of a 
predominantly PrPsen isoform during disease, a time-course study of GSS/101LL 
animals was set up (see chapter 4). This will allow the comparison of progressive 
disease in GSS/101LL animals exhibiting predominantly PrPsen isoforms of PrPd to 
other models exhibiting both PrPsen and PrPres isoforms [308]. 
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4. Time-course analysis of the GSS/101LL model 
 
Chapter aim: To define the progressive pathology of the GSS/101L model from the 
perspective of understanding the relationship between PrPd, neurodegeneration and 
glial cell responses. Multiple brain regions will be examined along a time-course to 
additionally assess spread of pathology. 
 
4.1. Introduction 
Chronic neurodegenerative diseases occur over extended periods of time; in some 
human prion disease cases the incubation period can be as long as 50+ years [318]. 
Long incubation periods also exist in murine models of prion disease, relative to their 
expected life-time [319]. This allows the study of the spread and progression of 
pathology using animal models of disease. Studies in animal models have indicated a 
predictable sequential and progressive set of events, beginning with detection of 
disease-associated misfolded protein concurrently with morphological glial cell 
responses [189, 191, 320-325]. Synaptic degeneration [186, 189, 191, 192, 204, 217, 
238, 320, 326-331] and perineuronal net breakdown [237] are subsequently 
observed. Synaptic degeneration coincides with the onset of the behavioural [188] 
and electrophysiological deficits in mice [203]. As disease continues, pathology 
spreads to different regions of the brain [143, 144]. Finally, neuronal loss occurs 
followed by death of the animal [189, 216, 320]. This robust picture of progressive 
neurodegeneration provides a platform for further studies to compare and contrast 




The progression of neurodegeneration has been best defined in the hippocampus, due 
to its well-defined anatomy and functional role. These studies have demonstrated that 
synapses degenerate prior to neuronal cell loss [189, 191, 217, 320, 328, 329]. It is 
important to note, however, that different regions of the brain appear to exhibit 
different neuronal targets – for example, pre-synaptic vesicles correspond to the 
earliest observable neurodegenerative phenotype in the hippocampus of two murine 
models of prion disease [189, 191, 192], but the post-synaptic density appears to be 
the initial target in the cerebellum [238]. Nevertheless, morphological glial cell 
responses and PrPd deposition occur prior to detectable neurodegeneration. 
Therefore, the identification of these events is indicative of the initiation of a 
pathway leading to neurodegeneration, prior to overt signs of neurodegeneration. 
 
The spread and distribution of pathological lesions throughout the incubation of a 
number of chronic neurodegenerative diseases has been extensively mapped [143, 
144, 303]. This occurs in a pattern suggesting spread along neuronal pathways [281, 
283, 284]. The precedence of the transmissible properties in prion diseases has led to 
the notion that disease-associated misfolded proteins can spread in a “prion-like” 
mechanism [146, 154, 161, 286-293]. The association between misfolded proteins 
and neurodegeneration in multiple models of chronic neurodegeneration has led to 
the hypothesis that preventing the spread of disease-associated proteins may be an 




Murine models of prion disease, particularly those studied in extensive detail such as 
ME7 or RML [186, 188, 189, 191, 192, 203, 204, 217, 237, 238, 326], demonstrate 
the association between detection of accumulated PrPd and neurodegeneration. In all 
cases, a morphological glial cell response occurs concurrently or immediately after 
detection of PrPd. The PrPd is commonly detected using IHC or Western blot. In the 
instance of Western blot, the PrPres isoform is the desired conformation of interest. 
As mentioned previously, it is becoming increasingly evident that PK-sensitive 
isoforms of PrPd, PrPsen, are present in prion diseases known to accumulate large 
quantities of PrPres [308]. These studies highlight a probable relationship between 
PrPd and neurodegeneration but are not sufficient to establish whether limited subsets 
of isoforms are responsible for progressive neurodegeneration. Results outlined in 
chapter 3 highlight the presence of a predominant PrPsen species of PrPd in region of 
the brain undergoing overt neurodegeneration in the GSS/101LL model. Although 
very limited amounts of PrPres were detected in some GSS/101LL cortex samples, 
this was not associated with neurodegeneration or glial cell responses. As a result, 
understanding the sequential order of pathological events will be important for 
understanding the relationship between the PrPsen isoforms detected in GSS/101LL 
animals and neurodegeneration. Similarly important is whether the spread of lesions 
between brain regions takes place in a sequence related to neuronal connectivity. 
 
4.2. Results 
As described in chapter 3, the incubation period of previous studies using the 
GSS/101LL model is approximately 286.66 ± 2.95 days (archive group). Therefore, a 
study to examine pathology at a number of stages during disease progression was set 
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up. Since previous studies examining murine prion strains have demonstrated initial 
signs of pathology from between 40-50% incubation period, this study examined five 
time-points. These were 150dpi, 200dpi, 220dpi, 240dpi and clinical stages 
(terminal) – see figure 4.1B. The incubation period measured in GSS/101LL animals 
progressing to clinical stages of disease was 291.11 ± 5.29 days. All mice were 




Figure 4.1 - Time-course of GSS/NBH transmission. A total of 96 101LL mice were bred and 
genotyped. A – 1 = water (no DNA). 2 = 101LL positive control. 3 = WT control. 4-14 = 
experimental animals. All animals were found to exhibit the proline to leucine alteration at codon 101. 
B – animals were either injected with 1% human GSS frontal cortex homogenate or 1% uninfected 
hamster brain homogenate. All animals were between 6-8 weeks of age at time of injection. Mice 
were subsequently culled at 150, 200, 220 and 240 days post inoculation and another group was left to 
progress to overt clinical stages (terminal), at which point animals were culled for ethical 
considerations.  
 
4.2.1. PrPd is observed at 150dpi in GSS/101LL animals 
The same IHC protocol with citric acid buffer-autoclave and BH1 antibody, as 
described in chapter 3 was used to assess the targeting of PrPd at early stages of 
disease. GSS/101LL animals at 150dpi were stained and compared to NBH/101LL. 
Non-specific antibody isotype control (IgG1) was used to determine whether non-
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specific staining is occurring. Serial sections through numerous regions of the brain 
were used, including; medulla, pons, cerebellum, midbrain, hippocampus, thalamus, 
hypothalamus, cortex (Bregma -1 to -3) and striatum, as described in chapter 2. 
 
Figure 4.2A shows PrP staining within midbrain. This was observed in five of twelve 
GSS/101LL mice in this group. No other detectable PrP could be identified across all 
other regions; figure 4.2B shows typical examples of medulla and thalamus sections 
with no PrP staining. The PrP staining observed is not present in region matched 
sections of NBH/101LL animals. Additionally, the isotype control does not 
demonstrate staining. This shows the accumulation of PrPd restricted to the midbrain 
at 150dpi in GSS/101LL animals. The staining observed is associated with neurons 
of the midbrain, such as the interpeduncular nuclei which innervate the medial 
lemniscus and substantia nigra, pars compacta (SNc). 
 
PrPd was not observed in the surrounding medial lemniscus, despite the relatively 
large number of axons which comprise this white matter tract from affected neurons. 
This could either be a result of restricted targeting of PrPd to the neuronal soma 
which does not allow the axonal migration of the agent, or a technical inability to 
identify PrPd in axons. Nevertheless, these results demonstrate the initial targeting of 
PrPd to the midbrain. 
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Figure 4.2 - PrP staining at 150dpi in 101LL mice. A – PrP is detected in the midbrain. Specifically, 
this appears to be associated with the interpeduncular nuclei innervating the medial lemniscus (purple 
arrow and box) and also in the substantia nigra, compart part (black arrow and box). (B) No PrP 
staining could be observed in other regions of the brain, including the medulla and thalamus (left 
panel). No PrP deposition could be detected in NBH aged matched controls (right panel). Scale bars = 
200μm. 
 
4.2.2. No glial cell responses are detected at 150dpi 
Previous studies have shown glial cell responses occur concurrently, or shortly after 
initial detection of PrPd [189, 191, 325]. This glial cell activation phenotype is also 
observed association with deposits of misfolded protein in other neurodegenerative 
diseases [321, 322]. The morphological alterations of both microglia and astrocytes 
can therefore be indicative of early pathological events in the incubation period (see 
[98] 
 
1.4.4. Astrocytes and prion disease and 1.4.5. Microglia and prion disease). To 
assess the possible morphological activation of glial cells at 150dpi, antibodies 
against GFAP were used. 
 
The neurons of the midbrain which are associated with PrPd deposition at this stage 
do not concur with a morphological alteration of glial cells as determined by GFAP 
staining (figure 4.3B). An up-regulation of GFAP comparative to NBH/101LL 
controls does occur in the medial lemniscus. As these midbrain neurons, such as the 
interpeduncular nuclei, project axons in the medial lemniscus, this could possibly be 
indicative of down-stream effects of PrPd detection associated with the neuronal cell 
bodies. The morphology of the astrocytes up-regulating GFAP is characteristic of 
fibrous astrocytes which are known to commonly up-regulate GFAP even in 
uninfected brains (see 1.4.4. Astrocytes and prion disease). Nevertheless, this up-
regulation comparative to NBH/101LL region matched controls appears to be a 
common phenotype across all GSS/101LL animals tested at this stage of disease. In 
regions which do not show any detection of PrPd, such as the brain stem, there were 
no apparent differences in GFAP staining intensity or morphology of astrocytes 
(figure 4.3A). During prion disease, the number of GFAP positive astrocytes 
increases [262]. It is important to recognise that the increase in GFAP positive 
astrocytes may not reflect an increase in the absolute number of astrocytes but up-
regulation of the expression of GFAP [280]. Overall, whether a glial cell response 




Figure 4.3 – GFAP staining at 150dpi. (A) GFAP staining in cerebellum, cortex, brain stem and 
thalamus. Cerebellum and thalamus scale bars = 100μm. Cortex and brain stem scale bars = 50μm.  
(B) GFAP staining midbrain where PrPd has been detected. In cerebellum, cortex, brain stem and 
thalamus there is no observable GFAP up-regulation or astrogliosis. In midbrain, fibrous astrocytes 
appear to exhibit minor increases in GFAP but this is not extended to protoplasmic astrocytes and 
occurs in both GSS and NBH/101LL animals. Scale bars = 100μm. 
 
 4.2.3. No neuronal deficits are observed at 150dpi 
The detection of PrPd associated with the interpeduncular nuclei and SNc indicates 
possible neuronal deficits. To examine whether morphological or structural changes 
have arisen in association with the deposited PrPd, antibodies to MAP2 were used to 
assess neuronal structure. Figure 4.4B demonstrates no detectable change in neurons 
associated with the GSS/101LL midbrain compared to NBH/101LL animals at 
150dpi. Similarly, figure 4.4A shows no change in MAP2 staining pattern in any 




Figure 4.4 – MAP2 staining at 150dpi. (A) MAP2 staining in cerebellum, cortex, brain stem and 
thalamus shows no change in staining quality or intensity between GSS or NBH/101LL animals. 
Cerebellum, cortex and brain stem scale bars = 50μm. Thalamus scale bars = 100μm. (B) MAP2 
staining in midbrain, which is where initial PrPd accumulation is observed. No change in staining 
quality or intensity is observed between GSS or NBH animals. Scale bars = 200μm. 
 
The neurons of the SNc are known to synthesise large quantities of dopamine for 
neurotransmission and express high levels of tyrosine hydroxylase. Using antibodies 
specific for this enzyme thus allows the level of expression of this critical enzyme 
and the number of neurons to be assessed. No detectable differences could be 
observed in the quality of staining in tyrosine hydroxylase positive neurons at this 
time-point (figure 4.5). Together, this data suggest that there are no structural or 
functional deficiencies in SNc or interpeduncular neurons, which are associated with 
PrPd accumulation, at 150dpi.  
[101] 
 
Figure 4.5 – Tyrosine hydroxylase staining at 150dpi of the midbrain nuclei. No change in staining 
quality or intensity could be observed between GSS or NBH/101LL animals at this stage indicating no 
loss of tyrosine hydroxylase staining in neurons associated with PrPd at this stage. Scale bars = 
100μm. 
 
4.2.4. Glial cell responses are observed at 200dpi, prior to neuronal deficits 
The neuronal-associated PrPd observed in GSS/101LL animals at 150dpi exhibits a 
similar staining pattern at 200dpi in the midbrain (figure 4.6), but observed in a 
higher proportion of animals tested; in eight of twelve GSS/101LL mice. The 








time-point (figure 4.6). When using antibodies against GFAP and Iba1, the glial cells 
in GSS/101LL animals in the SNc had undergone cell body hypertrophy with 
shortening and thickening of cell processes (figure 4.8A). These morphological 
changes are typical of activated microglia and reactive astrogliosis. Five serial 
sections through the midbrain were used to count the number of microglia identified 
using Iba1 in the SNc. No increase in average number of microglial cells per tissue 
section could be detected at this time-point in GSS/101LL animals despite the 
morphological changes of these cells (t-test; p=0.26, figure 4.7). An increase in the 
number of microglia in the substantia nigra, pars reticularis (SNr) is observed (t-test; 
p=0.0196, figure 4.7). This is a region which does not exhibit detectable PrPd  at this 
stage (figure 4.6), but there is high connectivity between different parts of the 
substantia nigra [333]. No glial cell responses could be observed in medulla, 
thalamus, cortex or cerebellum (figure 4.8B). This demonstrates a glial cell response 
specifically in regions of the brain exhibiting PrPd. Neuronal structure in the 
midbrain was assessed using antibodies specific to tyrosine hydroxylase (figure 4.9). 
No qualitative difference in staining between GSS/101LL animals and NBH/101LL 
could be observed. Together, this data indicates the initial detection of PrPd, followed 





Figure 4.6 – PrP staining at 200dpi. (A) Staining was observable in midbrain neurons (indicated by 
arrow), similar to 150dpi but no staining could be observed in other regions, for example, medulla or 
thalamus (B). 
 
 Figure 4.7 – Quantification of microglial cell number in SNc and SNr. No significant change could 
be observed in microglia cell number between GSS and NBH/101LL animals in SNc (t-test; p=0.26). 
A significant increase in number of microglial cells could be observed between GSS and NBH/101LL 




Figure 4.8 – Glial cell responses at 200dpi in SNc. (A) GFAP and Iba1 staining. Left panels represent 
GSS/101LL animals, right panels represent NBH/101LL animals. Significant morphological glial cell 
responses are observed using both glial cell markers. Scale bars = 50μm. (B) No glial cell changes in 
morphology could be observed between GSS and NBH/101LL animals in other regions of the brain, 
such as brain stem, thalamus, cerebellum or cortex. Cortex scale bars = 50μm. Medulla, thalamus and 
cerebellum scale bars = 200μm. 
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Figure 4.9 – Tyrosine hydroxylase staining at 200dpi of the midbrain nuclei. No change in staining 
quality or intensity could be observed between GSS or NBH/101LL animals at this stage indicating no 
loss of tyrosine hydroxylase staining in neurons associated with PrPd and glial cell responses at this 
stage. Scale bars = 100μm. 
 
4.2.5. PrPd accumulation occurs in a pattern akin to neuronal connectivity 
The spread of pathological lesions around the CNS in chronic neurodegenerative 
diseases is a well-established phenomenon [143, 144]. The detection of PrPd 
associated with midbrain neurons raises the prospect that PrPd and/or 








our understanding of neuroanatomy. The interpeduncular nucleus has been shown to 
be connected to neuronal populations of the brain stem, such as the medial and dorsal 
raphe nuclei [334, 335]. The dorsal raphe nuclei, for example, project axons to 
numerous regions of the brain, such as the striatum [336], the medial prefrontal 
cortex [337], the cerebellum [338, 339] and the paraventricular nucleus of the 
thalamus [340]. The interpeduncular nuclei also receive numerous innervations from 
the habenula [341]. The SNc exhibits extensive connectivity with other neurons of 
the midbrain, especially with the SNr [333]. The major thalamic projection of the 
SNr is to the ventromedial (VM) thalamus [342]. The SNc also has numerous 
afferent and efferent connections with the striatum [343]. This allows a platform to 
test the localisation of PrPd accumulation along well-established neuronal pathways, 
which are highlighted in figure 4.10, and compare them to the development of 
neurodegeneration or glial cell responses. 
[107] 
 
Figure 4.10 – Neuronal networks of the interpeduncular nuclei and SNc. Pathway A – This represents 
the neuronal connections of the interpeduncular nuclei. The habenula nuclei project axons to the 
interpeduncular nuclei. These nuclei then project axons to the dorsal and medial raphe nuclei. Further 
axons are then projected from the dorsal raphe nuclei to other regions such as medial pre-frontal 
cortex, paraventricular thalamus, cerebellum and striatum. Pathway B – This represents neuronal 
connections of the SNc. The SNc project most axons either to the SNr or striatum. Down-stream 
axons are then projected from the SNr to the VM thalamus. 
 
Using PrP specific antibodies on GSS/101LL and NBH/101LL animals at 220dpi, 
PrP could be detected in brain stem regions such as the medial raphe nuclei and 
dorsal raphe nuclei specifically in GSS/101LL animals (figure 4.11). This is of 
interest as the interpeduncular nuclei and the brain stem exhibit known neuronal 
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connections [334, 335]. No PrPd could be observed in the paraventricular thalamus or 
cerebellum, which are known to be connected to the dorsal raphe nuclei [339, 340], 
indicating a limited distribution of misfolded protein accumulation which is not 
associated with further down-stream brain regions at this stage. In addition, no PrPd 
could be observed in the habenula, which is known to exhibit anterograde projections 
to the interpeduncular nuclei [341]. 
[109] 
 
Figure 4.11 – PrP staining of Pathway A, represented in figure 4.10. PrPd staining is observed in 
interpeduncular nuclei, dorsal raphe nuclei and medial raphe nuclei. No PrP staining could be 
observed in the paraventricualr thalamus, cerebellum or habenula nuclei. Cerebellum and habenula 
scale bars = 100μm. Thalamus, brain stem and midbrain scale bars = 50μm. 
 
PrPd could also be observed in the SNr neurons of the midbrain at this time-point 
(figure 4.12). This is of particular relevance due to the known connectivity between 
[110] 
 
the SNc and SNr [333]. No PrPd could be observed in the VM thalamus or the 
striatum in GSS/101LL animals at this time-point (figure 4.12). 
Figure 4.12 – PrP staining of Pathway B, represented in figure 4.10. PrPd staining is observed in SNc 
and SNr. No PrP staining could be observed in the striatum or VM thalamus at this stage, indicating a 









4.2.6. Pathological spread is associated with regions of PrPd accumulation 
The distribution of PrPd between midbrain and brain stem populations represents an 
ideal platform to study the association between PrPd accumulation, the glial cell 
response and neurodegeneration between neuroanatomical distinct regions. Due to 
the sensitivity of glial cells as markers of neurodegeneration, these cells were 
assessed at 220dpi in the medial raphe nuclei of the brain stem. A notable alteration 
in cellular morphology of both astrocytes and microglia was observed in the medial 
raphe nuclei (figure 4.13). No glial cell response was observed in any part of the 
thalamus, striatum, cerebellum or retrosplenial granular cortex at this time-point 
(figure 4.13). 
Figure 4.13 – Glial cell responses at 220dpi. GFAP and Iba1 show astrocytosis and activated 
microglia associated with the medial raphe nuclei of the brain stem at this stage. No other glial cell 
responses were observed in other brain regions such as thalamus, cerebellum or cortex at this stage. 




Due to limited tissue availability, the dorsal, medial raphe nuclei, SNc or 
interpeduncular nuclei were not available to be assessed for neuronal deficits. 
Alternatively, the neuronal structure was assessed in other parts of the brain stem, 
such as the Gi nuclei, which as shown in chapter 3, undergoes neurodegeneration. 
Using antibodies specific to MAP2, as described previously at 220dpi, the MAP2 
staining quality was consistent with that of NBH/101LL brain stem (figure 4.14). At 
240dpi, the Gi nuclei are present (figure 4.14A; green arrow), but have lost MAP2 
staining. Hypertrophy of dendritic processes also occurs in this region (figure 4.14A; 
black arrow). This is a process known to occur in synaptic varicosities in other 
murine models of prion disease [204]. No change in MAP2 staining quality could be 
observed in other regions such as the retrosplinal cortex in GSS/101LL animals 











Figure 4.14 – MAP2 staining of Gi nuclei at 220 and 240dpi. (A) No change in staining intensity or 
quality could be observed in the GI nuclei at 220dpi compared to NBH. A significant loss of MAP2 
staining is observed in the Gi nuclei at 240dpi in GSS/101LL animals. Neurons still remain at this 
stage in this neuronal population, green arrow, but have lost MAP2 staining. Hypertrophy of the 
dendritic process is also observed at this stage in MAP2 stained neurons, black arrow. Scale bars = 
20μm. (B) No change in staining intensity or quality between GSS/101LL cortex (right) or 
NBH/101LL cortex (left). Scale bars = 50μm. 
 
Upon clinical onset of disease, VM thalamic MAP2 staining appeared substantially 
reduced (figure 4.15). The neuronal deficits observed in the thalamus at clinical 
stages of disease are similar to those observed in chapter 3, whereby MAP2 staining 
is generally lost in the ventral-lateral parts of the thalamus, but some neurons remain 
with MAP2 positive staining. To confirm the presence of PrPd spread to this region, 
PrP was assessed using IHC in GSS/101LL and NBH/101LL animals. PrP staining 
was observed in the thalamus of GSS/101LL animals at clinical stages of disease, but 
not in NBH/101LL animals (figure 4.16). In addition, the staining intensity of PrPd in 
the midbrain, for example, appears substantially increased compared to earlier stages 
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of disease. This data reaffirms the association between the IHC detectable PrPd and 
neurodegeneration.  
Figure 4.15 – MAP2 staining at clinical stage pathology in VM thalamus. Left panel represents 
GSS/101LL animals, right panel represents NBH/101LL animals. Significant loss of MAP2 staining is 
observed. Neurons which remain still retain MAP2 staining. Scale bars = 50μm. 
 
Figure 4.16 – PrP staining at clinical stage of pathology. Large quantities of PrPd accumulate in 
thalamus at this stage. In midbrain, the PrPd has increased from small quantities at 150dpi (see figure 




4.3. Results summary 
- PrPd is observed restricted to the midbrain at 150dpi, but no glial cell 
responses or neuronal deficits could be defined 
- Glial cell responses are observed at 200dpi correlating with the same region 
of PrPd targeting at 150dpi and 200dpi – this occurs prior to overt neuronal 
deficits 
- Distribution of PrPd accumulation in interpeduncular nuclei and dorsal and 
medial raphe nuclei and in SNc and SNr at 220dpi is associated with neuronal 
deficits and glial cell responses across both regions 
- Accumulation of PrPd occurs in a pattern which resembles neuronal 
connectivity, however other regions of physical connection do not exhibit 
PrPd or pathology spread 
4.4. Discussion 
The results in chapter 3 highlighted the presence of a predominantly PrPsen isoform 
of PrPd which is associated with regions of the brain undergoing neurodegeneration 
and associated glial cell responses. It was therefore important to consider whether the 
general progression of disease, from detection of PrPd to glial cell response to 
neurodegeneration, was present in the GSS/101LL model as has been described in 
some other prion diseases. Further, assessing the spread of pathology between 
regions could also strengthen the relationship between IHC detectable PrPd and 
neurodegeneration. A final important question is whether PrPsen isoforms accumulate 
in patterns resembling neuronal connectivity, as may expected from previous studies 
[143, 144, 281, 283, 284, 303], and whether this is associated with development of 




Using the IHC conditions that reliably detect PrPd at terminal disease (chapter 3), 
PrPd was observed at 150dpi in the midbrain of GSS/101LL animals. The detectable 
PrPd appeared associated with the interpeduncular nuclei and SNc. No PrPd could be 
identified in any other region of the brain. The exact sub-cellular localisation of 
detectable PrPd was not tested due to tissue limitations, but could be of value in 
future studies to decipher how affected cells respond to PrPd in early stages of 
disease. Using IHC with appropriate antibodies, no glial cell response or overt 
neuronal deficits could be defined at 150dpi. Given the known sensitivity of glial 
cells to changes in neuronal homeostasis, it is perhaps surprising no concurrent glial 
response is observed. This indicates either that: (i) there are no changes in neuronal 
homeostasis, (ii) the host is able to inhibit or ‘dampen’ the glial cell response or (iii) 
glial cell responses do occur, but assessing the morphology of the cells is insufficient 
to assess responses. In the first instance (i), no change in neuronal homeostasis would 
indicate that the detectable PrPd is having limited or no effect on the cells associated 
with or in closest proximity to the PrPd deposition. Similarly, the host could maintain 
neuronal homeostasis or inhibit the glial cell response from potentially exacerbating 
pathology, as hypothesised in scenario (ii). A likely option is (iii), whereby the 
markers being used in this study are simply not sensitive enough to identify a glial 
cell response. Further work is therefore required to elucidate the interaction of glial 




At later time-points, glial cell responses are observed in the midbrain where PrPd was 
first detectable and sustained. These glial cell responses precede detectable neuronal 
deficits, a phenotype observed previously [189, 191, 320-325]. At later time-points, 
the specifically targeted regions of the midbrain exhibit overt neuronal deficits. 
These are exemplified by the intrinsic disorder and loss of MAP2 stained neurons. 
These neurodegenerative phenotypes are associated with the spread of PrPd and glial 
cell responses from the interpeduncular nuclei to the medial and dorsal raphe nuclei. 
This data indicates an association between accumulation of IHC detectable PrPd, 
glial cell responses and neurodegeneration – reaffirming results in chapter 3.  
 
The accumulation of PrPd and associated pathology in anatomical distinct brain 
regions which have known neuronal connections is of further importance due to its 
implications in understanding interaction of disease components. The prion-like 
mechanism of misfolded protein propagation traditionally relies on detection of 
increased levels of misfolded protein or spread of misfolded proteins from injection 
site to interconnected regions [146, 154, 161, 286-293]. Here, PrPd is initially 
detected associated with specific neurons of the midbrain, namely the 
interpeduncular nuclei and SNc. The reasons for this initial targeting are unclear and 
will require further work. The subsequent observation of PrPd in neurons of the brain 
stem (such as the dorsal raphe nuclei) and in the SNr shows accumulation of PrPd in 
neuronal populations with known connectivity. The restricted observation of PrPd 
along these pathways and not to other known connected neuronal populations, 
however, shows this distribution is selective. It is unclear why specific neuronal 
populations are associated with PrPd accumulation whilst others are not. Selective 
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vulnerability is a well-established phenomenon in chronic neurodegenerative 
diseases (reviewed in [311]). The mechanism(s) for such selectivity is under 
considerable attention. 
 
In this study, we performed an intracerebral (i.c) 20μL injection of 1% GSS brain 
homogenate. This will likely result in widespread dispersion of the homogenate 
which will be quickly degraded, becoming undetectable [344]. Of course a small but 
undetectable quantity of misfolded prion protein may remain localised or widespread 
in the brain. Therefore, it is important to consider that the accumulation of detectable 
PrPd between brain regions may not be the result of a ‘spread’ along neuronal 
connections, although this is certainly a possibility. Alternatively, accumulation may 
result specifically due to physiological differences between brain regions, or other 
non-misfolded protein factors migrating in neurons which result from the initial 
deficits associated with protein misfolding. 
 
In summary, in the presence of previously defined PrPsen isoforms of PrPd, the 
relationship between IHC detectable PrPd, glial cell responses and neurodegeneration 
are reaffirmed in this chapter. This is particularly highlighted at 220dpi, where 
alongside the accumulation of PrPd in distinct brain regions which have neuronal 
connections, glial cell responses, for example, can be observed restricted to the same 
regions. This indicates that isolation of a predominant PrPsen isoform of PrPd in the 
GSS/101LL model does not disrupt the association of PrPd and neurodegeneration or 
alter the spread of pathology. 
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5. In vitro amplification of GSS/101LL CNS regions 
 
Chapter aim: To evaluate the relationship between PrPd and appearance of 
neurodegeneration using an assay with enhanced misfolded prion protein detection. 
 
5.1. Introduction 
The GSS/101LL model shows the same key features of vacuolation, activated 
microglia, astrogliosis and neurodegeneration as other murine prion diseases at 
clinical stages of disease, and in progression. However, the accumulation of a 
predominant species of PrPsen in this model represents a disease-specific feature, 
without the requirement for PrPres isoforms of PrPd. The initial aggregates of PrPd 
appear to be associated with neurons of the midbrain, for example the SNc, at early 
stages of disease. The deposited PrPd at later stages then appears to spread 
specifically to interconnected regions alongside the establishment of overt neuronal 
deficits, although this only occurs selectively along some but not all neuronal 
pathways. This suggests an association between PrPd and neurodegeneration. 
However, these results rely upon the detection of misfolded prion protein via IHC, 
which may not represent the full extent of PrPd present. Therefore, it was considered 
important to use more sensitive measures of detectable misfolded protein to discover 




A number of methods to detect PrPd exist, but highly sensitive techniques have been 
developed recently for the use as diagnostic tests for misfolded prion protein in 
samples. These are the PMCA [97] and the QuIC assay [101, 104]. Both techniques 
take advantage of the understanding of protein-template misfolding, using a small 
quantity of PrPd “seed” to induce a conformational conversion of PrPc “substrate” to 
a misfolded isoform. Originally, the CFCA was developed to encapsulate this 
reaction [94], but the PMCA was later published using periods of sonication to break 
down larger aggregates to form larger surface areas for additionally seeded 
conversion to take place. The in vitro misfolding is then measured using Western 
blots of the PMCA products with PK digestion. This experimental set up yielded 
extremely sensitive detection of PrPd species [97] (see 1.1.5. Prion diseases: 
Misfolding of PrPC to disease-associated isoforms for details). The immediate 
benefit of this method was the prospect of developing an ultra-sensitive diagnostic 
assay for screening and detection of pre-clinical prion disease. Additionally, further 
studies have used PMCA to investigate important questions regarding the protein-
only hypothesis and the prion hypothesis [99, 345]. Firstly, it was discovered that the 
conformationally re-arranged product of the PMCA was infectious to animals [100]. 
This demonstrated the importance of the assay’s ability to propagate the unique 
properties of individual prion strains [346]. Important studies by Delault et al. 
demonstrated that polyanionic co-factors such as lipids and/or non-specific RNA 
products are required for propagation of PrPd using recPrP as a substrate [99]. These 
results suggest that a minimal number of factors are required for the in vitro 
generation of PrPd. However, these results also represent a limitation of PMCA, as a 
more recently developed technique, the QuIC assay [101, 104], requires only 
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misfolded prion protein in the presence of recPrP (and in the absence of polyanionic 
co-factors) for misfolded protein amplification. Other limitations of the PMCA are 
the batch effect of the assay. Due to the use of sonication to disrupt protein 
aggregates, only relatively small numbers of samples can be amplified at any one 
time. Furthermore, the individual variation between sonicators means it is unlikely 
that the reaction conditions in each sample remains consistent throughout. In this 
study, the in vitro amplification technique to be used will compare detection of 
misfolded prion protein between different regions of the same GSS/101LL brain. It is 
not known whether different isoforms of misfolded prion protein exist between 
anatomically distinct regions of the brain, but due to the distinct microenvironments 
present in individual regions, this would not be unexpected. Therefore, as a result of 
the potential batch effect, variability in sonication and the requirement for specific 
co-factors for aggregation/misfolding of recPrP (which may or may not be present in 
an isolated brain region), the PMCA has a limited capability for comparative analysis 
between different regions of the same brain. 
 
The QuIC assay was subsequently developed, which uses a similar founding 
principle to the PMCA, with periods of disrupting protein aggregates and periods of 
rest for annealing and conformational rearrangement of recPrP to occur [101]. In 
contrast to PMCA, however, this assay uses a programmable and controlled intense 
shaking to disrupt aggregates rather than sonication. Furthermore, the shaking 
method allows the use of a shaking-incubator platform to be used. Importantly, 
shaking-incubators commonly hold 96-well plates and elicit a consistent shaking 
intensity across all wells of the plate. This development bypasses some of the 
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problems associated with PMCA by generating a sample-to-sample consistency 
which is also high-throughput. The conditions of the QuIC assay permit the 
misfolded recPrP to form fibrils. Initially, the detection of amplified PrPd was 
performed using Western blot analysis to detect the formation of PrPres isoforms 
[101], however, the fluorescent compound, ThT, can be used to identify fibril 
formation. This is due to the increased fluorescence of this compound when in 
contact with fibrils. The reasons for this increased fluorescence is unclear, but recent 
studies have begun to elucidate this enigmatic phenomenon (reviewed in [347]), and 
allowed the real-time detection of PrP fibril formation using a plate-reader, a 
technique termed the Real-Time QuIC, or RT-QuIC [104]. In recent studies, it has 
also been shown that RT-QuIC can propagate the strain properties of two distinct 
murine prion strains – including a comparable incubation period [348]. These results 
implicate the faithful propagation of conformations of misfolded prion protein using 
RT-QuIC. 
 
The reproducibility of the QuIC assay, as a result of the 96-well shaking-incubator 
platform, allows the comparative analysis of the presence/absence of misfolded prion 
protein species between brain regions. In addition, the recent demonstration of 
conformational properties of misfolded prion protein resulting from the RT-QuIC 
propagating the original prion strains used, including infectivity [348], highlight the 
RT-QuIC as an ideal method to assess the presence/absence of misfolded prion 
protein between different brain regions of the same brain. A caveat of the RT-QuIC 
however, is that the species of misfolded prion protein being detected is unknown. It 
is highly likely a misfolded prion protein species is responsible for the 
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aggregation/misfolding of recPrP in the RT-QuIC. This is because the product from 
PrP immunoprecipitation [105] and PK-digestion [299] are both capable of seeding 
the QuIC assay (aggregating/misfolding recPrP). Further, recent studies show the 
aggregated/misfolded recPrP product from the QuIC assay retain the original “seed” 
prion strain properties, including the transmissibility to mice [348]. Whether QuIC 
detection represents the entire cohort of PrPd or a subset is unknown. Due to a 
sample’s capability to seed/propagate ThT positive product from a recPrP substrate, 
the term prion seed is used in this thesis as an operational definition of the agent in 
diseased (but not control) tissue that initiate the generation of a ThT-positive reaction 
with recPrP. Therefore the distinction between prion seeds and PrPd is that PrPd 
represents all detectable forms of PrP using IHC and/or Western blot analysis. Prion 
seeds may represent the same species of PrPd as IHC or Western blot, or different 
misfolded prion protein species. Certainly, previous reports indicate the increased 
sensitivity of the RT-QuIC comparative to IHC or Western blot [101, 103, 104, 298]. 
Therefore other uncharacterised misfolded prion protein isoforms may also be 
identified using this method. 
 
Data presented in chapters 3 and 4 of this thesis present the close association 
between IHC detectable PrPd and neurodegeneration. To reaffirm this correlation, the 
QuIC assay will be utilised as a tool for ultra-sensitive detection of prion seeds 
between different brain regions of the same individual. It is known in some instances 
that different tissues within the same individual can influence the propagation of PrPc 
to a misfolded isoform. For example, known prion-infected whole brain tissue can 
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show prion seeding in the QuIC assay, however that same infected brain homogenate 
cannot propagate the misfolding of recPrP when spiked into blood [105].  
 
This study set out to test the distribution of prion seeds in GSS/101LL brain regions 
to determine whether the QuIC assay detects prion seeds correlating with 
neurodegeneration, similar to IHC detectable PrPd, or not, such as PrPres identified in 
the GSS/101LL cortex. Due to the prior understanding of different tissues inhibiting 
the propensity for recPrP aggregation/misfolding, this study will firstly test: (i) the 
propensity of brain homogenates from a range of murine prion strains to seed the 
QuIC assay; (ii) whether different brain regions propagate prion seeding with an 
equal capacity and (iii) whether prion seeds can be detected in GSS/101LL animals. 
Based on the results for the above questions, this study outlines stringent parameters 
to determine whether a sample can be classified as QuIC positive or negative. All 




5.2.1. Set up of the QuIC assay 
Previous work by Vascallari et al. demonstrated that murine prion strains could be 
detected via the QuIC assay using either murine recPrP or a hamster-sheep (ham/shp) 
chimeric recPrP substrate [299]. The ham/shp recPrP was used exclusively as a 
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substrate in this study and the QuIC protocol outlined in by Vascellari and colleagues 
was followed.  
 
To confirm that the assay worked in our laboratories, 263K hamster scrapie was used 
as a positive control to seed the QuIC assay, as previous studies have demonstrated 
high sensitivity using 263K as a seed [101, 104]. Initial findings showed that the 
263K brain homogenate used could be diluted to 10-6 concentration and continue to 
yield increased ThT fluorescent readings – indicative of recPrP misfolding fibril 
formation (figure 5.1). A 10-8 concentration of the original brain homogenate also 
showed an increased ThT fluorescent reading; however 10-7 did not. Therefore it is 
considered the reaction had a consistent sensitivity of 10-6 or 0.0001% of the original 
brain mass. 
Figure 5.1 - RT-QuIC assay set-up using 263K as a seed for converting Hamster-Sheep chimeric 
recPrPc to an abnormal conformation. Each line represents the mean Thioflavin-T fluorescence (n=8) 
within a log dilution series of an original 10% 263K hamster scrapie brain homogenate. The NBH and 
recPrP only (black lines) are used as negative controls to confirm that the seeding is disease-specific 
and not an entity within either an uninfected hamster brain or outwith the brain homogenate which is 




5.2.2. Prion seed detection in various murine prion strains 
An important consideration in the development of the QuIC assay for the use in these 
studies is the ability of the QuIC assay to detect prion seeds in murine prion disease 
brain. A previous study has reported that the QuIC assay can reliably and efficiently 
produce increases in ThT fluorescence of both murine and Ham/Shp recPrP when 
using murine prion disease tissue as a seed [299]. To establish whether murine prion 
seeds can be detected within the protocol presented here, brain homogenates from a 
number of murine prion strains (79A, ME7, 22A and 22L) were tested. This selection 
of strains was used to assess whether the QuIC assay could identify murine prion 
seeds which has been derived from the infection of a number of different original 
sources. For example, 79A is the result of a series of infections (sub-passages) of 
“Drowsy Goat” in mice with a PrnpA allele. ME7 is the result of sub-passages of 
natural scrapie into mice, whereas 22A and 22L are different strains obtained from 
the sub-passages of SSBP-1 ovine scrapie in mice. The detection of prion seeds from 
such diverse strains, established from a variety of different sources gives some 
confidence that prion seeds can be detected in murine tissue, regardless of the 
original source. This is important when considering the GSS/101LL model which 
involves the primary passage of human tissue into mice. 
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Figure 5.2 – (A) RT-QuIC assay seeds a number of different murine prion strains using Hamster-
Sheep chimeric recPrPc. Uninfected murine brain and recPrP (grey) are used as negative controls to 
demonstrate that neither brain homogenate or the reaction conditions alone are capable of seeding the 
assay. Each line represents the mean of 4 replicates. (B) Dilution series of each prion strain. The 
sensitivity of the QuIC assay was high in all strains tested as all gave increased ThT fluorescence even 
at 10-7 concentrations. 
 
When testing each of these strains in the QuIC assay, all strains altered the ThT 
fluorescence above the baseline, as established by uninfected controls (figure 5.2A). 
This shows that misfolded protein species can be detected in all murine prion strains 
tested here. Interestingly, each strain exhibits a different lag-phase and altered 
plateau of ThT fluorescence. When considering only the ThT plateau, this phenotype 
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categorised the prion strains according to the original sources. A dilution series of 
each strain was performed to determine if the differences in ThT plateau were the 
result of potentially different quantities of prion seeds. In each murine prion strain, a 
dilution of 10-7 could be readily detected (figure 5.2B). Unexpectedly, within 22A 
and 22L strains a concentration of 10-5 showed a higher ThT plateau compared to a 
higher concentration of 10-3. The reasons for this are unclear but suggest the plateau 
of ThT fluorescence may not necessarily represent the total quantity of misfolded 
prion protein originally added into the assay. Instead, the dilution series of the 
sample to be added into the QuIC assay likely provides a more accurate quantitation 
of prion seeds. Overall these results demonstrate that misfolded prion protein can be 
detected from murine brain homogenates from a multitude of different prion strains. 
 
5.2.3. GSS/101LL infected brain tissue can be detected by the QuIC assay 
In these studies, it is important to establish whether GSS/101LL animal tissue can 
seed the QuIC assay effectively. Previous studies have tested 263K infected 101LL 
animals (263K/101LL) and found detectable prion seeds without evidence of 
inhibition of the reaction or spontaneous false-positive prion seeding [299]. To test 
whether prion seeds could be detected in GSS/101LL animals, a dilution series of 
clinical stage GSS/101LL whole brain was performed. The animals (n=2) chosen had 
been previously demonstrated to exhibit no detectable PrPd by IHC using protocols 
replicated from previous publications [41], but were found to express relatively 
larger quantities of PrPd using optimised conditions with citric acid-buffer as detailed 
in chapter 3. It was found that in both animals, the brain homogenate could be diluted 
to a concentration of 10-5 and exhibit an increased ThT fluorescence (figure 5.3A). 
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Figure 5.3 – (A) RT-QuIC is capable of seeding GSS/101LL infected material. NBH is an uninfected 
101LL aged matched control and together with recPrP demonstrate that neither are capable of seeding 
the QuIC assay. (B) ThT fluorescence at 48 hours in the QuIC assay with ME7 or GSS dilutions. ME7 
consistently dilutes to 10-6 concentration, whereas GSS consistently dilutes to 10-5. Purple dashed line 
represents 10 standard deviations added to the negative control which is used as baseline. 
 
As described in chapter 3 of this study, the PrPd detected within the GSS/101LL 
models is predominantly PrPsen, although some PrPres isoforms are detected. To test 
the propensity of GSS/101LL brain homogenate to seed the QuIC assay versus a 
murine prion strain which exhibits large quantities of both PrPsen and PrPres, a 
dilution series of GSS/101LL material was tested comparative to ME7. The data 
presented in figure 5.3B show ThT fluorescence values after 48 hours of seeding in 
the QuIC assay. Despite the differing isoform ratios of PrPd between ME7 and 
GSS/101LL animals, prion seeds could be detected within the QuIC assay in both 
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samples. ME7 could detect prion seeds to a concentration of approximately 0.0001% 
of the brain mass, whereas GSS/101LL could detect a concentration of 0.001%. This 
represents a quantitative difference in prion seed detection between ME7 and 
GSS/101LL animals. 
Figure 5.4 – Western blot of ME7 PrP levels. Dilution series ranging from 5% (w/v) of total brain 







To compare the sensitivity of prion seed detection to other biochemical methods of 
PrPd detection, such as Western blot, a dilution series of ME7 brain homogenate was 
performed and tested using Western blot. To do this, a few adaptations were made to 
the Western blot protocol outlined in chapter 2. These were a 15μL brain 
homogenate of ME7 was diluted in 5μL of 4% sarcosyl, 5μL Western sample buffer 
(Invitrogen), 3μL sample reducing agent (Invitrogen) and 2μL dH2O or PK was 
added. This generated a sample which was 5% (w/v) of the original brain mass. A 
dilution series from 5% to 0.04% (5%, 2.5%, 1.25%, 0.625%, 0.3125%, 0.156%, 
0.078% and 0.04%) was then performed. Western blot detection using the PrP-
specific BH1 antibody could identify overall PrP levels to a concentration of 0.078% 
of the original brain mass. PrPres levels could also be detected to this level (figure 
5.4). In comparison to the QuIC assay detection of 0.0001% of the original brain 
mass in ME7 or even 0.001% of the original brain mass in GSS/101LL demonstrates 
the increased sensitivity of the QuIC assay comparative to Western blot analysis. 
 
5.2.4. No regional differences within an infected murine prion disease brain 
are observed 
Previous reports of the QuIC assay have highlighted the fact that different tissues can 
have different propensities to seed the QuIC assay. Most notable is the difference in 
the ability to detect prion seeds within the brain versus known infected blood. For 
example, previous studies by Orru et al. have demonstrated that when “spiking” 
uninfected blood with a known prion infected brain homogenate, the QuIC assay 
detection appears to be compromised [105]. This data suggests that components of 
blood are capable of inhibiting the QuIC assay. To date, the majority of studies used 
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to identify prion seeds have tested whole brain or peripheral tissues. As a 
consequence, it is unknown whether anatomically distinct regions of the brain exhibit 
prion seeding with equal capacity. 
Figure 5.5 - QuIC assay detection of individual regions of 79A prion infected brain. All regions of the 
brain can readily and specifically seed the conformational conversion of recPrP at comparably 
sensitive levels. 
 
To test this, 79A murine prion strain was regionally dissected into brain stem, 
cerebellum, cortex, thalamus, forebrain and rest of brain. In all these regions, it is 
known that PrPres can be detected (figure 3.13). This therefore allowed the 
normalisation of misfolded protein across regions, therefore regional effects upon 
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QuIC assay seeding could be tested. No difference in prion seed detection was 
observed in any brain region (figure 5.5). This shows that despite different brain 
regions being used, there is no difference in the propensity of any brain region to 
seed the QuIC assay. Therefore, unlike blood components, it is unlikely any factor 
exists within any compartment of the brain which is an inhibitor to the QuIC assay. 
 
5.2.5. Development of parameters to allow positive/negative reading of 
QuIC assay 
The QuIC assay in this study, and in other published studies, is shown to be a 
sensitive detection system for the presence of prion seeds. A confounding factor, 
however, is the limited understanding whether the QuIC assay detects all misfolded 
prion protein species or a sub-set of conformations. It is therefore necessary to 
establish stringent parameters to allow a positive or negative read-out from the QuIC 
assay. Previous studies have used an approach to identify a sample as positive or 
negative based on whether it passes a threshold which is the baseline (as determined 
by the average ThT fluorescence of an appropriate negative control) plus 10 standard 
deviations of the baseline. Generally, at least 3 or 4 replicates per sample are run per 
QuIC assay, and a sample which tests positive in at least 50% of replicates is 
considered positive [298]. In order to establish a positive or negative read-out from 
the QuIC assay, this study used the same threshold parameters outline above (i.e. any 
sample which accumulates a ThT fluorescence which is over 10 standard deviations 




In previous studies, the threshold parameters used are set up per assay. This is a 
useful tool to compensate for false-positive readings within an individual QuIC assay 
experiment. However, in this study it was found that different batches of purified 
recPrP exhibited different average ThT baselines (figure 5.6). Furthermore, between 
QuIC assay runs using the same samples, it was found that samples from uninfected 
animals had a random propensity to spontaneously increase ThT fluorescence over 
time (figure 5.7). Therefore, a system of generating a novel threshold for every assay 
would result in random de novo levels of spontaneous seeding being hidden amongst 
genuine, template-mediated conformational rearrangement. As a consequence, the 
levels of false-positive seeding are not recognised and thus compromise the 
comparison of results between QuIC assays, especially when using two different 
batches of purified recPrP. To overcome this, a standard threshold across all samples 
tested within and between batches of recPrP is important to establish.  
Figure 5.6 - The baseline of individual batches of hamster-sheep chimeric recPrP produced. Although 
the average baseline fluorescence is markedly different between batches, the average fluorescence in 
any recPrP batch does not appear to rise above 100,000 fluorescent units. The combined average 




This study accumulated all known-negative control samples run across all QuIC 
assays tested here using the Ham/Shp recPrP under consistent conditions. The ThT 
fluorescence for all negative control samples was averaged at each time-point within 
the QuIC assay, as depicted in figure 5.7.  
Figure 5.7 - All NBH controls corroborated in a single average ThT fluorescence line over time. This 
line can thus be referred to as the baseline ThT fluorescence. 
 
Figure 5.8 shows the average ‘combined baseline’ of all negative samples across all 
QuIC assays performed in this study (n=127 – black line). The baseline remains 
consistent at all time-points throughout the assay. Around cycle 220 (approximately 
50 hours), however, the standard deviation rises. When comparing data to average 
baselines for individual batches of recPrP, it is clear in some recPrP batches this is 
the time-point at which increased ThT “false-positives” are observed (figure 5.6; 
green line). This data suggests that de novo generation of a positive signal (a false-
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positive) can occur after 50 hours, therefore a 48 hour time-point (figure 5.8; purple 
dashed line) was chosen as the determinant time-point at which to apply the above 
positive/negative parameters. The threshold according to the baseline plus 10 
standard deviations is thus represented in figure 5.8 as the grey line. As a result, all 
samples will be adjudged according to whether the ThT fluorescence overcomes this 
standard threshold.  
Figure 5.8 - The combined baseline with standard deviations. At 48 hours into the QuIC assay (purple 
dashed line) the standard deviation (SD) is 14910 arbitrary fluorescent units. 10 SDs are added to this 
to established a threshold (grey line). Any fluorescence reading below this threshold will be counted 
as a negative QuIC result and any reading above this line will be regarded positive. 
 
5.2.6. Prion seeds are detected independent of neurodegeneration 
Thus far this study has demonstrated that GSS/101LL brain tissue is capable of 
seeding the QuIC assay (figure 5.3) and different regions of the brain from other well 
established prion models appear to have no effect on the detection of prion seeds 
(figure 5.4). With this understanding and under the parameters outlined above, 
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different regions (brain stem, thalamus, cerebellum and cortex) of the GSS/101LL 
brain were tested. As described in chapter 3, the brain stem and thalamus are regions 
which have neuronal populations undergoing severe neurodegeneration; however the 
cerebellum and cortex appear ‘unaffected’. It would be expected that prion seeds 
would be restricted to only those regions undergoing neurodegeneration. However, 
an increase in ThT fluorescence associated was observed in all regions of the 
GSS/101LL brain tested (figure 5.9A). The individual assay runs are shown in figure 
5.9B to demonstrate the limited variability between assay runs. It was found that 
100% of GSS/101LL animals tested at clinical stages of disease (n=4) surpassed the 
threshold, with the exception of a cortex sample of a single animal (figure 5.10). An 
individual NBH/101LL animal sample from cortex demonstrated a positive result, as 
did a NBH whole brain negative control. This demonstrates a low level of de novo 
seeding of recPrP. When comparing this data to findings in chapters 3 and 4 and 
what is currently understood of the correlation of PrPd and neurodegeneration, this 
finding shows that prion seeds do not correlate with neurodegeneration. 
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Figure 5.9 – (A) Average ThT fluorescence for each region of GSS/101LL ‘terminal’ tissue tested. 
All negative controls are marked as grey lines. (B) The plots of each region tested in the QuIC assay 








Figure 5.10 - Number of regions which surpass the threshold outlined in figure 5.8 at 48 hours in all 
animals tested (n=4). All regions tested within a GSS/101LL animal at clinical stage of disease are 
capable of seeding the conformational rearrangement of recPrP in the QuIC assay, with the exception 
of 1 animal which did not surpass the thresholds of ThT fluorescence within the cortex. The grey bars 
in ‘NBH whole brain’ and ‘NBH/101LL cortex’ demonstrated false positive results in 1/4 animals 
 
5.2.7. Characterisation of prion seeds in GSS/101LL animals 
The finding that ‘unaffected’ regions of the brain, with no detectable vacuolation, 
neurodegeneration or activated glia, are capable of seeding the QuIC assay is 
surprising. Although no PrPres is detectable via Western blot with the exception of 
the GSS/101LL cortex, the QuIC assay has been demonstrated to be exquisitely 
sensitive. Therefore, samples from three GSS/101LL clinical stage animals were 
exposed to 20μg/ml PK for 90 minutes prior to protease inhibition. These conditions 
are sufficient to detect partially PK resistant isoforms of PrPd in a number of 
different prion strains [349]. As demonstrated in chapter 3, these conditions reveal no 
detectable PrPres in clinical stage GSS/101LL animals in all regions with the 
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exception of a small quantity observed in the cortex. When using identical conditions 
to seed the QuIC assay, all regions tested identified prion seeds (figure 5.11). These 
results indicate either the presence of small levels of PrPres within multiple regions of 
the brain in GSS/101LL animals, or that prion seeds are indeed PrPres, but are 
possibly a different isoform to those detectable on Western blot or IHC analysis. 
Figure 5.11 - ThT fluorescence in regional samples from clinical stage GSS/101LL animals. The 
samples are either exposed to proteinase K (PK+) or water (PK-) for 90 minutes prior to addition of 
the homogenate to the assay. All samples, regardless of PK- or PK+ within GSS/101LL animals 




5.2.8. The quantity of prion seeds does not differ between regions 
The targeted neurodegeneration within the CNS of GSS/101LL animals, despite the 
detection of prion seeds in unaffected brain regions, could be explained by 
quantitative differences in prion seed accumulation and subsequent generation of 
neurotoxic species between regions of the brain. A region may accumulate larger 
quantities of prion seeds and as a result may be more susceptible to 
neurodegeneration. Therefore, the quantity of prion seeds was assessed in each 
region outlined above. Brain regions from GSS/101LL and NBH/101LL animals 
were diluted to a series of concentrations and added to the QuIC assay. It is 
hypothesised that as the concentration is lowered, samples containing small 
quantities of prion seeds will cease to give positive QuIC results before samples 
containing larger quantities of prion seeds. 
 
Regions of GSS/101LL brains at clinical stage pathology were used. Concentrations 
used in the assay were 0.1% [10-3], 0.01% [10-4], 0.001% [10-5], 0.0001% [10-6] and 
0.00001% [10-7] of the original sample mass. In order to control the experiment, 
NBH/101LL aged matched brain regions were used at 10-3 and 10-7 concentrations in 
the same assay. The regional dissections from three terminally sick GSS/101LL and 
three aged matched NBH/101LL animals were used to test this hypothesis. Each 
sample within an assay used three replicates and each individual assay run was 
repeated twice (figure 5.12). 
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Figure 5.12 - Dilution series of regions within GSS/101LL animals. Each line represents the average 





It was found that each region had the propensity to seed the QuIC assay to at least 
0.001% of the original sample mass (figure 5.12 and 5.13). The brain stem, thalamus 
and cortex samples exhibit a raised ThT fluorescence no further than 0.001% of the 
original tissue mass. The cerebellum on the other hand appears to dilute to a 
concentration of 0.0001% of the original tissue mass. Why there is a difference 
between cerebellar samples propensity to seed the QuIC assay is unknown. The 
results show that the quantity of prion seeds in each region studied bears no influence 
upon whether a region will succumb to neurodegeneration or remain ‘unaffected’.  
 
Figure 5.13 - Number of animals in dilution series from figure 5.12 which surpass threshold outlined 
in figure 5.8. At a concentration of 10-5, all animals tested exhibited a ThT fluorescence higher than 
the threshold. No animals overcame the threshold when tested at a concentration of 10-8.  
 
5.2.9. Prion seeds accumulate in a similar time-frame in affected and 
‘unaffected’ regions 
In chronic neurodegenerative diseases, the incubation period prior to onset of overt 
clinical symptoms is relatively large. During this time period, it is known that many 
subclinical stages of neurodegeneration occur, the best elucidated are synaptic 
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deficits and degeneration [189, 191, 203, 204, 217]. Prior to such neurodegenerative 
phenotype, accumulation of PrPd is detected – a finding recapitulated in this thesis 
(see chapter 4). These results hint that a region may only undergo neurodegeneration 
upon prolonged exposure to a misfolded protein. To test this, samples from the time-
course outlined in chapter 4 were used (150, 200, 220, 240 dpi and upon clinical 
onset [figure 4.1]). We hypothesised that regions which are undergoing 
neurodegeneration likely accumulate prion seeds earlier in disease and are exposed to 
such prion seeds for relatively longer periods of time. 
 
At each time-point (with exception of terminally sick animals), five GSS/101LL and 
five NBH/101LL animals were tested at a concentration of 10-3 of the original brain 
homogenate. In each individual QuIC assay, three replicates of a sample were used 
and every QuIC assay was repeated twice. At 150 dpi, two out of five (40%) of 
GSS/101LL animals tested were able to seed the QuIC assay in the brain stem (figure 
5.14). In other regions tested, only one out of five (20%) of GSS/101LL animals 
were positive, therefore suggesting the initial targeted accumulation of prion seeds in 
the brain stem in a subset of animals. At 200dpi, three out of five (60%) animals 
exhibit prion seeds in brain stem, thalamus and cerebellum. Two out of five (40%) 
showed positive QuIC seeding in the cortex at this time-point. This demonstrates an 
exponential spread of prion seeds in a larger number of animals, which is not 
restricted to specific brain regions and independent of neurodegeneration (as defined 
in chapter 4). At later time-points, at least three out of five GSS/101LL animals 
exhibit QuIC positive seeding in all regions tested with four out of five (80%) testing 
positive in brain stem and cerebellum at 220dpi and in the brain stem, thalamus and 
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cortex at 240dpi. As described above, all terminally sick (onset of clinical symptoms) 
GSS/101LL animals show prion seeds accumulated in all regions tested, with 
exception of one GSS/101LL cortex sample. 
Figure 5.14 - Percentage number of animals positive in QuIC assay in each region at each time-point 
tested. Overlaid grey bars represent NBH time-point controls. Red bars represent GSS/101LL 
samples. Each positive is categorised based on the parameters outlined earlier in this chapter. 
 
This data shows the accumulation of prion seeds at similar time-points in both brain 
regions which suffer neurodegeneration or are unaffected. For example prion seeds 
accumulate in the cerebellum and thalamus at similar time-points in a cohort of 
GSS/101LL mice at 200dpi. The thalamus will subsequently undergo 
neurodegeneration, whereas the cerebellum appears to remain pathologically 




5.3. Results summary 
- Multiple murine prion strains exhibit the property to seed the QuIC assay, 
including GSS/101LL 
- Inherent differences in brain regions have no effect on the capacity of QuIC 
detection of prion seeds 
- Prion seeds can be detected in regions with typical prion disease pathology 
and which appear to remain ‘unaffected’ in GSS/101LL animals 
- The lack of neurodegeneration in unaffected regions is not due to (i) 
quantitative differences between the levels of expression of prion seeds in 
different brain regions or (ii) the time from disease initiation at which each 
region is exposed to prion seeds 
- prion seeds detected in every region tested are PrPres 
 
5.4. Brief discussion 
In this thesis, the term prion seed refers to the detection of misfolded prion protein 
species in a particular sample using the QuIC assay. Prion seeds are the operational 
definition given to the capability of a sample to propagate the aggregation and/or 
misfolding of recPrP to a fibril-species of recPrP. Such prion seeds are disease-
specific and likely represent misfolded prion protein. However, what exact species of 
misfolded prion protein that prion seeds represent is, as yet, unknown.  
 
To study the relationship between misfolded prion protein and neurodegeneration, no 
study to date has been performed using novel techniques developed for enhanced-
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detection of prion seeds, such as the QuIC assay. It is unknown whether a possible 
association between prion seeds and neurodegeneration will be helpful in 
understanding the progress to neurodegeneration. In order to use the QuIC assay as a 
suitable protocol for the sensitive detection of prion seeds, a number of confirmatory 
experiments were required. The first step was to prove that prion seeds could be 
detected in murine prion strains, regardless of original source (including GSS/101LL 
animals) and that different regions of the infected mouse brain could seed the assay 
with equal propensity. As described above, all murine prions strains tested, including 
in the GSS/101LL model, could act as starting material for the QuIC assay and thus 
contained prion seeds. Furthermore, experiments with samples from 79A murine 
prion strain infected brain demonstrated that each region of the brain tested exhibited 
an equal capacity to identify prion seeds. 
 
Prion seeds were identified in all regions of the brain tested (brain stem, cerebellum, 
thalamus and cortex) at clinical stage in GSS/101LL animals. This data shows the 
distribution and accumulation of prion seeds does not correlate with 
neurodegeneration. This data therefore refutes the hypothesis that misfolded prion 
protein is closely associated with neurodegeneration. As mentioned earlier, the exact 
species of misfolded prion protein that prion seeds represent is unknown, and may or 
may not overlap with IHC or Western blot detectable PrPd. 
 
The presence of prion seeds but absence of neurodegeneration could be explained in 
a number of ways. Firstly, different brain regions may be exposed to different 
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quantities of prion seeds, whereby a neuron belonging to a specific brain region, such 
as the brain stem, are exposed to larger quantities of prion seeds comparative to the 
cerebellum. This study addressed this question using a dilution series of the sample 
being used to seed the QuIC assay. Each brain region tested, independent of 
neurodegeneration, was consistently capable of being diluted to at least 0.001% (w/v) 
of the original brain mass before losing the ability to seed the QuIC assay. This 
showed no quantitative difference in levels of prion seeds between brain regions 
could be observed. Another possible explanation for the absence of 
neurodegeneration in regions exposed to prion seeds could be accounted for by the 
time-exposure of prion seeds to a specific brain region. For example, a particular 
brain region may suffer neurodegeneration as it was exposed to prion seeds for 
comparatively longer than a region which appears pathologically unaffected. To test 
this, a number of GSS or NBH/101LL animals were tested at all time-points set up in 
these experiments (namely 150dpi, 200dpi, 220dpi, 240dpi and at clinical onset). It 
was found that a region which eventually undergoes neurodegeneration (e.g. 
thalamus) was exposed to prion seeds at a comparative time-period as a region which 
appears pathologically unaffected (e.g. cerebellum). A small cohort of GSS/101LL 
animals accumulates prion seeds in the brain stem at 150dpi. This may explain the 
earlier pathology observed in the brain stem comparative to the thalamus, as shown 
in chapter 4. 
 
Overall, prion seeds accumulate within the brain stem initially at earliest stages of 
disease. This coincides with the appearance of IHC detectable PrPd at 150dpi 
associated with midbrain neurons. No IHC detectable PrPd was detected in the brain 
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stem at this stage however. The interpeduncular nuclei and SNc of the midbrain 
which are associated with the IHC detectable PrPd at this stage exhibit neuronal-
connectivity with neurons of the brain stem, such as the dorsal and medial raphe 
nuclei [334, 335]. This could mean the prion seeds detected in the brain stem at 
150dpi may be the result of neuronal-specific migration of prion seeds from midbrain 
neurons to the brain stem. This study was not set up to answer such specific 
questions, therefore future studies could study the spread of prion seeds between 
individual neurons by laser micro-dissecting specific neurons associated with IHC 
detectable PrPd, such as the interpeduncular nuclei or SNc, and their respective 
interconnected neuronal populations before and around the 150dpi time-point. At 
later time-points, however, prion seeds are observed widespread across all brain 
regions tested, independent of neurodegeneration. This data indicates that prion seeds 
most likely spread in a non-disease-associated mechanism from one anatomical 
distinct brain region to another. How and why specific neuronal populations then 
undergo neurodegeneration is unknown. A possible explanation is the potential for 
different species of misfolded prion protein present in each brain region or a specific 
host response elicited from individual regions which renders one brain region 
susceptible to neurodegeneration, whilst others are resilient. 
 
In this thesis, the species of PrPd identified in regions of neurodegeneration are 
defined by the inability to detect PrPres using Western blot analysis. Using the QuIC 
assay, PrPres isoforms of misfolded prion protein can be detected in these regions 
however. This could either be due to the additional sensitivity of the QuIC assay to 
detect PrPres isoforms which were not detectable using Western blot, or as a result of 
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not establishing optimal conditions for the detection of PrPres species using Western 
blot on GSS/101LL brain regions. Certainly, the detection of small quantities of 
PrPres specifically in the cortex of GSS/101LL animals using Western blot analysis 
but the comparative identification of PrPres in cortex and other brain regions tested 
using the QuIC assay suggests the latter explanation is more likely correct. Future 
studies may therefore concentrate on defining the exact species of misfolded prion 
protein present between brain regions. A recent study by Choi et al. used sucrose 
gradients to separate aggregates of PrP in known prion-infected human brains [350]. 
Unique aggregates of PrP were separated in concentrations of sucrose between prion-
infected brain regions in comparison to uninfected brain regions [350]. These 
differences therefore represent unique misfolded prion protein species detectable 
between different brain regions of the same individual. Future work could apply this 
approach to elucidate differences/similarities of PrP aggregates between brain 
regions in GSS/101LL animals which may explain the selective vulnerability of 
neuronal populations in specific brain regions. Another explanation for this selective 
vulnerability may be due to the host response to prion seeds, which may differ 
between brain regions. To test this, chapter 6 will use a microarray analysis to assess 
the transcriptome of regions exposed to prion seeds and undergoing 







6. Genome-wide expression changes between different regions 
of GSS/101LL brains 
 
Chapter aim: To evaluate the host response in multiple brain regions of clinical 
stage GSS/101LL brains using a microarray analysis. 
 
6.1. Introduction 
The appearance of prion seeds exposed to regions of the brain which appear 
pathologically unaffected, even at clinical stages of disease, led to the hypothesis that 
the host response is an important factor in determining neurodegeneration. There are 
a number of methods to study the molecular differences between specific brain 
regions, such as assessing the transcriptome, proteome or metabolome.  
 
Genome-wide transcriptional analysis using a microarray is a well-established and 
widely used technique. In prion diseases, a number of microarray studies have been 
performed previously in mice [218, 228, 230, 351-354], sheep [355, 356], cattle 
[227, 357-361], non-human primates [362, 363] and humans [364-367]. Other 
studies assessed the transcriptome of in vitro murine infected neurons [368] and 
identified a number of differentially expressed genes with functions attributed to the 
cell structure, signal transduction, ribosome biogenesis amongst many others. In this 
study, differential gene expression was observed between prion infected cell lines, 
suggesting different neuronal backgrounds respond to the same prion strain in unique 
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mechanisms [368]. In whole brain analysis however, the predominant signature was 
represented by the glial cell response, specifically the innate immune response [228, 
230, 351-353]. Differential gene expression associated with a number of molecular 
functions was also observed, for example, genes associated with transcription, RNA 
splicing, translation, cell proliferation, cell adhesion and signal transduction [228, 
230, 351-353]. A more precise, mixed cell analysis was performed on dissected brain 
regions from ME7 and RML prion infected animals. These arrays concentrated on 
regions of the brain exhibiting overt neurodegeneration and, similar to whole brain 
analysis, a predominant glial cell response was also observed [354]. In other animal 
models of prion disease, the glial cell response is also observed as a predominant 
feature [227, 355, 356, 358-360] and is also observed in humans [365, 366]. 
Additionally, a number of other functions overlap with murine microarray studies, 
for example gene expression changes in genes associated with transcription, RNA 
splicing, translation and signal transduction [227, 355, 356, 358-360, 364-367]. A 
number of stress responses have also been identified using the microarray approach, 
such as ER stress [227, 355, 356]. 
 
A recent microarray analysis was performed on laser micro-dissected CA1 pyramidal 
neurons of the hippocampus of RML-prion disease mice over time. The findings 
from this study indicated that gene expression in neurons can be separated into 
distinct active phases [218]. Briefly, a set of genes associated with NMDA receptor 
signalling are up-regulated in pre-clinical stages of disease, but return to basal levels 
of expression upon clinical onset of disease [218]. The NMDA receptor signalling is 




A number of proteomic and metabolomic studies on prion disease animal models 
have been performed. These have mostly concentrated on detecting differentially 
regulated compounds to use as biomarkers in readily available tissue or fluid samples 
from animals infected with prion disease, such as the blood or CSF [370, 371]. A 
recent study has assessed the hippocampal proteome [372]. Additionally, this study 
assessed the astrocyte specific response, identifying a set of proteins which 
potentially protects against protein misfolding, excitotoxicity and ROS production 
[372]. Other proteomic studies have assessed the phosphor-states of proteins in prion 
diseases to evaluate the post-translational modifications incurred during prion disease 
[373]. The metabolome (profile of endogenous metabolites such as amino acids, 
nucleic acids, fatty acids, sugars etc.) can be assessed using mass spectrometry or 
NMR spectroscopy. A recent metabolomics study on the blood of CWD infected elk 
was performed to test for key biomarkers in prion-infected samples and identified 
several metabolites potentially specific for prion disease cases [374]. Specific 
changes in metabolites have also been observed in the brains of AD patients 
compared to healthy controls [375]. It is likely that as a result of the vast changes in 
the proteome and transcriptome during disease, the metabolome will exhibit large 
alterations. What relevance these changes have in neurodegeneration remains 
unknown. 
 
In the context of this thesis, a tool to assess the host response to prion seeds 
identified in unaffected regions in comparison to regions of neurodegeneration was 
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required. As a result of the extensive analysis and overlap of the transcriptome in 
prion diseases in both animal models and human prion diseases, a microarray is the 
most appropriate tool to study the host response. To interpret the large data set to 
compare differentially expressed genes within and between brain regions, a network 
analysis tool, termed BioLayout Express3D, was used [300]. This software allows the 
visualisation of biological data as a network. In contrast to a typical statistical 
approach to identify differentially expressed genes of interest, this software uses a 
correlation measure (pairwise Pearson) to gauge similarities between expression 
profiles of all transcripts. Data can then be subsequently divided into groups 
(clusters) using the Markov clustering algorithm (MCL) [302]. This means the 
software will cluster transcripts together without biasing data with assumptions on 
experimental design (questions being asked of the experiment) or microarray 
platform. As a result, this network analysis approach can result in clusters of genes 
which are co-expressed but not necessarily differentially expressed between the 
samples being compared. Examples of these are genes which are represented by 
multiple probe-sets on the microarray platform used [300]. Where clusters of genes 
are observed that show an interesting pattern of expression; analysis can be verified 
using statistical approach to test differentially expressed transcripts within a region 
(two-tailed t-test) or between regions (ANOVA).  
 
6.2. Results 
The left hemisphere brain stem, thalamus, cerebellum and cortex from six clinical 
stage GSS/101LL and aged matched NBH/101LL animals were dissected in artificial 
CSF followed by RNA extraction and purification (see chapter 2 for details). This 
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allows the RNA purification from regions of the brain which are undergoing 
neurodegeneration (brain stem and thalamus) or remain unaffected (cerebellum and 
cortex) in GSS/101LL animals. NBH/101LL samples are aged matched controls 
which received an i.c. injection of 1% uninfected brain homogenate at the same time 
as the GSS infection of 101LL experimental animals. Samples from each mouse 
were then paired and pooled to minimise individual sample variability, i.e. two 
GSS/101LL animals paired together and each brain region pooled. This resulted in 
three RNA samples per brain region for both GSS and NBH/101LL animals. The 
pooled RNA samples can be viewed in table 6.1. A microarray was then performed 
using the Affymetrix Mouse Gene 2.0 arrays and transcript intensity was scanned 
using the Affymetrix GeneTitan Instrument. Raw results were received in the 
Affymetrix .CEL file format. Overall probe intensity was initially analysed using 
Affymetrix Expression Console. 21 of 24 array samples used in this analysis 
exhibited relatively consistent probe intensities across all GSS and NBH brain 
regions (figure 6.1A). This allowed for normalisation of this data using the 
parameters outlined in chapter 2. The outlying samples in figure 6.1A do not appear 
to show any probe cell intensity in comparison to other arrays (figure 6.1B). The 
reason for this is unclear, but could be due to degraded or low quality RNA or a 
technical error when performing the microarray. As shown in table 6.1, the 260:280 
ratio shows relatively high nucleic acid to protein contaminant proportions in the 
three samples of interest, similar to those other samples which exhibit good probe 
intensity on the arrays. This suggests the RNA quality of the three samples is not of a 
noticeably lower quality compared to other samples which successfully hybridised. 
Nevertheless, as a result these three array samples have been omitted from this study. 
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Figure 6.1 – (A) Sample variability in intensity read-out from microarray plate. Red dotted lines 
indicate GSS samples, green lines NBH. Samples generally show equivalent intensity values, 
however, three samples (GSS Cortex ii and iii and Thalamus i) exhibit intensity values far outside the 
general intensity probe. (B) Raw data from .CEL files shows that the three samples run by Edinburgh 
Genomics failed to adhere to the probe sets on the array chip.  
 
 
The similarity of samples was assessed after normalisation of data. Figure 6.2 shows 
the principle component analysis (PCA) of each sample constructed using Pearson 
correlation coefficient. This type of plot allows the visualisation of sample similarity, 
whereby the nodes represent an individual sample and the edges represent their 
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correlation. Thus the closer two samples are together, the higher the sample 
similarity. This PCA shows an overall clustering of GSS/101LL samples (figure 6.2; 
red box) and NBH/101LL samples (figure 6.2; green box). The regions of the brain 
in GSS/101LL animals undergoing overt neurodegeneration (brain stem and 
thalamus) show relative similarity between NBH thalamus samples. The GSS brain 
stem however does not show any correlations with NBH brain stem. Similarly, the 
GSS cerebellum exhibits no correlation to NBH cerebellum. The GSS brain stem and 
cerebellum however do show sample correlation as do the NBH brain stem and 
cerebellum. The GSS and NBH cortex samples are clustered as a group, but also 
show high correlation between GSS and NBH thalamic samples. 
Figure 6.2 - Principle component analysis (PCA) constructed in Biolayout Express 3D representing 
sample variance. Each node represents a specific sample. Edges are colour coded to represent strength 
of correlation between samples ranging from red to purple to blue. No edge represents no significant 
correlation between samples. Red nodes = Brain stem. Pink nodes = Thalamus. Blue nodes = Cortex. 
Yellow nodes = Cerebellum. The widest variation in samples are the cerebellar samples. The GSS 
cerebellum clusters together with the closest similarity with GSS brain stem. NBH cerebellum clusters 
together but has closest similarity to NBH brain stem. The regions of neurodegeneration (GSS brain 
stem and thalamus) are clustered together also and show the highest similarity to their respective NBH 
control regions. The GSS and NBH cortex samples cluster together and also show high similarities to 
the thalamus samples – indicative of the neuroanatomical connections between these regions. Overall 
clusters of samples are highlighted in the red or green boxes to represent GSS/101LL samples (red) or 





6.2.1. Network analysis of all array samples 
Network topology showed three distinct major groups of clusters (figure 6.3) and 
using the MCL algorithm, groups of highly connected nodes were identified. Each 
cluster of nodes is colour coded and represents transcript expression patterns which 
are highly correlated. The edges show the correlation coefficient of individual nodes 
and thus are spatially ordered to show highly correlated samples closely arranged. 
These groups are defined by clusters of differentially expressed genes in GSS/101LL 
animals (Figure 6.3; groups B & C) and the non-disease related gene expression 
differences inherent to individual brain regions (Figure 6.3; group A). Figure 6.4 
shows example clusters of each of these three major groups. Group A shows no 
expressional differences between GSS or NBH individual brain regions, but are 
identified in this network analysis due to the inherent differential gene expression 
between individual brain regions. Group B represents a number of highly related 
clusters showing down-regulated transcripts across all regions of GSS/101LL brains 
in comparison to NBH/101LL animals. Group C shows up-regulation of genes 
specifically in brain regions which have been shown to undergo neurodegeneration in 
chapters 3 and 4. 
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Figure 6.3 - Network graphs constructed by BioLayout Express3D. Each node represents an individual 
transcript and each edge represents the correlation coefficient. Three major groups are defined in this 
network. Nodes are coloured according to individual clusters based on MCL algorithms. 
 
Figure 6.4 - Transcript expression changes in clusters arranged by the Markov algorithm. This data 
shows the mean expression levels of genes within a sample and shows the comparison to the mean 
expression levels of other samples. For instance, group B shows high expression in NBH/101LL brain 
regions in two distinct clusters identified by Biolayout Express3D but comparatively lower expression 
in all brain regions tested within GSS/101LL mice. X-axis shows samples ranging from GSS/101LL 
brain regions undergoing neurodegeneration (red bars; brain stem and thalamus respectively); 
GSS/101LL brain regions which are unaffected (green dashed bars; cerebellum and cortex 
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respectively). Grey bars show NBH/101LL brain regions (solid grey bars; brain stem and thalamus 
respectively//dashed grey bars; cerebellum and cortex respectively. 
 
 
6.2.2. Down-regulated transcripts across all brain regions of GSS/101LL 
animals 
Group B exhibits a number of clusters which exhibit down-regulated transcripts 
across all regions of the GSS/101LL brain in comparison to NBH/101LL animals.  
These comprise 799 transcripts, of which 380 could be attributed to known or 
predicted genes, 11 encoded microRNAs, and 40 other non-coding RNAs and 
pseudogenes. A complete gene list can be found in Appendix 1. The remainder 
represented multiple transcripts for individual genes. Of the 380 genes identified in 
this group, 235 had a known function. Figure 6.5a shows a breakdown of functions 
attributed to the 235 genes, which include genes related with sensory function, 
immune function, genes involved in transcription, transcriptional regulation, pre-
mRNA splicing, and translation. The largest proportion of genes is attributed to 
sensory function. These represent large families of vomeronasal receptors (42 genes) 
and olfactory receptors (41 genes), in addition to two taste receptor genes. Figure 6.6 
shows examples of down-regulated sensory related genes across all regions tested. 
[162] 
 
Figure 6.5 - (A) Breakdown of functions of genes identified in clusters assigned to group B. The 
largest proportion of genes belong to 3 families of sensory receptors; olfactory receptors, 
vormeronasal receptors and taste receptors (38%). Other general gene functions identified were 
immune related (13%) and transcriptional regulation (9%). (B) Average transcript intensity per sample 
found in all clusters of group B. (Red solid bars; GSS brain stem and thalamus, respectively. Green 
dashed bars; GSS cerebellum and cortex, respectively. Grey solid bars; NBH brain stem and thalamus, 
respectively. Grey dashed bars; NBH cerebellum and cortex, respectively. 
 
A number of genes related to immune function have also been identified in this 
group. These consist of pro-inflammatory cytokines and receptors (e.g. interferon 1α 
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and TLR4), chemokines (e.g. CCL2) and genes related to neutrophil (e.g. Defensin-α 
23) and Natural Killer cell (CD244) recruitment and function. Figure 6.7 shows the 
expression changes of some down-regulated immune related genes across all regions. 
A set of transcriptional regulatory proteins, Sp100/Sp110/Sp140, are also shown to 
be down-regulated (Figure 6.8). These form a complex, which is a constituent of the 
PML nuclear body (NB) [376] the expression of which is controlled by interferon 
levels [377]. Sp100 is most widely studied, and has been shown to play an important 
anti-viral function [378-380], through the transcriptional regulation of the 
transcription factor ETS1 [381, 382]. The ETS1 transcription factor directly controls 
the expression of a number of defensins, cytokines and chemokines [383]. The ETS1 
gene, however, shows no evidence of changed expression in any region. Other 
functions of the Sp100/Sp110/Sp140 complex involve transcriptional control, as 
RNA polymerase II has been shown to co-localise with NBs [384-386] and nascent 
RNA has been identified in the periphery of NBs [387]. Indeed, genes involved in 
regulating RNA polymerase activity (e.g. CTDSPL [388] and Med7 [389]) and a 
subunit of RNA polymerase II (Polr2k) are found down-regulated (figure 6.9). A 
component of the Cullin-RING-based BCR E3 ubiquitin-protein ligase complex, 
Speckle-type POZ protein (SPOP), is also down-regulated in all brain regions (figure 
6.10). This complex mediates ubiquitination and proteasomal degradation of target 
proteins, such as breast cancer metastasis suppressor 1 (BRMS1) and death-domain 
associated protein (DAXX) [390, 391], of which are repressors of NF-κB activation 
and constituents of the PML nuclear body, respectively [376, 392]. It was found that 
a general increase in expression of these down-stream genes occurred, although this 
is only statistically significant in brain stem and cerebellum for BRMS1 (t-test; 
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p<0.05) and only brain stem for DAXX (t-test; p=<0.05) (figure 6.10). The down-
regulation of SPOP indicates that the protein products of such genes are likely to be 
increased during disease and the observation of an increase gene expression level 
supports this.  
Figure 6.6 - Down-regulation of genes associated with sensory reception. Representative genes from 
the olfactory receptor family (Olfr1381), taste receptor family (Tas2r120) and vomeronasal receptor 
family (Vmn2r85) show down-regulation across all regions tested. Red bars; GSS brain stem and 
thalamus as assigned. Green bars; GSS cerebellum and cortex as assigned. Grey bars represent the 
respective NBH control. 
 
A number of ribosomal proteins have also been shown to be down-regulated across 
all regions tested (figure 6.11). These include genes which encode components of the 
40S (Rps12 and Rps18) and 60S (Rps7a) ribosomal subunits, suggesting loss of 
translation. Overall, the down-regulation of the Sp100/Sp110/Sp140 gene complex, 
possibly by the down-regulation of interferons, appears to be central to a large 
proportion of differentially regulated genes. The Sp100/Sp110/Sp140 complex is 
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commonly expressed in cells of the innate immune system, including macrophages 
[393]. As microglia represent the predominant macrophage population within the 
CNS, it is likely the substantial down-regulation of many of the genes identified in 
this group may be predominantly within microglia. 
Figure 6.7 - Down-regulation of genes associated with the immune response, such as pro-
inflammatory genes Toll-like receptor 4 (TLR4) and interferon1α (Infa1). Defa23 and CD244 are 
molecules expressed on neurophils and NK cells respectively and Ccl11 is a chemokine. All show 




Figure 6.8 - Down-regulation of transcription regulatory genes involved in anti-viral responses. These 
genes also regulate transcription, via interaction with RNA polymerase II and translation via ribosome 
biogenesis. All regions show down-regulation of this complex. 
Figure 6.9 - Down-regulation of the RNA Polymerase II subunit, Polr2k, and other genes involved in 
mediating RNA Polymerase II activity. This is likely the result of the down-regulation of the 
Sp100/Sp110/Sp140 complex of genes in cells of the innate immune system, such as microglia. This 
therefore represents a possible loss of transcription of RNA Polymerase II targets in microglia and 





Figure 6.10 - Down-regulation of speckle-type POZ protein (SPOP) across all brain regions tested (t-
test; p=<0.01). A increase in BRMS1 and DAXX, targets of SPOP-mediated ubiquitination, are also 
observed, although this is only significantly observed at the transcript level in brain stem and 






Figure 6.11 - Decreased expression of genes encoding ribosomal subunits. RPS12 and RPS18 encode 
subunits of the 40S ribosome, whereas RPL7a encodes a subunit of the 60S ribosome. 
 
6.2.3. Neurodegeneration specific up-regulation of genes 
In GSS/101LL animals, the brain stem and thalamus suffer neurodegeneration at 
clinical stages of disease. The cerebellum and cortex, however, appear unaffected 
using histopathological analysis. Figure 6.3 shows a separate group (Group C) which 
exhibits an up-regulation of genes specifically within regions of the brain which are 
undergoing overt neurodegeneration. This group comprises 117 transcripts which 
consist of 113 known or predicted genes (a complete gene list can be found in 
Appendix 2). The attributed functions of these genes are predominantly orientated 
around the immune response (figure 6.12 and figure 6.13). Cell proliferation and 
phagocytosis are also up-regulated (figure 6.14).  
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Figure 6.12 - (A) Breakdown of functions of genes identified in clusters assigned to group C. The 
largest proportion of genes are related to immune function (39%). Other general gene functions 
identified were genes related with cell proliferation (10%), phagocytosis and lysosomes (10%). (B) 
average transcript intensity per sample found in all clusters of group C. Red solid bars; GSS brain 
stem and thalamus, respectively. Green dashed bars; GSS cerebellum and cortex, respectively. Grey 
solid bars; NBH brain stem and thalamus, respectively. Grey dashed bars; NBH cerebellum and 
cortex, respectively. 
 
Some astrocyte specific genes are also observed in this group, such as GFAP and 
major facilitator super family domain containing 2a (Mfsd2a) which are involved in 
reactive astrogliosis [248] and BBB [394] respectively. Due to the fact that GSS 
thalamus and GSS cortex samples had to be omitted, resulting in a loss of power of 
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analysis of these regions, analysis of group C genes will concentrate on a 
comparative analysis of the brain stem against the cerebellum. Figure 6.13 highlights 
a cohort of genes up-regulated specifically in the brain stem, which include TGFβ-1, 
components of the complement pathway, Relt, Toll-like receptors and TREM2. 
These indicate a hybrid pro- and anti-inflammatory response in these regions. There 
is some evidence of an increase of such genes within the cerebellum, such as TGFβ 
and Relt; however this is not statistically significant in comparison to the brain stem 
(ANOVA; p=<0.001).  
Figure 6.13 - Increased expression of genes related to immune function, particularly within the innate 
immune response. Some increase in TGF-beta and Relt are observed (t-test; p=<0.05) in the 
cerebellum, however the increased expression of these genes is more extensive in the brain stem 
compared to the cerebellum (ANOVA; p=<0.001). 
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Figure 6.14 - Increased expression of genes related to cell proliferation (e.g. Bcl3 and Igfb2) and 
phagocytosis and lysosome specific genes (such as Gns or Laptm5). These genes are statistically 
significantly increased in GSS brain stem (t-test; p=<0.05) but no change is observed in the 
cerebellum. 
 
Despite the expression of genes predominantly involved in the innate immune 
response, such as TGFβ1, no interleukins and only interleukin receptor 13α1 
(IL13Ra) were identified in this group. Using transgenic mice which exhibit KO of 
cytokines or cytokine receptors, a number of studies have shown significant 
alterations of the incubation period of prion infected mice comparative to a WT prion 
infection. These include KO of genes which increase the incubation period, such as 
IL1r1 [395, 396], Ccl2 [397] and Cxcr3 [398] and KO or knock-down of genes 
which shorten the incubation period such as TGFβ1 [276], IL4 [399], IL10 [396, 
399], IL13 [399] and Ccr1 [400]. In addition, KO of the CD14 surface antigen, 
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which is preferentially expressed on monocytes/macrophages and plays a role in 
activating the pro-inflammatory mediators TLR2 and TLR4, results in an increased 
incubation period [401]. It is important to note a number of other cytokine or 
cytokine receptor KO transgenic mice have been infected with prion diseases with 
little observable effect. These include Tnf, Tnfr1, Tnfr2, Ccr2, Ccr5 [396], and IL6 
[402]. Table 6.2 shows the change in expression of these particular gene expression 
profiles in this study. Generally, KO genes from previous studies which show an 
increased incubation period are either up-regulated specifically in regions of 
neurodegeneration (e.g. CD14), or in both brain stem and cerebellum (e.g. IL1r1). 
Others do not show a change in expression comparative to NBH brain regions (e.g. 
Ccl2 and Cxcr3). Conversely, KO of genes which result in shortened incubation 
period are down-regulated in both brain stem and cerebellum (e.g. IL13) or only GSS 
cerebellum (Ccr1), whereas IL4 and IL10 show no change. 
Table 6.2 - Expression changes of genes in previously shown to impact incubation period of murine 
prion diseases when knocked out. Genes which confer an elongated incubation period when knocked 
out are Il1r1, Ccl2, Cxcr3 and CD14. All genes are comparative to the appropriate NBH brain stem or 
NBH cerebellum controls. Il1r1 and CD14 show an increase in expression in GSS brain stem and 
Il1r1 also shows an increased expression in GSS cerebellum. Genes which confer a shortened 
incubation period are IL4, IL10, IL13 and Ccr1. Ccr1 shows decreased expression in only the GSS 
cerebellum, but IL13 shows decreased expression in both GSS brain stem and GSS cerebellum. All 




6.2.4. Up-regulation of genes specifically in cerebellum 
In addition to the two major groups of genes which are differentially expressed either 
across all regions or in regions of neurodegeneration, a smaller group of up-regulated 
genes specifically in the cerebellum were identified (figure 6.15A). This cluster of 
genes is found in group A (figure 6.3; group A) due to the correlation with 
cerebellum-only expressed genes in GSS and NBH/101LL animals (figure 6.15B). 
Figure 6.15 - (A) Average transcript intensity of a group of clusters which show increased transcript 
intensity in GSS cerebellum comparative to NBH cerebellum. (B) Average transcript intensity of a 
cluster of genes which show high expression specifically in cerebellum, independent of disease. Red 
bars, GSS brain stem and GSS thalamus respectively. Green dashed bars, GSS cerebellum and GSS 
cortex respectively. Grey bars, NBH brain stem and NBH thalamus respectively. Grey dashed bars, 
NBH cerebellum and NBH cortex respectively. 
 
This group consists of 41 transcripts which can be assigned to 40 known or predicted 
genes. 31 genes have a known function. A complete gene list can be found in 
Appendix 3. The largest groups of these genes are involved within neuronal function 
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(6 genes) and transcriptional regulation (7 genes) (figure 6.16). As shown in chapter 
3 of this thesis, brain regions which are pathologically unaffected (such as the 
cerebellum and cortex) appear to show an increased staining intensity of neuronal 
specific markers, such as MAP2. Figure 6.17A shows the increased expression of 
each gene associated with neuronal function in the cerebellum. Previous studies have 
identified an increased level of parvalbumin staining which precedes 
neurodegeneration in organotypic slice cultures of the cerebellum [403]. Although 
parvalbumin expression wasn’t correlated with the six genes identified in this group; 
transcripts for parvalbumin are statistically significantly increased in the cerebellum 
also (figure 6.17B). 
Figure 6.16 - Breakdown of functions of genes identified in clusters which show increased expression 
in GSS cerebellum comparative to NBH cerebellum. Genes attributed to neuronal function (6 genes) 
and transcriptional regulation (7 genes) represent the largest proportions of this cluster. 
[175] 
 
Figure 6.17 - (A) Increased expression of genes related to neuronal function in GSS cerebellum 
(green bars) comparative to NBH cerebellum (grey bars). (B) Increased expression of parvalbumin 
within GSS cerebellum comparative to NBH cerebellum (t-test; p=<0.05). 
 
6.2.5. Differential stress responses in individual brain regions 
Recent studies have suggested the involvement of ER stress and activation of the 
UPR in neurons as a potential neurotoxic mechanism in prion diseases [225-227]. 
Other studies have implicated oxidative DNA damage as a key mechanism of 
neurodegeneration in prion diseases [404]. The network analysis performed in this 
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study does not highlight the differential expression of such stress response pathways. 
However, to probe whether differential gene expression occurs in response to 
stresses, the activated transcription factors (ATFs) were assessed for differential 
expression. These are known to be activated as a result of various stresses, including 
cytokines [405], DNA damage [406] and misfolded proteins [407] and regulate the 
expression of stress response pathways [405-414]. Figure 6.18 shows the 
transcriptional changes of a number of transcripts assigned to the ATF transcription 
factors. As can be seen, the brain stem exhibits a statistically significant up-
regulation of ATF2 (t-test; p=<0.05), ATF4 (t-test; p=<0.05), ATF6β (t-test; 
p=<0.01) and ATF7 (t-test; p=<0.05). The thalamus exhibits an up-regulation of 
ATF6 (t-test; p=<0.05) and ATF7 (t-test; p=<0.05). This data shows that in two 
anatomically distinct regions undergoing overt neurodegeneration, the specific stress 
response observed can differ. The cerebellum exhibits a statistically significant up-
regulation of ATF1 (t-test; p=<0.05), ATF6 (t-test; p=<0.05) and ATF6β (t-test; 
p=<0.01). Due to omission of cortex samples, statistical analysis could not be 
performed on cortex, however up-regulation of ATF1 and ATF6β were prominent. In 
regions which appear pathologically unaffected, there appears to be a consistent 
stress response which differs only by the involvement of ATF6 in the cerebellum. 
ATF7 is consistently up-regulated in regions of neurodegeneration. Overall this data 
indicates the expression changes of transcription factors which have broad 
implications within stress response pathways in both regions of neurodegeneration 




Figure 6.18 - Differential gene expression in activated transcription factors (ATFs). In GSS brain 
stem, an increase in ATF2 (t-test; p=<0.05), ATF4 (t-test; p=<0.05), ATF6-beta (t-test; p=<0.01) and 
ATF7 (t-test; p=<0.05) is observed. In GSS thalamus, an increase in ATF6 (t-test; p=<0.05) and ATF7 
(t-test; p=<0.05) is observed. In GSS cerebellum, an increase in ATF1 (t-test; p=<0.05), ATF6 (t-test; 
p=<0.05) and ATF6-beta (t-test; p=<0.01) is observed. No statistical analysis can be performed in 







6.3. Results summary 
- Two major groups of differentially regulated genes were observed; a down-
regulation of genes across all regions tested and an up-regulation of genes 
specifically in regions of neurodegeneration. These can both be attributed to a 
microglial response 
- Within regions of neurodegeneration, a hybrid pro- and anti-inflammatory 
response is observed 
- A small up-regulation of genes specifically in the cerebellum which are partly 
involved in neuronal function (concurring with an up-regulation of neuronal 
specific proteins shown in chapter 3. 
- Stress response pathways are suggested to be present across all regions, 
including cerebellum and cortex 
 
6.4. Discussion 
To test the hypothesis that different brain regions may protect/prevent 
neurodegeneration from occurring in pathologically unaffected regions exposed to 
prion seeds, a microarray analysis was performed. Two major groups of differentially 
expressed genes were identified. These consisted of a group of genes down-regulated 
across all brain regions tested and a group of genes up-regulated only in regions of 
overt neurodegeneration. A large proportion of genes which are down-regulated are 
related to sensory function, namely olfactory, vomeronasal and taste reception. What 
implications this has, if any, upon neurodegeneration is unclear and requires further 
studies to elucidate whether this is indeed an important mediator of disease or simply 
a consequence. The remaining genes in this group represented a down-regulation of 
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pro-inflammatory cytokines and anti-viral response genes. The down-regulation of 
this anti-viral response (orientated around the Sp100/Sp110/Sp140 complex) can thus 
have an impact upon transcription and ribosome biogenesis [377, 381, 382, 384-387]. 
Indeed, a large number of genes and non-coding RNA are down-regulated in a 
pattern correlating with the down-regulation of RNA polymerase II and other genes 
regulating its expression (e.g. CDTSPL and Med7). Additionally, a number of 
ribosomal genes encoding parts of the 40S and 60S ribosome subunits have also been 
shown to be down-regulated. The Sp100/Sp110/Sp140 complex is predominantly 
thought to function in the NB in cells of the innate immune system, including 
macrophages [377-380]. Therefore, this down-regulation of genes is most likely a 
microglial specific response, although this requires further verification. The down-
regulation of pro-inflammatory cytokines observed in this group, such as interferons, 
has previously been shown to transcriptionally control the expression of the 
Sp100/Sp110/Sp140 complex of genes [377]. The down-regulation of Speckle-type 
POZ protein (SPOP) is likely having an additive effect to the overall down-
regulation of many pro-inflammatory cytokines and receptors down-regulated in this 
group. SPOP is a component of the cullin-RING-based BCR ubiquitin-protein ligase 
complex [415] which mediates the proteasomal degradation of a number of target 
proteins, such as BRMS1 and DAXX. BRMS1 has previously been described to 
inhibit nuclear translocation of NF-κB [416]. This prevents the NF-κB transcriptional 
activation by cytokines shown to up-regulate in this study (e.g. Relt or IL1a) [417]. 
Therefore the decrease in SPOP levels, leading to an increase in BRMS1 results in 
the inhibition of the NF-κB pathway. This may act in competition to the activation of 
the NF-κB activation by pro-inflammatory cytokines which are up-regulated in this 
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study in regions of neurodegeneration. The down-regulation of SPOP can also lead to 
increased levels of DAXX, as mentioned above. DAXX has been shown to activate 
the Jun NH2-terminal kinase (JNK) pathway through the mitogen-activated protein 
kinase, ASK1 [418]. ASK1 is activated as a result of cytokine [419] and/or other 
stress stimuli [420]. Therefore the increase in DAXX therefore represents a possible 
mediator of cell death in prion diseases, which is controlled by the signalling of pro-
inflammatory cytokines to the neuron. Supporting this, studies in Parkinson’s disease 
have shown mutations in the DJ-1 gene present in a monogenic form of human 
parkinsonism [421]. DJ-1 was subsequently shown to prevent DAXX binding to 
ASK1 and as a result, prevented apoptosis [422]. Therefore, it is hypothesised the 
loss of DJ-1 function in these patients leads to increased apoptosis which is a major 
contributor to disease in these patients. 
 
In regions specifically undergoing neurodegeneration, pro-inflammatory cytokines 
(such as Relt, a member of the TNF superfamily) and anti-inflammatory or wound 
repair cytokines (such as TGFβ-1) are up-regulated. A number of genes involved in 
cell proliferation have also been identified in this group. Previous studies have shown 
that microglial proliferation can exacerbate prion disease but inhibition of this 
proliferation can lengthen prion disease incubation [280]. Further, genetic KO 
models of genes involved in the innate immune response have shown to influence the 
incubation period of prion disease. For example, KO of Il1r1, Ccl2, Cxcr3 and CD14 
results in a prolonged incubation period [396-398, 401]. KO or knock-down of 
TGFβ-1, IL4, IL10, IL13 or Ccr1 on the other hand results in a shortened incubation 
period [276, 396, 399, 400]. Expression changes in the brain stem when assessing 
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these genes showed an increase of CD14, an activator of TLR2 and TLR4, and IL1r1 
in both brain stem and cerebellum. A down-regulation of IL13 was observed in both 
brain stem and cerebellum and Ccr1 was also found decreased in cerebellum only. 
Broadly, genes which result in a shortened incubation period in KO animals infected 
with prion disease are shown here to be down-regulated in disease. Conversely, KO 
of genes resulting in a lengthened incubation period are shown here to be up-
regulated. It is important to note however, other genes which impact incubation 
period (e.g. Ccl2, Cxcr3, IL4 and IL10) do not exhibit differential gene expression. 
Taken together, innate immune response and cell proliferation observed in regions 
undergoing neurodegeneration exemplify the importance of these factors within 
neurodegeneration.  
 
The contradictory down-regulation of other pro-inflammatory cytokines and 
receptors, such as interferons and TLR4 (figure 6.3; group B) hints at the host’s 
response to inhibit specific aspects of the innate immune response within an 
individual microglial cell. Alternatively, these differential responses may occur in 
different populations of microglia within the same brain region (represented in figure 
6.19). Indeed, results in chapter 3 demonstrate this whereby, for example, thalamic 
degeneration appears to occur in the ventral-lateral parts of the thalamus however the 
dorsal thalamus does not show neurodegeneration. One possible explanation for this 
decrease of pro-inflammatory cytokines is the well-established interaction of 
macrophages with apoptotic cells, which results in a down-regulation of pro-
inflammatory cytokines in surrounding cells [423, 424]. If this mechanism also 
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occurs here, the down-regulation of pro-inflammatory cytokines may act as a 
protective entity against the toxic effects of a pro-inflammatory event [273]. 
Figure 6.19 – Diagrammatic representation of microglial morphology within and between different 
brain regions of the same individual. The up- and down-regulated signal hypothesised to occur in 
microglia could occur in all microglia within a particular brain region, or could be the result of 
different populations of microglia which give different signals in different parts of a particular brain 
region. 
 
Another small group of genes were found up-regulated specifically within the 
cerebellum. These encompassed genes related to neuronal function (such as 
synaptotagmin XII, parvalbumin and shank3). Results in chapter 3 show an up-
regulation of neuronal specific proteins in pathologically unaffected regions, such as 
the cerebellum and cortex. Shank3 is a post-synaptic density protein found in the 
dendrites of neurons [425], whereas parvalbumin and MAP2 staining are localised to 
the cell body and dendrites of neurons. The increased expression of shank3 and 
parvalbumin therefore correlates with the observation of an increased MAP2 staining 
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(figure 3.6). Previous studies have shown an up-regulation of parvalbumin in neurons 
of the cerebellum at early stages of PrPd accumulation, prior to neurodegeneration 
[403]. This could therefore suggest the increased gene (shank3 and parvalbumin) and 
protein (MAP2) levels in neurons may relate to disease events prior to overt 
neurodegeneration. An alternative explanation is that the pathologically unaffected 
regions are acting protectively by up-regulating neuronal specific genes in response 
to external cues present in a degenerative CNS. In order to test whether these regions 
are undergoing a potential pathological event, a host of ATF expression levels were 
assessed, which are known proteins to be activated in response to stress stimuli [405-
407] and transcriptionally regulate genes associated with stress pathways [405-414]. 
Within regions of neurodegeneration, different subsets of ATF transcription factors 
were up-regulated. This indicates that each region undergoing neurodegeneration up-
regulates ATF transcription factors in a regional-specific mechanism. The 
cerebellum and cortex, however exhibit a common up-regulation of ATF1 and 
ATF6β. Little work has been performed assessing the role of ATF1 in response to 
stress in mammals, however in yeast ATF1 has been shown to be activated by a 
stress-activated kinase in a similar fashion to ATF2 in mammals [426]. In the 
cerebellum, both ATF6 and ATF6β are shown to be significantly up-regulated. ATF6 
is a transmembrane protein expressed predominantly on the surface of the ER and 
bound to the ER chaperone, immunoglobin binding protein (BiP). Upon ER stress 
BiP binding is disrupted and ATF6 is delivered to the Golgi [427], cleaved and 
imported into the nucleus [428]. ATF6 then is thought to activate a subset of genes 
involved in the UPR [411]. The combination of an up-regulation of neuronal genes 
and proteins in the cerebellum and up-regulation of ATF6 indicates that regions 
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defined via histopathological analysis as “pathologically unaffected” regions are in 
fact undergoing a possible stress response. The prion seeds may therefore be acting 
as a stress stimuli for the activation of such transcription factors, and hence having a 
detrimental effect on the tissue. However this is not sufficient to trigger overt 
neurodegeneration, as can be defined by histopathological analysis. 
 
The presence of an innate immune response which encapsulates a hybrid pro- and 
anti-inflammatory response specifically in regions undergoing overt 
neurodegeneration highlights the importance of such a response in 
neurodegeneration. The down-regulation of other genes, most probably in microglia, 
including pro-inflammatory cytokines and receptors, could be explained by the 
interaction of activated microglia with degenerating neurons in neighbouring or 
connected tissue. Whether this phenomenon occurs only to directly neighbouring 
tissues or can be conferred along neuroanatomical pathways is unknown, but the 
latter could explain the widespread down-regulation of pro-inflammatory cytokines 
found in this study. 
 
The results in this chapter detail the gene expression changes observed between brain 
regions in GSS/101LL and NBH/101LL mice. Microarray chips, including the 
Affymetrix chip used in this study, include numerous repeat transcripts and many 
genes are represented by a number of transcripts specific for different RNA segments 
in the gene. This allows an internal control to assess whether a transcript which 
shows differential expression levels in a sample of interest is indeed differentially 
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expressed or a technical error in the fluorescence read-out of that transcript. Of 
course, this is further controlled by using multiple array repeats. Nevertheless, the 
differential expression of genes which are identified require further work to validate 
expression changes. This can be done using other RNA quantifying techniques, such 
as real-time PCR. Of perhaps more importance, gene expression analysis only 
represents the transcriptional changes within a sample but not all transcripts 
produced are translated to protein. Therefore, testing whether the gene expression 
changes observed translate into protein expression is required to further understand 
the data output of this study. 
 
The data in this chapter indicates that prion seeds are most likely having a 
detrimental impact in the cerebellum and cortex. As discussed in chapter 5, it is 
unclear whether specific toxic conformations are responsible for the presence or 
absence of neurodegeneration. However, this study indicates that prion seeds do 
exhibit some level of toxicity, resulting in increased expression of ATF1 and ATF6. 
Nevertheless, prion seeds, alone, do not appear sufficient to trigger overt 
neurodegeneration. The predominating innate immune response restricted to the 
brain stem and thalamus implicates the importance of glial cell responses, such as 
microglial activation, in neurodegeneration. It is possible the deficits caused by the 
accumulation of prion seeds results in microglial activation due to compromised 
neuronal homeostasis. This may lead to neurodegeneration, possibly resulting in 
apoptosis via the interaction of DAXX and ASK1, which is controlled by cytokine 
signalling. Why specific regions appear to be prevented from undergoing a glial cell 
response when exposed to compromising prion seeds is unknown. It can be 
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hypothesised that the interaction of activated microglia with degenerating neurons 
results in an inhibition of microglial activation in surrounding, or possibly neuronally 
connected tissue, thereby preventing a glial cell response. This may then prevent the 
toxic effects of a pro-inflammatory event in specific regions, thereby preventing 
neurodegeneration. An alternative explanation could be that glial cells, such as 
microglia, react to specific species of misfolded protein, thereby resulting in 















Current perspectives in many chronic diseases of the CNS are that misfolded proteins 
are responsible for neurodegeneration. In prion diseases, the identification of an 
infectious, aberrantly folded protein [21], devoid of nucleic acids [16] is the 
underlying basis of the prion hypothesis [3, 6, 22-25]. This led to the hypothesis that 
the misfolded prion protein is required for the temporal and spatial lesions in prion 
diseases [260, 261, 429, 430], although some studies indicate that not all forms of 
misfolded prion protein are necessarily toxic [431, 432]. A similar ambiguity 
between misfolded protein and neurodegeneration is also suggested in other chronic 
neurodegenerative disease [163, 433-436]. Dose [437], spread [161, 162, 286, 288, 
290-293, 438] and species of aggregate [168-176] are implicated as critical factors in 
determining toxicity of misfolded proteins.  
 
7.1. Determining the correlation between misfolded prion protein and 
neurodegeneration 
In this thesis, the relationship between the accumulation and spread of misfolded 
prion protein and neurodegeneration was studied. In contrast to previous studies, this 
study also took advantage of a highly sensitive assay, the QuIC assay, to detect the 
presence of prion seeds. Using IHC analysis, it was found that the spatial distribution 
of PrPd is associated with neurodegeneration in a manner akin to previous studies 
[189, 191]. Further investigation showed the deposition of PrPd coincided with the 
spread of neurodegeneration from one anatomically distinct region to another in a 
pattern resembling neuronal connectivity. This is conceptually identical to studies 
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assessing spread in other disease-associated misfolded proteins [161, 162, 286, 288, 
290-293, 438] and pathological spread in humans [143, 144]. Microglial and 
astrocyte morphological cellular responses were also observed specifically in regions 
of IHC positive PrPd prior to neurodegeneration. This progression of disease in 
GSS/101LL animals matched previous studies assessing disease progression in other 
models of murine scrapie [189, 191]. This data suggests morphological alterations in 
microglia and astrocytes are exquisitely sensitive biomarkers of neurodegeneration, 
but also highlight their functional role in prevention or induction of 
neurodegeneration. It has been shown the astrocyte can propagate PrPd [263], but 
whether this has any impact upon disease is unknown. Microglia exhibit an innate 
immune response [275] which appears to be regulated by TGFβ-1 [276]. Inducing a 
systemic inflammatory response, by injection of LPS for example, results in 
exacerbation of disease [190]. Conversely, genetic KO of pro-inflammatory 
mediators results in amelioration of disease [401, 439]. Recent studies show that 
inhibiting the proliferation of microglia in prion disease ameliorates disease [280]. 
This indicates that the function and/or the oxidative stress of highly proliferative 
microglia represent a toxic entity. This data does not elucidate whether such 
microglial responses are a consequence of disease or play a significant role in 
neurodegeneration. 
 
The detectable PrPd via IHC was observed associated with the interpeduncular nuclei 
and SNc at early stages of disease, followed by accumulation in the dorsal and 
medial raphe nuclei of the brain stem or the SNr of the midbrain. Glial cell responses 
are observed associated with the spread of PrPd and overt signs of neurodegeneration 
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can also be detected at this stage. This neurodegeneration can be characterised by the 
loss of neuronal structural integrity. It has been shown previously that neurons 
undergo atrophy prior to neuronal cell loss [191]. This implicates a loss of cell-
structure integrity of neurons at early stages of disease in both GSS/101LL animals 
and other models of murine scrapie. 
 
Using the QuIC assay as a tool to detect prion seeds, this study found no relationship 
between prion seeds and neurodegeneration. As mentioned earlier in this thesis, it is 
highly likely the QuIC assay detects misfolded prion protein; whether this represents 
species of PrPd or different isoforms is as yet unknown. A recent study has shown the 
recPrP that aggregates/misfolds in the QuIC assay can recapitulate the prion strain 
characteristics of the sample that was used to seed the QuIC assay. For example, 22L 
murine prion strain used to seed the QuIC assay caused aggregation/misfolding of 
recPrP which consequently exhibited similar structural properties of 22L PrPd. 
Furthermore, when inoculating into mice the recPrP seeded with 22L, the incubation 
period was comparative to the expected 22L incubation period [348]. A similar 
approach, sub-passaging GSS/101LL brain regions and/or the QuIC seeded product 
into mice could be useful to assess whether different species of misfolded prion 
protein exist between brain regions. 
 
It is possible different misfolded prion protein conformations exist in different 
regions of the brain. Therefore a basic interpretation would be that toxic 
conformations exist in brain regions undergoing neurodegeneration, and non-toxic 
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conformations exist in unaffected regions. Conformational differences between brain 
regions of the same individual have been observed previously in human prion disease 
patients. The thalamus was shown to exhibit different aggregations of PrPd to the 
cerebellum [350]. This however, draws attention to the fixed perspectives of “toxic” 
or “non-toxic” protein conformations alluded to in previous publications [432, 437]. 
These publications hypothesise that neurodegenerative diseases occur in a two-phase 
mechanism. The exponential increase in non-toxic conformations of misfolded 
protein. In the instance of prion diseases, these conformations of protein represent 
the infectious material [432, 437]. The levels of infectivity then plateau but overall 
misfolded prion protein levels continue to increase. The authors therefore propose 
that this plateau represents a ‘switch’ from infectious prion protein conformations to 
toxic conformations. If true, this would suggest infectivity levels in brain regions 
undergoing neurodegeneration have reached a plateau, whereas in brain regions 
without overt neurodegeneration but with accumulation of misfolded protein will be 
in the phase of increasing infectivity levels. Whether the infectivity plateau truly 
represents the switch from infectious to toxic protein isoforms has yet to be 
established. Nevertheless, the infectivity plateau is a well-known phenomenon in 
prion diseases [440-442]. Such a change in dynamics of disease must therefore be 
related to a significant alteration in host physiology. As the primary structure of the 
prion protein is the same across all brain regions tested in this study, differences in 
protein conformation must be represented at the secondary or tertiary protein 
structure levels. These can be influenced by a variety of conditions, including 
changes in environmental pH, temperature, nearby proteins/lipids/carbohydrates 
amongst many other factors. As a result, such a substantial change in host 
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physiology, represented by the plateau of infectivity, is likely having a major role in 
determining protein conformation and the role of the misfolded protein in 
neurodegeneration. An alternative argument can be made however. As misfolded 
protein accumulates, it aggregates into oligomers, fibrils and amyloid plaques. 
Whether this is a continuous pathway of aggregation or these protein constructs are 
observations of distinct pathways of aggregations is still unclear. As amyloid plaques 
form, some studies have shown that in the surrounding vicinity of the plaque, 
oligomers are formed [443]. This is associated with a concurrent glial cell response 
[444], but the burden of oligomers directly correlates with loss of excitatory synapses 
[443]. In this instance, it can be argued that the amyloid plaque generates an 
environment in its surrounding vicinity which is conducive to oligomer formation 
and neurodegeneration. Therefore rather than host environment impacting protein 
conformation, this would stipulate that misfolded protein aggregation can directly 
generate an environment for further protein misfolding which is correlated with 
toxicity. Overall, with only having the capability, at present, to detect prion seeds 
using the RT-QuIC assay, such studies on the impact of misfolded protein are 
limited. However, it is possible to define the host response to the accumulation to 
prion seeds and therefore determine the impact this may have on neurodegeneration. 
 
7.2. Dose and spread of prion seeds play no discernible role in determining 
toxicity 
As mentioned above, dose and spread of misfolded proteins have also been 
hypothesised to be factors determining misfolded protein toxicity. To answer 
whether these are indeed factors between brain regions in GSS/101LL animals, two 
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experiments were performed. Firstly a dilution series of each brain region was 
performed. The assumption being a region exposed to smaller quantities of prion 
seeds will not seed the QuIC assay at lower homogenate concentrations comparative 
to regions with larger quantities of prion seeds. Comparative quantities of prion seeds 
were found between brain regions in this study, suggesting no quantitative difference 
in prion seeds. Secondly, different brain regions were tested throughout the 
incubation period to determine whether prion seeds spread in a selective mechanism 
which would correlate with neurodegeneration. At earliest stages of disease (i.e. 
150dpi), prion seeds were restricted to a small number of mice specifically within the 
brain stem. This is the point at which PrPd detectable via IHC was observed in the 
midbrain. Due to the known connectivity between midbrain neurons associated with 
PrPd and those of the brain stem [334, 335], this may indicate an early specific spread 
of prion seeds via neuronal connectivity. Further work is required to confirm this. 
After this stage, however, the prion seeds exponentially spread to all brain regions 
tested. The thalamus appears exposed to prion seeds at a similar stage to the 
cerebellum and cortex, yet the thalamus eventually undergoes neurodegeneration 
whereas the cerebellum and cortex do not. Why a specific region, such as the 
thalamus, would specifically undergo neurodegeneration when exposed to similar 
quantities of prion seed for the same time-frame as cerebellum or cortex is unknown. 
Taken together, this data demonstrates that prion seeds are present at equal quantities 
and are widespread at early stages of disease – ruling out the dose or spread as 
factors determining toxicity in this model. However, the early specific targeting to 
neurons of the midbrain, and potentially interconnected nuclei of the brain stem 
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could represent an important interplay between early targeting and spread of PrPd 
and the subsequent host response to restrict/prevent neurodegeneration. 
 
7.3. Host responses in determining prion seed toxicity 
It was hypothesised that, due to the presence of prion seeds across all brain regions 
tested, the host must elicit a specific response to either protect against the toxic 
effects of prion seeds or aberrantly induce an environment which preferentially forms 
toxic isoforms of prion seeds in some regions and not others. A number of studies 
have used microarray to study genome-wide transcriptional changes during prion 
disease as a method to elucidate the mechanisms of neurodegeneration [218, 227, 
228, 230, 351-356, 358-360, 362-368]. Earlier studies used whole brain analysis 
across a range of different strains either at clinical stages of disease [228, 230, 351-
353] or throughout a time-course [228]. The major signature identified in these 
studies was a gene list related to gliosis [228, 230, 351-353], specifically an innate 
immune response which orientates around TGFβ-1 [228, 230, 351-353]. Later 
studies thus concentrated on the neuronal transcriptome in prion infected mice [218]. 
These studies indicate that degenerating neurons may elicit a protective response to 
prevent neuronal cell death prior to clinical onset of disease (reviewed in [445]). 
 
The findings in this thesis allow a novel approach for the comparison of the host 
transcriptional profile in neurodegeneration against the host response to prion seeds, 
independent of neurodegeneration. Three major groups were identified as a result of 
the microarray; (i) a specific up-regulation of genes associated with gliosis in regions 
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of neurodegeneration, (ii) a down regulation of genes across all regions, also 
associated with a glial cell response and (iii) intrinsic gene expression differences 
between brain regions used in this study. A small cluster of genes which are 
specifically up-regulated only in cerebellum was also detected. Similarly, the 
activating transcription factors (ATFs), which are involved in active response 
pathways to stress stimuli, such as cytokines, misfolded proteins and DNA damage, 
have also been shown to be differentially regulated between brain regions in this 
study. 
 
7.3.1. Up-regulation of genes in regions of neurodegeneration 
The up-regulation of a gene expression profile in regions of neurodegeneration was 
an expected result. Results in chapters 3 and 4 in this thesis show glial cells undergo 
a substantial morphological response in regions of neurodegeneration. In addition, 
previous microarray studies have implicated a signature indicative of gliosis which is 
orientated around TGFβ-1 [228, 230, 351-353], a finding also observed in 
pathological and genetic analysis in previous studies [275, 276]. Indeed in this study, 
a hybrid pro- and anti-inflammatory response was identified, which included cellular 
proliferation, the complement pathway, pro-inflammatory cytokines and chemokines, 
TGFβ-1 and GFAP. This group of genes is therefore representative of a glial cell 
response, orientated predominantly around the innate immune response. Overall, this 




7.3.2. Down-regulation of genes across all brain regions tested 
The down-regulation across all regions tested is also indicative of a glial cell 
response. The predominant signature appears to surround the down-regulation of the 
viral response transcription factors Sp100, Sp110 and Sp140. These are major 
constituents of a multi-protein matrix, termed nuclear bodies (NBs) [377]. The 
consequences of the down-regulation of such NB proteins are deficits in transcription 
and translation and also an inability to translocate CREB transcription factors to the 
nucleus [377, 381, 382, 384-387]. As shown in chapter 6, a sub-unit of RNA 
polymerase II is down-regulated, and a large set of transcripts also appear down-
regulated in a pattern correlating with RNA polymerase II down-regulation. As 
discussed previously, the Sp100/110/140 nuclear body complex has previously been 
shown to co-localise with RNA polymerase II transcripts [384, 385]. This suggests 
this nuclear body complex may play a scaffold role in RNA polymerase II 
transcription. What causes the down-regulation of Sp100/110/140 nuclear body 
complex is unclear. It has been shown previously that interferons control the 
activation of this complex [377, 446-449]. Indeed, interferons are shown to be down-
regulated across all regions in this study. Therefore, the down-regulation of 
interferons can lead to down-regulation of the Sp100/110/140 nuclear body complex, 
which thus has implications on transcription and translation in cells of the innate 
immune system, such as microglia.  
 
Further work is required to understand why interferons are down-regulated across all 
regions tested. Some studies have demonstrated an important host protective 
response when apoptotic cells come into contact with macrophages [423, 424]. 
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Specifically, surrounding connected tissue exhibits a down-regulation of pro-
inflammatory cytokines to prevent an unnecessary inflammatory response or tissue 
damage in neighbouring cells. In this study, the appearance of a down-regulation of 
pro-inflammatory cytokines, such as interferons may indicate a protective response 
conferred in tissue neighbouring regions of neurodegeneration. This subsequent 
down-regulation of probable microglial specific genes thus hints at a protective 
response. It is clear from histopathological analysis that both microglia and 
astrocytes show no morphological alteration throughout disease in either the cortex 
or cerebellum, therefore it can be hypothesised that this down-regulation of innate 
immune response genes is possibly a host prevention of an activated microglial 
response. The pro-inflammatory response which may result from activated microglia 
(and which is observed as a hybrid pro- and anti-inflammatory response in brain stem 
and thalamus in this study) has previously been hypothesised to be toxic in 
neurodegenerative diseases [273]. Further work will thus be required to assess 
whether the macrophage-apoptotic cell interaction firstly occurs in the CNS, and 
secondly whether it impacts the (potentially toxic) function of an activated microglial 
cell. 
 
7.3.3. Stress responses observed across all brain regions tested 
To test whether prion seeds have an impact upon “unaffected” brain regions, the 
activating transcription factor (ATF) gene expression levels were assessed. This 
group of transcription factors are activated as a result of specific stress stimuli [405-
407] and transcriptionally regulate genes associated with stress pathways, such as 
UPR [405-414]. Within the brain stem and thalamus, an up-regulation of ATFs was 
[197] 
 
observed, but these differed depending on region (e.g. brain stem exhibited up-
regulation of ATF2, ATF4, ATF6β and ATF7, whereas the thalamus exhibited up-
regulation in ATF6 and ATF7). This data suggests different brain regions may 
undergo specific stress response pathways during neurodegeneration. In regions of 
the brain previously defined as pathologically unaffected, however, ATF1 and ATF6 
appeared up-regulated. Of particular relevance is ATF6, which is transcriptionally 
activated in instances of ER stress and is thought to regulate a subset of genes 
involved in the UPR [411]. Recent studies have indicated UPR activation as an 
important factor in mediating neurodegeneration [225, 226]. In these studies, rising 
levels of misfolded protein is proposed to be detected by BiP/Grp78 which leads to 
phosphorylation of PERK [225, 411]. This pathway leads to the activation of ATF4, 
which consequently activates the UPR pathway. ATF6 however is bound to BiP 
proteins on the surface of the ER. In instances of ER stress, this interaction is 
disrupted, resulting in translocation of ATF6 to the Golgi apparatus [427], where it is 
then cleaved and transported into the nucleus [428] and subsequently activates genes 
of the UPR pathway [411]. This data indicates that all brain regions tested exhibit 
stress responses. Whether this is a response restricted to neurons or found in other 
cell types has not been defined. Nevertheless, this profile suggests that the presence 
of prion seeds elicit a stress response across all brain regions. However, this response 
alone is not sufficient to trigger overt neurodegeneration. 
 
Taken together, the data in this study indicates a complex relationship of different 
cell types in the CNS and the appearance and accumulation of PrPd. The 
accumulation of prion seeds across all regions tested in this study appears to elicit a 
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cellular stress response. The context of the accumulation of PrPd initially associated 
with neurons of the midbrain, followed by a specific neuronal spread to the brain 
stem suggests these stress pathways may be implicated early in disease. Indeed, this 
stress response is likely to elicit glial cell responses due to disrupted neuronal 
homeostasis, hence why glial cell responses are observed shortly after the initial 
accumulation of PrPd. Microglial interactions with the stressed neurons of the 
midbrain and/or brain stem may thus elicit a protective anti-inflammatory response to 
surrounding tissue, including thalamus, cerebellum and cortex. Why the thalamus 
eventually results in overt neurodegeneration whereas the cerebellum and cortex 
appear unaffected is unknown. Further work is required to answer in more detail 
what the pathological processes occurring in the cerebellum and cortex are. 
Certainly, the stress responses occurring in these regions indicate a pathological 
event, but the reasons for an absence of the hybrid pro- and anti-inflammatory 
response and neurodegeneration (as seen in brain stem and thalamus) remain 
unanswered. 
 
7.4. Concluding remarks 
In summary, it appears the accumulation of misfolded prion protein, and the 
consequent stress responses associated with this, are not sufficient to trigger 
neurodegeneration. This could be due to the host down-regulation of pro-
inflammatory cytokines, resulting in down-regulation of transcriptional and 
translational regulation in cells of the innate immune response, such as microglia. 
This may be indicative of a pathway inhibiting microglial activation and preventing 
toxicity, although this is highly speculative and requires further work. At early 
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stages, in the absence of a putative host protective response, gliosis may occur as a 
response to misfolded prion protein-mediated neuronal stress. The sustained and 
unresolved inflammation as a result of this, in conjunction with stress pathway 
activation, may therefore lead to neurodegeneration. These results lead to a “multi-
hit” hypothesis, whereby two or more factors (e.g. accumulation of misfolded prion 
protein and microglial activation) are required to trigger neurodegeneration. 
 
The results in this study therefore change our perspective on the progression of 
neurodegeneration and the putative role of the misfolded protein within this. The 
multi-hit hypothesis encapsulates the current perspectives regarding the importance 
of disease-associated misfolded proteins in neurodegeneration; however this study 
shows misfolded protein, alone, is not sufficient to trigger neurodegeneration. In 
conjunction with a growing understanding of the importance of the glial cell 
response in neurodegenerative diseases, the multi-hit hypothesis encapsulates how 
the interaction between misfolded protein and the glial cell responses may act 
additively to trigger neurodegeneration. Such an understanding changes our 
perception on disease progression and identifies new avenues to study this. 
Furthermore, future research into the multi-hit hypothesis may yield new therapeutic 
targets, for example, preventing the inflammatory response by understanding the host 
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Down regulation of genes associated with group B (figure 6.3) 
Function Count Genes 
Autophagy 1 Gm10377 
Cell adhesion 3 Cdh11; Crisp1; Spam1 
Cell proliferation 2 Dbf4; Ttk 
Cell structure 7 Capza1; Gm19924; Grxcr1; Dlg5; Rp1; Sptlc3; Tcte3 
Production of CSF 1 Car1 
DNA structure, repair 
and division 
12 Aspm; H2-T3; H3f3a; Hmgb1; Hmgb2; Ncapg; Ott; Rad54b; 
Sfi1; Slx; Sly; Top2a 
Immune related 31 Pla2g10os; Ccl11; Cd244; COX2; Csprs; Defa17; Defa20; 
Defa23; Defa5; Defb12; Fam60a; Cd194; SPOP; Ifna1; Ighg3; 
Ighv1-72; Igh-VJ558; Igkv4-70; Igkv5-43; Il12b; Sp140-l; 
Mgst2; Ms4a2; Nlrp4e; Slamf6; Sp100; Sp110; Sp140; Tlr4; 
Trav12-2; Trav7-4;  
Intracellular trafficking 5 Atp6v1g1; Rab11b; Rab19; Slc30a8; Slco1a6 
Metabolism 7 Acbd7; Amy2a5; Arg1; Mptx; Lipm; Mgam; Mup1 
Metal ion homeostasis 3 Caps2; Ftl1; Gm15421 
Misfolded protein 
regulation 
2 Sel1l2; Ugt2b1 
Mitochondrial function 7 Atp5l; ATP6; Cps1; Cyp3a25; Cyp3a41a; Cyp3a41b; Gm10921 
Neuronal function 3 Gabrr3; Gm3002; Gm3591 
Other 1 Uts2d 
Protease inhibitor 2 Cst8; Cst9 
Protein kinase 4 AU018829; Gm10324; Itln1; Lrriq3 
RNA splicing 6 Cwc22; Ear14; Esrp1; Hnrnpf; Lsm5; Rbmy1a1 
Sensory function 90 Vmn1r102; Mup17; Olfr1036; Olfr1162; Olfr1234; Olfr1252; 
Olfr1289; Olfr1294; Olfr1330; Olfr1362; Olfr1368; Olfr1373; 
Olfr1381; Olfr1467; Olfr1477; Olfr177; Olfr205; Olfr247; 
Olfr347; Olfr355; Olfr43; Olfr447; Olfr452; Olfr485; Olfr559; 
Olfr568; Olfr575; Olfr591; Olfr594; Olfr6; Olfr656; Olfr671; 
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Olfr728; Olfr749; Olfr796; Olfr8; Olfr810; Olfr819; Olfr890; 
Olfr901; Olfr917; Olfr968; Olfr974; Olfr983; Tas2r118; 
Tas2r120; Trpa1; Vmn1r100; Vmn1r101; Vmn1r104; 
Vmn1r107; Vmn1r111; Vmn1r112; Vmn1r114; Vmn1r117; 
Vmn1r118; Vmn1r119; Vmn1r120; Vmn1r126; Vmn1r127; 
Vmn1r129; Vmn1r130; Vmn1r132; Vmn1r135; Vmn1r142; 
Vmn1r143; Vmn1r151; Vmn1r152; Vmn1r159; Vmn1r174; 
Vmn1r196; Vmn1r218; Vmn1r32; Vmn1r43; Vmn1r77; 
Vmn1r91; Vmn1r93; Vmn1r94; Vmn1r-ps79; Vmn2r21; 
Vmn2r29; Vmn2r32; Vmn2r33; Vmn2r34; Vmn2r38; Vmn2r42; 
Vmn2r43; Vmn2r44; Vmn2r51; Vmn2r85 
Signal transduction 9 Arhgap15os; Abca13; Abcb11; Gm10375; Gm14482; Mcoln2; 
Sirpb1b; Gm14484; Gm14850 
Transcriptional 
regulation 
40 Dppa2; Dppa3; Gcl1; 1700020N01Rik; 1700029I01Rik; 
Zbed4ps; Zfp30; CTDSPL; Med7; Polr2k; Tdpoz5; Zbed4; 
Zfp600; Zfp772; Zfp808; Zscan4a; Zscan4b; Zscan4e; Zscan4f;  
Translational regulation 8 Nop16; eIF2a; Alyref1; Alyref2; Rpl23al; Rpl7a; Rps12; Rps18;  









Up-regulation of genes associated with group C (figure 6.3) 
Function Count Gene 
Apoptosis 1 Rassf4 
Astrocyte function 2 Gfap; Mfsd2a 
Cell proliferation 11 Axl; Csf3r; Emp3; Fgf18; Fstl1; Gata2; Gpnmb; Igfbp2; 
Inpp5d; S1pr3; Timp1 
Cell structure 4 Abi3; Arpc1b; Dock2; Rhoj 
ECM 3 Adamtsl5; Fxyd5; Sh3pxd2b 
Protease 7 Ctsb; Ctsc; Ctsd; Ctse; Ctsh; Ctss; Ctsz 
Fatty acid biosyntesis 2 Soat1; Anxa3 
Golgi function 1 Gltpd1 
Immune related 44 Vista; Asb13; Bcl3; C1qa; C1qb; C1qc; C3; C3ar1; C4b; 
Ccl3; Cd109; Cd180; Cd52; Cd53; Cd63; Cd9; Clec7a; 
Csk; Cst7; Cxcl13; Cxcl16; Dap; Emr1; Eng; Fcer1g; 
Fcgr1; Grn; H2-Ab1; Il13ra1; Irf8; Itgax; Itgb2; Ly86; 
Mpeg1; Osmr; P2ry6; Relt; Tapbp; Tgfb1; Tlr13; Tlr7; 
Trem2; Tyrobp; Unc93b1 
Intracellular trafficking 2 Rab31; Rin2 
Metabolism 7 Cyba; Cybb; Dhrs1; Gpt2; Hsd17b11; Man2b1; Nnt 
Metal ion homeostasis 4 Crip1; Cybrd1; S100a1; Slc11a1 
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mRNA degradation 2 Zfp36l2; Apobec1 
Neuronal function 3 Nfasc; Rgma; Tmem176b 
Other 7 Acy3; Flnc; Gusb; Slc43a3; Smoc1; Tagln2; Plek 
Phagocytosis/Lysosomal 11 Cd68; Cyth4; Gns; Hexb; Ifi30; Laptm5; Lipa; Lyz2; Pld4; 
Plin3; Vps33b 















Up-regulated genes of the GSS/101LL cerebellum in group A (figure 6.3) 
Function Count Gene 
Cell adhesion 1 Clmp 
Cell structure 3 Ttll3; Mtss1; Rhod 
DNA structure, 
repair and division 
1 Cep120 
Immune related 3 Darc; Stk10; Rorc 
Intracellular 
trafficking 
2 Git2; Pard6g 
mRNA degradation 1 Pan2 
Neuronal function 6 Hpcal1; Nrg2; Sh3gl2; Syt12; Shank3; Unc5b 
other 2 Ece1; Hs3st1 
Ubiquitination 1 Rnf123 
Protein kinase 1 Ubash3b 
Signal transduction 3 Kcnk1; Kcnk3; Spag1 
Transcriptional 
regulation 
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